

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 398 032 A1**

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:

**17.03.2004 Bulletin 2004/12**

(51) Int Cl.<sup>7</sup>: **A61K 31/517**, C07D 239/95,  
C07D 401/12, C07D 405/12,  
A61P 3/06

(21) Application number: **03020417.6**

(22) Date of filing: **10.09.2003**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IT LI LU MC NL PT RO SE SI SK TR**

Designated Extension States:

**AL LT LV MK**

(30) Priority: **10.09.2002 EP 02020255**

(71) Applicant: **PheneX Pharmaceuticals AG  
69120 Heidelberg (DE)**

(72) Inventors:

- **Kober, Ingo  
69251 Gaiberg (DE)**
- **Albers, Michael  
69221 Dossenheim (DE)**

• **Koegl, Manfred**

**69214 Eppelheim (DE)**

• **Blume, Beatrix**

**69221 Dossenheim (DE)**

• **Deuschle, Ulrich**

**69120 Heidelberg (DE)**

• **Kremoser, Claus**

**69121 Heidelberg (DE)**

(74) Representative: **Huhn, Michael, Dr.**

**Isenbruck Bösl Hörschler**

**Wichmann Huhn**

**Patentanwälte**

**Theodor-Heuss-Anlage 12**

**68165 Mannheim (DE)**

(54) **4-Oxo-quinazolines as LXR nuclear receptor binding compounds**

(57) The present invention relates to 4-oxo-quinazolines which bind to the Liver X receptors (LXR receptors, LXRalpha/NR1 H3 and LXRBeta/NR1H2) and act as selective agonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptors and

selective agonistic effects by said compounds and the production of medicaments using said compounds. In particular the compounds are useful in the treatment of hypercholesterimia, obesity or other diseases associated with elevated lipoprotein (LDL) levels.

**EP 1 398 032 A1**

## Description

**[0001]** Liver X Receptor (LXR) is a prototypical type 2 nuclear receptor which activates genes upon binding to promoter region of target genes in a prototypical heterodimeric fashion with Retinoid X Receptor (hereinafter RXR, Forman et al., Cell, 81, 687-93, 1995). The term LXR includes all subtypes of this receptor. Specifically LXR includes LXRA (also known as LXRA $\alpha$ , RLD-1 and NR1H3) and LXR $\beta$  (also known as LXR $\beta$ , NER, NER1, UR, OR-1, R1P15 and NH1H2) and ligands of LXR should be understood to include ligands of LXRA or LXR $\beta$ . The relevant physiological ligands of LXR seem to be oxidized derivatives of cholesterol, including 22-hydroxycholesterol and 24,25(S)-epoxyc-  
 5 cholesterol (Lehmann, et al., Biol. Chem. 272(6), 3137-40, 1997). The oxysterol ligands bound to LXR were found to  
 10 regulate the expression of several genes that participate in cholesterol metabolism (Janowski, et al., Nature, 383, 728-31, 1996).

**[0002]** LXR is proposed to be a hepatic oxysterol sensor. Upon activation (e.g. binding of oxysterols) it influences the conversion of dietary cholesterol into bile acids by upregulating the transcription of key genes which are involved in bile acid synthesis such as CYP7A1. Hence, activation of LXR in the liver could result in an increased synthesis of  
 15 bile acids from cholesterol which could lead to decreased levels of hepatic cholesterol. This proposed LXR function in hepatic cholesterol metabolism was experimentally confirmed using knockout mice. Mice lacking the receptor LXRA lost their ability to respond normally to an increase in dietary cholesterol and did not induce transcription of the gene encoding CYP7A1. This resulted in accumulation of large quantities of cholesterol in the livers and impaired hepatic function (Peet, et al., Cell, 93, 693-704, 1998).

**[0003]** Besides its important function in liver, LXR plays an important role in the regulation of cholesterol homeostasis in macrophages and intestinal mucosa cells where it upregulates cholesterol transporters from the ABC (=ATP binding cassette) family of membrane proteins (Repa, et al., J Biol Chem. 2002 May 24;277(21):18793-800).

**[0004]** These transporters are believed to be crucially involved in the uptake of cholesterol from the diet since mutations in their genes leads to diseases such as sitosterolemia (Berge, et al., Science (2000);290(5497):1771-5.).

**[0005]** Other members of the ABC transporter family seem to be responsible for the efflux of cholesterol from loaded macrophages, a process which is thought to prevent the generation of atherosclerotic lesions. Stimulation of LXR by synthetic ligands might result in an increased cholesterol efflux from macrophages and a decreased building up of cholesterol loaded atherosclerotic plaques (Venkateswaran, et al., PNAS (2000) 24;97(22):12097-102; Sparrow, et al., J Biol Chem (2002) 277(12):10021-7; Joseph, et al., PNAS (2002);99(11):7604-9). Direct evidence that synthetic LXR  
 25 ligands inhibit the development of atherosclerosis has been provided in two animal models of atherosclerosis: A significant reduction in the formation of atherosclerotic plaques were shown in two studies in animal models using full LXR agonists Joseph et al. PNAS (2002) 99:7604-9 and Terasaka et al. (2003) Terasaka et al. FEBS Lett. (2003) 536: 6-11. In addition, two recent reports have highlighted the potential use of LXR agonists in diabetes (Cao et al., (2003) J Biol Chem. 278:1131-6 and inflammatory disorders (Joseph et al., (2003) Nat Med. 9:213-9).

**[0006]** However, in animal studies it was observed that activation of LXR in the liver by full agonists like T0901317 does not only increase bile acid synthesis but also stimulates the de novo synthesis of fatty acids and triglycerids through the upregulation of key enzymes such as Fatty Acid Synthase (FAS) or Stearyl-CoA Desaturase (SCD-1) (Schultz, et al., Genes Dev (2000) 14(22):2831-8). Elevation of serum triglyceride levels is an independent risk factor for atherosclerosis (for review see Miller (1999) Hosp Pract (Off Ed) 34: 67-73.).

**[0007]** Thus, LXR activity needs to be selectively modulated for therapeutic benefit. In particular, compounds need to be found that stimulate reverse cholesterol transport, but do not significantly increase triglyceride levels. This might be particular relevant for the usage of such compounds in diabetic patients since a even more severe lipogenic effect was reported for the full agonist T0901317 in db/db mice which serve as an animal model for diabetes (Chisholm et al. (2003) J.Lipid Res (epub August 16)).

**[0008]** Therefore, an ideal synthetic LXR binding compound should have properties that retain the agonistic activity on hepatic bile acid formation and ABC-transporter-mediated decrease in cholesterol uptake from the diet and increased cholesterol efflux from macrophages. In parallel such a compound should lack the hyperlipidemic potential which is exerted through increased fatty acid and triglyceride synthesis.

**[0009]** To date only few compounds have been described which bind the LXR receptor and thus show utility for treating diseases or conditions which are due to or influenced by said nuclear receptor (Collins, et al., J Med Chem. (2002) 45(10):1963-6; Schultz, et al., Genes Dev (2000) 14(22):2831-8; Sparrow, et al., J Biol Chem (2002) 277(12): 10021-7). No non-steroidal compounds have so far been described which show selectivity regarding the induction of ABC transporter genes without simultaneous induction of lipogenic genes like FAS and SREBP-1c (Kaneko et al. (2003) J Biol Chem (epub July 7)).

**[0010]** It is thus an object of the invention to provide for compounds which by means of binding the LXR receptor act as partial agonists of said receptor with a selective property regarding the upregulation of genes like the ABC transporters in macrophages and/or other cell types and a strongly reduced liability to increase the expression of genes involved in triglyceride synthetic pathways (like FAS and SREBP-1c). These compounds should show utility for treating

diseases or conditions which are due to or influenced by said nuclear receptor.


**[0011]** It is further an object of the invention to provide for compounds that may be used for the manufacture of a medicament for the treatment of cholesterol associated conditions or diseases. It is still a further object of the invention to provide for compounds that lower serum cholesterol and/or increase High Density Lipoproteins (HDL) and/or decrease Low Density Lipoproteins (LDL). It is also an object of the invention to provide for compounds that may be used for the treatment of lipid disorders including hypercholesterolemia, atherosclerosis, Alzheimer's disease, skin disorders, inflammation, obesity and diabetes.

**[0012]** The present invention provides, inter alia, novel LXR nuclear receptor protein binding compounds according to the general formula (I) shown below. Said compounds are also binders of mammalian homologues of said receptor. Further the object of the invention was solved by providing for amongst the LXR nuclear receptor protein binding compounds according to the general formula (I) such compounds which act as partial agonists or mixed agonists / antagonists of the human LXR receptor or a mammalian homologue thereof. Further the object of the invention was solved by providing for amongst the LXR receptor protein binding compounds according to the general formula (I) such compounds which act as partial agonists of the human LXR receptor resulting therefore in the induction of ABC transporter proteins such as ABCA1 or ABCG1 in cell types such as macrophages but lacking a strong potential to induce genes involved in triglyceride synthetic pathways such as fatty acid synthase (FAS) or SREBP1c.

**[0013]** The invention provides for LXR agonists that may be used for the manufacture of a medicament for the treatment of cholesterol associated conditions or diseases. In a preferred embodiment compounds are provided that lower serum cholesterol and/or increase High Density lipoproteins (HDL) and/or decrease Low Density Lipoproteins (LDL). Also compounds are provided that may be used for the treatment of lipid disorders including hypercholesterolemia, atherosclerosis, Alzheimer's disease, skin disorders, inflammation, obesity and diabetes.

**[0014]** The invention provides for a compound of the formula (I), or pharmaceutical acceptable salts or solvates thereof, hereinafter also referred to as the "compounds according to the invention" including particular and preferred embodiments thereof.

### Formula (I)




The compounds of the invention can also exist as solvates and hydrates. Thus, these compounds may crystallize with, for example, waters of hydration, or one, a number of, or any fraction thereof of molecules of the mother liquor solvent. The solvates and hydrates of such compounds are included within the scope of this invention.

**[0015]** In one embodiment of the invention in formula (I) above, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, - independent from each other - H, halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or substituted or unsubstituted phenyl, for example a biphenyl, R<sub>5</sub> is H, C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>3</sub> to C<sub>8</sub> cycloalkyl, C<sub>3</sub> to C<sub>8</sub> substituted cycloalkyl, aryl, substituted aryl, C<sub>1</sub> to C<sub>6</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl

R<sub>6</sub> is H, a secondary or a tertiary amine, C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>3</sub> to C<sub>8</sub> cycloalkyl, C<sub>3</sub> to C<sub>8</sub> substituted cycloalkyl, aryl, substituted aryl, C<sub>1</sub> to C<sub>6</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl

**[0016]** Formula (II) shows another embodiment of the invention wherein

## Formula (II)




(II)

wherein  $R_7$  is  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_3$  to  $C_8$  cycloalkyl,  $C_3$  to  $C_8$  substituted cycloalkyl, aryl, substituted aryl,  $C_1$  to  $C_6$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl

[0017] Another embodiment of the invention is described in formula (III)

## Formula (III)



(III)

$R_1, R_2, R_3, R_4$ , is H, halogen, hydroxy, protected hydroxy, cyano, nitro,  $C_1$  to  $C_6$  alkyl,  $C_1$  to  $C_6$  substituted alkyl,  $C_1$  to  $C_7$  alkoxy,  $C_1$  to  $C_7$  substituted alkoxy,  $C_1$  to  $C_7$  acyl,  $C_1$  to  $C_7$  substituted acyl,  $C_1$  to  $C_7$  acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-( $C_1$  to  $C_6$  alkyl)carboxamide, protected N-( $C_1$  to  $C_6$  alkyl)carboxamide, N, N-di( $C_1$  to  $C_6$  alkyl)carboxamide, trifluoromethyl, N-(( $C_1$  to  $C_6$  alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl,

$R_5$  in formula (III) is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_3$  to  $C_8$  cycloalkyl,  $C_3$  to  $C_8$  substituted cycloalkyl, aryl, substituted aryl,  $C_1$  to  $C_6$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl,

$R_8$  in formula (III) is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_3$  to  $C_8$  cycloalkyl,  $C_3$  to  $C_8$  substituted cycloalkyl,  $C_1$  to  $C_7$  acyl,  $C_1$  to  $C_7$  substituted acyl, aryl, substituted aryl,  $C_1$  to  $C_6$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl, carboxamide, protected carboxamide, N-( $C_1$  to  $C_6$  alkyl)carboxamide, protected N-( $C_1$  to  $C_6$  alkyl)carboxamide, N, N-di( $C_1$  to  $C_6$  alkyl)carboxamide, trifluoromethyl, N-(( $C_1$  to  $C_6$  alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl,

$R_9$  in formula (III) is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_3$  to  $C_8$  cycloalkyl,  $C_3$  to  $C_8$  substituted cycloalkyl,  $C_1$  to  $C_7$  acyl,  $C_1$  to  $C_7$  substituted acyl, aryl, substituted aryl,  $C_1$  to  $C_6$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl, carboxamide, protected carboxamide, N-( $C_1$  to  $C_6$  alkyl)carboxamide, protected N-( $C_1$  to  $C_6$  alkyl)carboxamide, N, N-di( $C_1$  to  $C_6$  alkyl)carboxamide, trifluoromethyl, N-(( $C_1$  to  $C_6$  alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, or

$R_8$  and  $R_9$  in formula (III) are taken together with the N in formula (III) to form a ring of the following types:

$C_3$  to  $C_8$  mono, di- or tri- heteroatom-substituted cycloalkyl such as but not limited to piperidino, morpholino, thiomorpholino, piperazino, or  $C_1$  to  $C_6$  alkyl-,  $C_1$  to  $C_6$  substituted alkyl substituted- or benzocondensated

derivatives thereof

C<sub>4</sub> to C<sub>10</sub> mono, di- or tri- heteroatom-substituted bi- or tricycloalkyl or C<sub>1</sub> to C<sub>6</sub> alkyl-, C<sub>1</sub> to C<sub>6</sub> substituted alkyl substituted- or benzocondensated derivatives thereof

C<sub>3</sub> to C<sub>8</sub> mono, di- or tri- heteroatom-substituted heteroaryl such as but not limited to pyrrolo, pyrazolo, oxazolo, thiazolo, pyridino, pyridazino, pyrimidino, pyrazino, triazino, indolo, quinolino, quinazolino or C<sub>1</sub> to C<sub>6</sub> alkyl-, C<sub>1</sub> to C<sub>6</sub> substituted alkyl substituted- or benzocondensated derivatives thereof

**[0018]** In a preferred embodiment of the invention according to formula (III)

R<sub>1</sub> and R<sub>3</sub> are preferably H,

R<sub>2</sub> and R<sub>4</sub> are preferably H, or a halogen such as iodo, bromo, chloro or fluoro or hydroxy methyl, trifluoromethyl, methoxy, amino, alkylated amino, or nitro R<sub>5</sub> is H, C<sub>1</sub> to C<sub>8</sub> alkyl, preferably isopropyl, vinyl, 2-isobutyl, or cyclohexyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>3</sub> to C<sub>8</sub> cycloalkyl, C<sub>3</sub> to C<sub>8</sub> substituted cycloalkyl, aryl, substituted aryl, C<sub>1</sub> to C<sub>6</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl,

R<sub>8</sub> and R<sub>9</sub> in formula (III) are taken together with the N in formula (III) to form a ring of the following types:

C<sub>3</sub> to C<sub>8</sub> mono, di- or tri- heteroatom-substituted cycloalkyl such as but not limited to piperidino, morpholino, thiomorpholino, piperazino, or C<sub>1</sub> to C<sub>6</sub> alkyl-, C<sub>1</sub> to C<sub>6</sub> substituted alkyl substituted- or benzocondensated derivatives thereof, preferably a 4-aryl- or 4-heteroaryl- or 4-alkyl-substituted piperazino or a 4-alkyl-substituted piperidino

C<sub>4</sub> to C<sub>10</sub> mono, di- or tri- heteroatom-substituted bi- or tricycloalkyl or C<sub>1</sub> to C<sub>6</sub> alkyl-, C<sub>1</sub> to C<sub>6</sub> substituted alkyl substituted- or benzocondensated derivatives thereof

C<sub>3</sub> to C<sub>8</sub> mono, di- or tri- heteroatom-substituted heteroaryl such as but not limited to pyrrolo, pyrazolo, oxazolo, thiazolo, pyridino, pyridazino, pyrimidino, pyrazino, triazino, indolo, quinolino, quinazolino or C<sub>1</sub> to C<sub>6</sub> alkyl-, C<sub>1</sub> to C<sub>6</sub> substituted alkyl substituted- or benzocondensated derivatives thereof

**[0019]** In another preferred embodiment of the invention according to formula (III)

R<sub>1</sub> and R<sub>3</sub> are preferably H,

R<sub>2</sub> and R<sub>4</sub> are preferably H, or a halogen such as iodo, bromo, chloro or fluoro or hydroxy methyl, trifluoromethyl, methoxy, amino, alkylated amino, or nitro

R<sub>5</sub> is H, C<sub>1</sub> to C<sub>8</sub> alkyl, preferably isopropyl, vinyl, 2-isobutyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>3</sub> to C<sub>8</sub> cycloalkyl, C<sub>3</sub> to C<sub>8</sub> substituted cycloalkyl, aryl, substituted aryl, C<sub>1</sub> to C<sub>6</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl,

R<sub>8</sub> is a C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>3</sub> to C<sub>8</sub> cycloalkyl, C<sub>3</sub> to C<sub>8</sub> substituted cycloalkyl, C<sub>1</sub> to C<sub>6</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl, preferably benzyl or (furan-2-yl)-methyl or (thiophen-2-yl)-methyl

and R<sub>9</sub> in formula is C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>3</sub> to C<sub>8</sub> cycloalkyl, C<sub>3</sub> to C<sub>8</sub> substituted cycloalkyl, C<sub>1</sub> to C<sub>6</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl, preferably, however, (ethyl)-propion-1-yl

**[0020]** The symbol "H" denotes a hydrogen atom.

**[0021]** The term "C<sub>1</sub> to C<sub>7</sub> acyl" encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, benzoyl and the like. Preferred acyl groups are acetyl and benzoyl.

**[0022]** The term "C<sub>1</sub> to C<sub>7</sub> substituted acyl" denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N,N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C<sub>1</sub> to C<sub>4</sub> alkylthio or C<sub>1</sub> to C<sub>4</sub> alkylsulfonyl groups. The substituted acyl groups may be substituted once or more, and pref-

erably once or twice, with the same or with different substituents.

**[0023]** The term "substituted phenyl" specifies a phenyl group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted) amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, wherein the phenyl is substituted or unsubstituted, such that, for example, a biphenyl results.

**[0024]** Examples of the term "substituted phenyl" includes a mono- or di(halo)phenyl group such as 2, 3 or 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2, 3 or 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2, 3 or 4-fluorophenyl and the like; a mono or di(hydroxy)phenyl group such as 2, 3 or 4-hydroxyphenyl, 2,4-dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 2, 3 or 4-nitrophenyl; a cyanophenyl group, for example, 2, 3 or 4-cyanophenyl; a mono- or di(alkyl)phenyl group such as 2, 3 or 4-methylphenyl, 2,4-dimethylphenyl, 2, 3 or 4-(iso-propyl)phenyl, 2, 3 or 4-ethylphenyl, 2, 3 or 4-(n-propyl) phenyl and the like; a mono or di(alkoxy)phenyl group, for example, 2,6-dimethoxyphenyl, 2, 3 or 4-methoxyphenyl, 2, 3 or 4-ethoxyphenyl, 2, 3 or 4-(isopropoxy)phenyl, 2, 3 or 4-(t-butoxy)phenyl, 3-ethoxy-4-methoxyphenyl and the like; 2, 3 or 4-trifluoromethylphenyl; a mono- or dicarboxyphenyl or (protected carboxy)phenyl group such as 2, 3 or 4-carboxyphenyl or 2,4-di(protected carboxy)phenyl; a mono-or di(hydroxymethyl)phenyl or (protected hydroxymethyl) phenyl such as 2, 3, or 4-(protected hydroxymethyl)phenyl or 3,4-di(hydroxymethyl)phenyl; a mono- or di(aminomethyl) phenyl or (protected aminomethyl)phenyl such as 2, 3 or 4-(aminomethyl)phenyl or 2,4-(protected aminomethyl)phenyl; or a mono- or di(N-(methylsulfonylamino))phenyl such as 2, 3 or 4-(N-(methylsulfonylamino))phenyl. Also, the term "substituted phenyl" represents disubstituted phenyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2-hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy 4-chlorophenyl and the like.

**[0025]** The term "heteroaryl" means a heterocyclic aromatic derivative which is a five-membered or six-membered ring system having from 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. Examples of heteroaryls include pyridinyl, pyrimidinyl, and pyrazinyl, pyridazinyl, pyrrolo, furano, thiopheno, oxazolo, isoxazolo, phthalimido, thiazolo and the like.

**[0026]** The term "substituted heteroaryl" means the above-described heteroaryl is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted) amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino or N-(phenylsulfonyl)amino groups.

**[0027]** The term "substituted naphthyl" specifies a naphthyl group substituted with one or more, and preferably one or two, moieties either on the same ring or on different rings chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino or N-(phenylsulfonyl)amino.

**[0028]** Examples of the term "substituted naphthyl" includes a mono or di(halo)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-chloronaphthyl, 2, 6-dichloronaphthyl, 2, 5-dichloronaphthyl, 3, 4-dichloronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-bromonaphthyl, 3, 4-dibromonaphthyl, 3-chloro-4-fluoronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-fluoronaphthyl and the like; a mono or di(hydroxy)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-hydroxynaphthyl, 2, 4-dihydroxynaphthyl, the protected-hydroxy derivatives thereof and the like; a nitronaphthyl group such as 3- or 4-nitronaphthyl; a cyanonaphthyl group, for example, 1, 2, 3, 4, 5, 6, 7 or 8-cyanonaphthyl; a mono- or di(alkyl)naphthyl group such as 2, 3, 4, 5, 6, 7 or 8-methylnaphthyl, 1, 2, 4-dimethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(isopropyl)naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(n-propyl)naphthyl and the like; a mono or di(alkoxy)naphthyl group, for example, 2, 6-dimethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-methoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(isopropoxy)naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(t-butoxy)naphthyl, 3-ethoxy-4-methoxynaphthyl and the like; 1, 2, 3, 4, 5, 6, 7 or 8-trifluoromethylnaphthyl; a mono-or dicarboxynaphthyl or (protected carboxy)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-carboxynaphthyl or 2, 4-di-(protected carboxy)naphthyl; a mono-or di(hydroxymethyl)naphthyl or (protected hydroxymethyl)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(protected hydroxymethyl)naphthyl or 3, 4-di(hydroxymethyl)naphthyl; a mono- or di(amino)naphthyl or (protected amino)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(amino)

naphthyl or 2, 4-(protected amino)-naphthyl, a mono- or di(aminomethyl)naphthyl or (protected aminomethyl)naphthyl such as 2, 3, or 4-(aminomethyl)naphthyl or 2, 4-(protected aminomethyl)-naphthyl; or a mono- or di-(N-methylsulfonylamino) naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(N-methylsulfonylamino)naphthyl. Also, the term "substituted naphthyl" represents disubstituted naphthyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxynaphth-1-yl, 3-chloro-4-hydroxynaphth-2-yl, 2-methoxy-4-bromonaphth-1-yl, 4-ethyl-2-hydroxynaphth-1-yl, 3-hydroxy-4-nitronaphth-2-yl, 2-hydroxy-4-chloronaphth-1-yl, 2-methoxy-7-bromonaphth-1-yl, 4-ethyl-5-hydroxynaphth-2-yl, 3-hydroxy-8-nitronaphth-2-yl, 2-hydroxy-5-chloronaphth-1-yl and the like.

**[0029]** The term "C<sub>1</sub> to C<sub>8</sub> alkyl" denotes such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, amyl, tert-amyl, hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 2-methyl-1-hexyl, 2-methyl-2-hexyl, 2-methyl-3-hexyl, n-octyl and the like.

**[0030]** The term "C<sub>2</sub> to C<sub>6</sub> alkenyl" denotes such radicals as propenyl or butenyl.

**[0031]** Examples of the above substituted alkyl groups include the 2-oxo-prop-1-yl, 3-oxo-but-1-yl, cyanomethyl, nitromethyl, chloromethyl, hydroxymethyl, tetrahydropyranyloxymethyl, trityloxymethyl, propionyloxymethyl, amino, methylamino, aminomethyl, dimethylamino, carboxymethyl, allyloxycarbonylmethyl, allyloxycarbonylamino, methoxymethyl, ethoxymethyl, t-butoxymethyl, acetoxymethyl, chloromethyl, bromomethyl, iodomethyl, trifluoromethyl, 6-hydroxyhexyl, 2,4-dichloro(n-butyl), 2-aminopropyl, 1-chloroethyl, 2-chloroethyl, 1-bromoethyl, 2-chloroethyl, 1-fluoroethyl, 2-fluoroethyl, 1-iodoethyl, 2-iodoethyl, 1-chloropropyl, 2-chloropropyl, 3-chloropropyl, 1-bromopropyl, 2-bromopropyl, 3-bromopropyl, 1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 1-iodopropyl, 2-iodopropyl, 3-iodopropyl, 2-aminoethyl, 1-aminoethyl, N-benzoyl-2-aminoethyl, N-acetyl-2-aminoethyl, N-benzoyl-1-aminoethyl, N-acetyl-1-aminoethyl and the like.

**[0032]** The term "C<sub>1</sub> to C<sub>8</sub> substituted alkyl" denotes that the above C<sub>1</sub> to C<sub>8</sub> alkyl groups are substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, C<sub>3</sub> to C<sub>7</sub> cycloalkyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N,N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C<sub>1</sub> to C<sub>4</sub> alkylthio or C<sub>1</sub> to C<sub>4</sub> alkylsulfonyl groups. The substituted alkyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

**[0033]** The term "C<sub>7</sub> to C<sub>12</sub> phenylalkyl" denotes a C<sub>1</sub> to C<sub>6</sub> alkyl group substituted at any position by a phenyl, substituted phenyl, heteroaryl or substituted heteroaryl. Examples of such a group include benzyl, 2-phenylethyl, 3-phenyl(n-propyl), 4-phenylhexyl, 3-phenyl(n-amyl), 3-phenyl(sec-butyl) and the like. Preferred C<sub>7</sub> to C<sub>12</sub> phenylalkyl groups are the benzyl and the phenylethyl groups.

The term "C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl" denotes a C<sub>7</sub> to C<sub>12</sub> phenylalkyl group substituted on the C<sub>1</sub> to C<sub>6</sub> alkyl portion with one or more, and preferably one or two, groups chosen from halogen, hydroxy, protected hydroxy, oxo, protected oxo, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-(C<sub>1</sub> to C<sub>6</sub> dialkyl)carboxamide, cyano, N-(C<sub>1</sub> to C<sub>6</sub> alkylsulfonyl)amino, thiol, C<sub>1</sub> to C<sub>4</sub> alkylthio, C<sub>1</sub> to C<sub>4</sub> alkylsulfonyl groups; and/or the phenyl group may be substituted with one or more, and preferably one or two, substituents chosen from halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl) carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl) carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, cyclic C<sub>2</sub> to C<sub>7</sub> alkylene or a phenyl group, substituted or unsubstituted, for a resulting biphenyl group. The substituted alkyl or phenyl groups may be substituted with one or more, and preferably one or two, substituents which can be the same or different.

**[0034]** Examples of the term "C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl" include groups such as 2-phenyl-1-chloroethyl, 2-(4-methoxyphenyl)ethyl, 4-(2,6-dihydroxy phenyl)n-hexyl, 2-(5-cyano-3-methoxyphenyl)n-pentyl, 3-(2,6-dimethylphenyl)n-propyl, 4-chloro-3-aminobenzyl, 6-(4-methoxyphenyl)-3-carboxy(n-hexyl), 5-(4-aminomethylphenyl)-3-(aminomethyl)n-pentyl, 5-phenyl-3-oxo-n-pent-1-yl and the like.

**[0035]** The term "heterocycle" or "heterocyclic ring" denotes optionally substituted five-membered to eight-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. These five-membered to eight-membered rings may be saturated, fully unsaturated or partially unsaturated, with fully saturated rings being preferred. Preferred heterocyclic rings include morpholino, piperidinyl, piperazinyl, 2-amino-imidazolyl, tetrahydrofurano, pyrrolo, tetrahydrothiophen-yl, hexylmethyl-

eneimino and heptylmethyleneimino.

**[0036]** The term "substituted heterocycle" or "substituted heterocyclic ring" means the above-described heterocyclic ring is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>12</sub> alkyl, C<sub>1</sub> to C<sub>12</sub> alkoxy, C<sub>1</sub> to C<sub>12</sub> substituted alkoxy, C<sub>1</sub> to C<sub>12</sub> acyl, C<sub>1</sub> to C<sub>12</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>12</sub> alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, heterocycle or substituted heterocycle groups.

**[0037]** The term "C<sub>1</sub> to C<sub>8</sub> alkoxy" as used herein denotes groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy and like groups. A preferred alkoxy is methoxy. The term "C<sub>1</sub> to C<sub>8</sub> substituted alkoxy" means the alkyl portion of the alkoxy can be substituted in the same manner as in relation to C<sub>1</sub> to C<sub>8</sub> substituted alkyl.

**[0038]** The term "C<sub>1</sub> to C<sub>8</sub> aminoacyl" encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, octanoyl, benzoyl and the like.

**[0039]** The term "C<sub>1</sub> to C<sub>8</sub> substituted aminoacyl" denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C<sub>1</sub> to C<sub>12</sub> alkoxy, C<sub>1</sub> to C<sub>12</sub> acyl, C<sub>1</sub> to C<sub>12</sub> acyloxy, nitro, C<sub>1</sub> to C<sub>12</sub> alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, N,N-di(C<sub>1</sub> to C<sub>12</sub> alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C<sub>1</sub> to C<sub>10</sub> alkylthio or C<sub>1</sub> to C<sub>10</sub> alkylsulfonyl groups. The substituted acyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

**[0040]** Examples of C<sub>1</sub> to C<sub>8</sub> substituted acyl groups include 4-phenylbutyryl, 3-phenylbutyryl, 3-phenylpropanoyl, 2-cyclohexanylacetyl, cyclohexanecarbonyl, 2-furanoyl and 3-dimethylaminobenzoyl.

**[0041]** This invention also provides a pharmaceutical composition comprising an effective amount of a compound according to the invention. Such pharmaceutical compositions can be administered by various routes, for example oral, subcutaneous, intramuscular, intravenous or intracerebral. The preferred route of administration would be oral at daily doses of the compound for adult human treatment of about 0.01-5000 mg, preferably 1-1500 mg per day. The appropriate dose may be administered in a single dose or as divided doses presented at appropriate intervals for example as two, three four or more subdoses per day.

**[0042]** For preparing pharmaceutical compositions containing compounds of the invention, inert, pharmaceutically acceptable carriers are used. The pharmaceutical carrier can be either solid or liquid. Solid form preparations include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories.

**[0043]** A solid carrier can be one or more substances which can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.

**[0044]** In powders, the carrier is generally a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active compound is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

**[0045]** For preparing pharmaceutical composition in the form of suppositories, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient-sized molds and allowed to cool and solidify.

**[0046]** Powders and tablets preferably contain between about 5% to about 70% by weight of the active ingredient, preferably comprising (especially consisting of) one or more of the compounds according to this invention. Suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter and the like.

**[0047]** The pharmaceutical compositions can include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier, which is thus in association with it. In a similar manner, cachets are also included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

**[0048]** Liquid pharmaceutical compositions include, for example, solutions suitable for oral or parenteral administration, or suspensions, and emulsions suitable for oral administration. Sterile water solutions of the active component or sterile solutions of the active component in solvents comprising water, ethanol, or propylene glycol are examples of liquid compositions suitable for parenteral administration.

**[0049]** Sterile solutions can be prepared by dissolving the active component in the desired solvent system, and then passing the resulting solution through a membrane filter to sterilize it or, alternatively, by dissolving the sterile compound in a previously sterilized solvent under sterile conditions.


**[0050]** In a preferred embodiment of the invention in the compounds claimed, or the pharmaceutical acceptable salts or solvates thereof, R<sub>1</sub>, R<sub>3</sub> and R<sub>4</sub> are H, R<sub>2</sub> is halogen and preferably iodine over bromine and chlorine and R<sub>5</sub> is H,



C<sub>1</sub> to C<sub>8</sub> alkyl or C<sub>1</sub> to C<sub>8</sub> substituted alkyl.


**[0051]** For the six preferred compounds as shown in formulae (XIII), (XII), (X), (IX), (VII), and (IV) below it was demonstrated that these compounds may act as a full or partial agonist of LXR

Formula (XIII); MOLNAME LN7181




(XIII)

Formula (XII); MOLNAME LN7179




(XII)

Formula (X); MOLNAME LN7172




(X)

Formula (IX); MOLNAME LN6672




(IX)

Formula (VII); MOLNAME LN7031



(VII)


Formula (IV); MOLNAME LN7033



(IV)


[0052] It has also been found that the compound according to formula (IV) (MOLNAME LN7033) to be active as partial agonist of the LXR human nuclear receptors with a selective upregulation of the target genes ABCA1 and ABCG1 in THP-1 cells compared to FAS and SREBP-1c in HepG2 cells (see also Fig. 8A and 8B).

[0053] Furthermore, the present invention includes compounds of the following formula:  
Formula (V), MOLNAME LN7025




(V)

Formula (VI), MOLNAME LN7184




(VI)

Formula (VIII); MOLNAME LN7032



(VIII)

Formula (XI); MOLNAME LN7174



(XI)

**[0054]** In particular the invention relates to a compound as described above wherein said compounds is capable of binding the LXR receptor protein or a portion thereof encoded by a nucleic acid according to SEQ ID NO:1 or NO:2 (Fig. 3) or a mammalian homologue thereof. This compound can bind to the LXR receptor protein or a portion thereof in a mixture comprising 10-200 ng of LXR receptor protein, a fusion protein containing LXR or a portion thereof, preferably the ligand binding domain, fused to a Tag, 5-100 mM Tris/HCl at pH 6,8-8,3; 60-1000 mM KCl; 0-20 mM MgCl<sub>2</sub>; 100-1000ng/μl BSA in a total volume of preferably about 25 μl).

**[0055]** A mammalian receptor protein homologue of the protein encoded by a nucleic acid according to SEQ ID NO: 1 or 2, as used herein is a protein that performs substantially the same task as LXR does in humans and shares at least 40% sequence identity at the amino acid level, preferably over 50 % sequence identity at the amino acid level more preferably over 65 % sequence identity at the amino acid level, even more preferably over 75 % sequence identity at the amino acid level and most preferably over 85 % sequence identity at the amino acid level.

**[0056]** The invention in particular concerns a method for prevention or treatment of a LXR receptor protein or LXR receptor protein homologue mediated disease or condition in a mammal comprising administration of a therapeutically effective amount of a compound according to the invention wherein the prevention or treatment is directly or indirectly accomplished through the binding of a compound according to the invention to the LXR receptor protein or to the LXR receptor protein homologue.

**[0057]** The term mediated herein means that the physiological pathway in which the LXR receptor protein acts is either directly or indirectly involved in the disease or condition to be treated or prevented. In the case where it is indirectly involved it could be that, e.g. modulating the activity of LXR by a compound according to the invention influences a parameter which has a beneficial effect on a disease or a condition. One such example is that modulation of LXR activity leads to decreased levels of serum cholesterol or certain lipoproteins which in turn have a beneficial effect on the prevention and treatment of atherosclerosis. Herein a condition is a physiological or phenotypic state which is desirably altered. One such example would be obesity which is not necessarily medically harmful but nonetheless a non desirable phenotypic condition. In a preferred embodiment of the invention the method for prevention or treatment of a LXR receptor protein mediated disease or condition is applied to a human. This may be male or female.

[0058] Pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific condition or conditions. Initial dosing in human is accompanied by clinical monitoring of symptoms, such symptoms for the selected condition. In general, the compositions are administered in an amount of active agent of at least about 100 µg/kg body weight. In most cases they will be administered in one or more doses in an amount not in excess of about 20 mg/kg body weight per day. Preferably, in most cases, doses is from about 100 µg/kg to about 5 mg/kg body weight, daily.

[0059] For administration particularly to mammals, and particularly humans, it is expected that the daily dosage level of active agent will be 0,1 mg/kg to 10 mg/kg and typically around 1 mg/kg.

[0060] By "therapeutically effective amount" is meant a symptom-alleviating or symptom-reducing amount, a cholesterol-reducing amount, a cholesterol absorption blocking amount, a protein and/or carbohydrate digestion-blocking amount and/or a de novo cholesterol biosynthesis-blocking amount of a compound according to the invention.

[0061] Likewise the invention concerns a method of treating in mammal a disease which is correlated with abnormal cholesterol, triglyceride, or bile acid levels or deposits comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to the invention.

[0062] Accordingly, the compounds according to the invention may also be used in a method of prevention or treatment of mammalian atherosclerosis, gallstone disease, lipid disorders, Alzheimer's disease, skin disorders, inflammation, obesity or cardiovascular disorders such as coronary heart disease or stroke.

[0063] The invention further concerns a method of blocking in a mammal the cholesterol absorption in the intestine in need of such blocking comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to the invention. The invention may also be used to treat obesity in humans.

[0064] The Liver X Receptor alpha is a prototypical type 2 nuclear receptor meaning that it activates genes upon binding to the promoter region of target genes in a heterodimeric fashion with Retinoid X Receptor. The relevant physiological ligands of LXR are oxysterols. The compounds have been demonstrated to have a high binding efficacy (binding coefficients measured as EC50 in the range of 1-5 µM) as well as agonistic and/or partial agonistic properties. Consequently they may be applied to regulate genes that participate in bile acid, cholesterol and fatty acid homeostasis as well as other downstream regulated genes. Examples of such genes are but are not limited to lipid absorption, cholesterol biosynthesis, cholesterol transport or binding, bile acid transport or binding, proteolysis, amino acid metabolism, glucose biosynthesis, protein translation, electron transport, and hepatic fatty acid metabolism. LXR often functions in vivo as a heterodimer with the Retinoid X Receptor. Published non-steroidal LXR agonists such as the "Tularik" compound "T0901317" (see figure 5) are known to influence the regulation of various liver genes. Genes found to be regulated by T0901317 can be found in figure 6. Thus, the invention also concerns a method of modulating a gene whose expression is regulated by the LXR receptor in a mammal comprising administration of a therapeutically effective amount of a compound according to the invention to said mammal.

[0065] A number of direct and indirect LXR target genes have been described whose regulated expression contributes to cholesterol homeostasis and lipogenesis. In this respect the direct regulation of Cyp7A, which was shown to be a direct target gene of LXR at least in the rodent lineage is an important aspect of cholesterol removal by increased metabolism of bile acids (Lehmann et al., J Biol.Chem. 272 (6) 3137-3140; 1007). Gupta et al. (Biochem. Biophys. Res. Com, 293; 338-343, 2002) showed that LXR α regulation of Cyp7A is dominant over FXR inhibitory effects on Cyp7A transcription.

[0066] A key transcription factor that was also shown to be a direct target gene for the LXR receptor is SREBP-1 C (Repa et al., Genes and Development, 14:2819-2830; 2000; Yoshikawa et al.; Mol.Cell.Biol.21 (9) 2991-3000, 2001). SREBP-1 C itself activates transcription of genes involved in cholesterol and fatty acid synthesis in liver but also other mammalian tissues. Some of the SREBP1c target genes involved in lipogenesis like FAS and SCD have shown to be additionally direct targets of the LXR receptors (Joseph et al.; J Biol Chem. 2002 Mar 29;277(13):11019-25; Liang et al., J Biol Chem. 2002 Mar 15;277(11):9520-8.).

[0067] A primary limitation for the applicability of LXR agonists as e.g. anti-atherosclerotic drugs comes from the observation that compounds with full agonistic activity, e.g. T0901317, not only elevate HDL cholesterol levels but do also increase plasma triglyceride levels in mice (Schultz et al., 2000 Genes Dev. 14:2831-8.). Concomitantly, not only genes that are involved in cholesterol efflux such as the cholesterol transporter ABCA1 (Venkateswaran et al., 2000 PNAS. 97:12097-102.), ABCG1 as well as the lipid binding protein Apolipoprotein E (Laffite et al. 2001 PNAS 98: 507-512) are induced by full LXR agonists, but also genes involved in lipogenesis, including the fatty acid synthase FAS (Joseph et al 2002 J Biol Chem. 277:11019-11025), and SREB P-1c (Yoshikawa et al., 2001 Mol Cell Biol. 21: 2991-3000). Elevation of serum triglyceride levels is an independent risk factor for atherosclerosis (for review see Miller, 1999). Thus, LXR activity needs to be selectively modulated for therapeutic benefit. In particular, compounds need to be found that stimulate reverse cholesterol transport, but do not significantly increase triglyceride levels.

[0068] Another gene that has been shown to be directly regulated by LXRs is the LPL gene, that codes for a key enzyme that is responsible for the hydrolysis of triglycerides in circulating lipoprotein, releasing free fatty acids to peripheral tissues. (Zhang et al. J Biol Chem. 2001 Nov 16;276(46):43018-24.) This enzyme is believed to promote

uptake of HDL cholesterol in liver, thereby promoting reverse cholesterol transport. A similar functional involvement in HDL clearance is described for the CETP gene product that facilitated the transfer of HDL cholesterol esters from plasma to the liver. LXR response elements were found in the CETP promoter and direct activation of this gene by LXR was demonstrated (Luo and Tall; J Clin Invest. 2000 Feb;105(4):513-20.).

**[0069]** The regulated transport of cholesterol through biological membranes is an important mechanism in order to maintain cholesterol homeostasis. A pivotal role in these processes in multiple tissues like e.g. macrophages and intestinal mucosa cells is maintained by the ATP-binding cassette transporter proteins (ABC). ABCA1 and ABCG1 were identified as direct LXR target genes (Costet et al.; J Biol Chem. 2000 Sep 8;275(36):28240-5) that mediate cholesterol efflux and prevent thereby e.g. generation of atherogenic plaques in macrophages (Singaraja et al. J Clin Invest. 2002 Jul;110(1):35-42). Other ABC transporters like ABCG5 and ABCG8, primarily expressed in hepatocytes and enterocytes have also been reported to be directly responsive to LXR agonists (Repa et al., J Biol Chem. 2002 May 24;277(21):18793-800. Kennedy et al., J Biol Chem. 2001 Oct 19;276(42):39438-47) and mediate the secretion of sterols from the liver and efflux of dietary sterols from the gut. Apolipoproteins E, C-I, C-II, and C-IV, that fulfill important roles in lipoprotein/lipid homeostasis have also been shown to be direct targets of the LXR receptor (Laffitte et al., Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):507-12; Mak et al.; J Biol Chem. 2002 May 24 [epub ahead of print]). These proteins have been found to be crucial components of chylomicrons, VLDL, IDL, and HDL and are among other things associated with hypertriglyceridemia and arteriosclerosis.

**[0070]** Recently the LXR $\alpha$  itself was shown to be regulated by both LXR receptors in human cell types including macrophages suggesting an autoregulatory amplification event in the response to LXR ligands which could e.g. lead to an enhanced stimulation of LXR target genes like e.g. ABCA1 (Bolten et al.; Mol Endocrinol. 2002 Mar;16(3):506-14.; Laffitte et al., Mol Cell Biol. 2001 Nov;21 (22):7558-68; Whitney et al.; J Biol Chem. 2001 Nov 23;276(47):43509-15).

**[0071]** Besides the important function of LXR receptors in tissues like liver and macrophages it has recently been reported that that stimulation of epidermal differentiation is mediated by Liver X receptors in murine epidermis. Differentiation marker genes like involucrin, loricin and profilaggrin have been shown to be upregulated upon LXR ligand treatment (Kömüves et al.; J Invest Dermatol. 2002 Jan;118(1):25-34.).

**[0072]** Another recent report describes the regulation of cholesterol homeostasis (primarily the regulation of ABCA1, ABCG1 and SREBP-1C) by the LXR receptors in the central nervous system suggesting that LXRs may prove beneficial in the treatment of CNS diseases such as Alzheimer's and Niemann-Pick disease that are known to be accompanied by dysregulation of cholesterol balance (Whitney et al.; Mol Endocrinol. 2002 Jun;16(6):1378-85).

**[0073]** Activation of LXR by an agonist improves glucose tolerance in a murine model of diet-induced obesity and insulin resistance. Gene expression analysis in LXR agonist-treated mice reveals coordinate regulation of genes involved in glucose metabolism in liver and adipose tissue, e.g. the down-regulation of peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1), phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase expression and induction of glucokinase in liver. In adipose tissue, activation of LXR led to the transcriptional induction of the insulin-sensitive glucose transporter, GLUT4. LXR agonist may limit hepatic glucose output and improve peripheral glucose uptake (Laffitte et al. (2003) PNAS 100:5419-24).

**[0074]** Therefore one other important embodiment of the invention concerns methods that enhances or suppresses amongst other today yet unknown LXR target genes the above mentioned genes and the associated biological processes and pathways through LXR compounds that are subject of this invention.

**[0075]** The compounds according to the invention may be used as medicaments, in particular for the manufacture of a medicament for the prevention or treatment of a LXR receptor protein or LXR receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according to the invention to the LXR receptor protein or LXR receptor protein homologue. These pharmaceutical compositions contain 0,1 % to 99,5 % of the compound according to the invention, more particularly 0,5 % to 90 % of the compound according to the invention in combination with a pharmaceutically acceptable carrier.

**[0076]** The invention concerns also the use of a compound according to the invention for the manufacture of a medicament for the prevention or treatment of a LXR receptor protein mediated disease or condition wherein the mammal described above is a human. The medicament may be used for regulating the cholesterol transport system, for regulating levels of cholesterol, triglyceride, and/or bile acid in a mammal preferentially a human by activating the LXR receptor. The medicament may be used for the treatment of atherosclerosis, gallstone disease, lipid disorders, Alzheimer's disease, skin disorders, obesity or a cardiovascular disorder.

**[0077]** The invention further concerns the use of a compound according to the invention for the manufacture of a medicament capable for blocking in a mammal, preferentially in a human the cholesterol absorption in the intestine. Further the claimed compound may be used for the manufacture of a medicament for treating obesity in humans and for modulating a gene whose expression is regulated by the LXR receptor (see details above and figures).

## EXAMPLES

## EXAMPLE 1

**[0078]** In vitro screening for compounds which influence LXR binding to coactivators.

**[0079]** For screening purposes a GST and 6 x His fusion of the LBD (from amino acids 155 of hLXRalpha to 447) of human LXRalpha is constructed by first cloning a Gateway cassette (Invitrogen) in frame into the Sma I site of the pAGGHLT Polylinker (Pharmingen). Then a PCR fragment specifically amplified from human liver cDNA is cloned into the resulting pACGHLT-GW following the manufacturers instructions for Gateway cloning (Invitrogen) to yield pACGHLT-GW-hLXRalphaLBD.

Primers used for Amplification are:

GGGGACAAGTTTGTACAAAAAAGCAGGCTCGCTTCGCAAATGCCGTCAG

and

GGGGACCACTTTGTACAAGAAAGCTGGGTCCCCTTCTCAGTCTGTTCCACTT .

100 % sequence integrity of all recombinant products is verified by sequencing. Recombinant Baculovirus is constructed from pACGHLT-GW-hLXRalphaLBD using the Pharmingen Baculovirus Expression vector system according to instructions of the manufacturer. Monolayer cultures of SF9 cells are infected by the virus as recommended by Pharmingen or 200ml cultures of  $1 \times 10^6$  cells/ml grown in 2 liter Erlenmeyer flasks on an orbital shaker at 30 rpm are infected by 10ml of same virus stock. In both cases cells are harvested 3 days after infection. All cell growth is performed in Gibco SF900 II with Glutamine (Invitrogen) medium without serum supplementation at 28°C. Since SF9 cells contain significant amounts of endogenous GST, purification is performed via His and not via GST affinity chromatography. To this end instructions of Pharmingen for purification of recombinant His tagged proteins from SF9 cells are followed with the following modifications: All detergents are omitted from the buffers and cells were lysed on ice by 5 subsequent sonication pulses using a sonicator needle at maximum power. All eluates are dialyzed against 20 mM Tris/HCl pH 6,8, 300 mM KCl; 5 mM  $MgCl_2$ ; 1 mM DTT; 0,2 mM PMSF; 10% Glycerol. A typical dialyzed eluate fraction contains the fusion protein at a purity of more than 80%. Total protein concentration is 0,1-0,3 mg/ml.

For E. coli expression of a NR coactivator, pDest17-hTif2BD expressing a NR interaction domain from amino acids 548-878 of human Tif2 (Acc. No: XM\_011633 RefSeq) tagged by 6 N-terminal His residues is constructed. Therefore, a PCR fragment specifically amplified from human liver cDNA is subcloned into pDest 17 (Invitrogen) following the manufacturers instructions for Gateway cloning (Invitrogen). Primers used for Amplification are:

GGGGACAAGTTTGTACAAAAAAGCAGGCTCGTTAGGGTCATCGTTGGCTTCACC

and

GGGGACCACTTTGTACAAGAAAGCTGGGTCTCAAAGTTGCCCTGGTCGTGGGT  
TA

For E. coli expression plasmid DNA is transformed into chemically competent E. coli BL21 (Invitrogen, USA) and cells are grown to an OD600 of 0.4-0.7 before expression was induced by addition of 0,5 mM IPTG according instructions of the manufacturer (Invitrogen). After induction for 8 hours at 30°C cells are harvested by centrifugation for 10 minutes at 5000 x g. Fusion proteins are affinity purified using Ni-NTA Agarose (QIAGEN) according to the instructions of the manufacturer. Recombinant Tif2 construct is dialyzed against 20 mM Tris/HCL pH 7.9; 60 mM KCl; 5 mM  $MgCl_2$ ; 1 mM DTT, 0,2 mM PMSF; 10% glycerol. A typical dialyzed eluate fraction contains the fusion protein at a purity of more than 80%. Total protein concentration is 0,1-0,3 mg/ml.

The TIF2 fragment is subsequently biotinylated by addition of 5-40µl/ml Tif2 fraction of a Biotinamidocaproate N-Hydroxysuccinimide-ester (Sigma) solution (20 mg/ml in DMSO). Overhead rotating samples are incubated for 2 hours at room temperature. Unincorporated label is then separated using G25 Gel filtration chromatography (Pharmacia Biotech, Sweden). Protein containing fractions from the column are pooled and tested for activity in the assay as

described below.

**[0080]** For screening of compound libraries as provided for by the methods shown below in the examples for substances which influence the LXR/Tif 2 interaction, the Perkin Elmer LANCE technology is applied. This method relies on the binding dependent energy transfer from a donor to an acceptor fluorophore attached to the binding partners of interest. For ease of handling and reduction of background from compound fluorescence LANCE technology makes use of generic fluorophore labels and time resolved detection (for detailed description see Hemmilä I, Blomberg K and Hurskainen P, Time-resolved resonance energy transfer (TR-FRET) principle in LANCE, Abstract of Papers Presented at the 3<sup>rd</sup> Annual Conference of the Society for Biomolecular Screening, Sep., California (1997))

For screening, 20-200 ng of biotinylated Tif 2 fragment and 10-200 ng of GST-LXR fragment are combined with 0.5-2 nM LANCE Eu-(W1024) labelled anti-GST antibody (Perkin Elmer) and 0.1-0.5 µg of highly fluorescent APC-labelled streptavidin (Perkin Elmer, AD0059) in the presence of 50 µM of individual compounds to be screened in a total volume of 25 µl of 20 mM Tris /HCl pH 6.8; 300 mM KCl; 5 mM MgCl<sub>2</sub>; 100-1000 ng/µl/ BSA DMSO content of the samples is kept below 4%. Samples are incubated for a minimum of 60 minutes in the dark at room temperature in FIA-Plates black 384well med. binding (Greiner).

**[0081]** The LANCE signal is detected by a Perkin Elmer VICTOR2V™ Multilabel Counter applying the detection parameters listed in Fig. 2. The results are visualized by plotting the ratio between the emitted light at 665 nm and at 615 nm. For every batch of recombinant proteins amount of proteins, including BSA and labeling reagents giving the most sensitive detection of hits is determined individually by analysis of dose response curves for 22R Hydroxycholesterol and TO 901317

## EXAMPLE 2

**[0082]** Experimental procedure for the preparation of the compounds according to the invention.

### *o*-AZIDOBENZOIC ACID SYNTHESIS (2)

**[0083]** The anthranilic acid (1, 1 eq., 0.5-1 M) is suspended in 6 M HCl, containing enough AcOH (0-20% dependent upon the anthranilic acid) to facilitate dissolution of the anthranilic acid and/or the intermediate diazonium salt, and cooled to 0 °C. NaNO<sub>2</sub> (1.1 eq., 1.3-2.5 M) dissolved in H<sub>2</sub>O is added to the anthranilic acid solution at a rate such that the temperature of the reaction solution remains below 5 °C. The resulting homogeneous solution of the diazonium salt is slowly filtered through a sintered glass funnel into a solution of NaN<sub>3</sub> (1.1 eq., 0.7-1.1 M) and NaOAc (12 eq.) in H<sub>2</sub>O. The reaction mixture is stirred/shaken for 30-60 min following cessation of vigorous N<sub>2</sub> evolution. Following acidification of the reaction mixture to pH 1 with concentrated HCl, the mixture was cooled to 0 °C to encourage complete precipitation of the *o*-azidobenzoic acid. The precipitate is collected by filtration and washed with 6 M HCl (2x) and H<sub>2</sub>O (2x). The *o*-azidobenzoic acid product (2) is dried *in vacuo* (500 mtorr, 30°C).

### ACYLATION OF HYDROXYMETHYL RESIN (4)

**[0084]** To hydroxymethyl resin (1.0 eq., 1.3 mmol/g) and the *o*-azidobenzoic acid (1, 2.5 eq.) is added DMF (to give 400 mM *o*-azidobenzoic acid, 1), CsCO<sub>3</sub> (2.0 eq.) and KI (2.0 eq.). Following agitation of the reaction mixture for 36-48 h, the resin-bound *o*-azidobenzoic acid (4) is washed with MeOH (2 cycles), CH<sub>2</sub>Cl<sub>2</sub> (3 cycles), MeOH (3 cycles), DMF (3 cycles), MeOH (3 cycles) and CH<sub>2</sub>Cl<sub>2</sub> (3 cycles), and dried *in vacuo*.

### AZA-WITTIG FORMATION (5)

**[0085]** To the resin-bound *o*-azidobenzoic acid (4, 1.0 eq.) is added a solution of PPh<sub>3</sub> (THF, 500 mM, 5.0 eq.). After 6 h, the resin is washed with 3 cycles of the following: THF (3 cycles), toluene (3 cycles), CH<sub>2</sub>Cl<sub>2</sub> (3 cycles) and hexanes (3 cycles). Followed by drying *in vacuo* to afford resin bound iminophosphorane (5)

### CARBODIIMIDE FORMATION (6)

**[0086]** To the resin-bound iminophosphorane (5, 1 eq.) is added isocyanate (9, 5 eq., 450 mM) dissolved in ClCH<sub>2</sub>CH<sub>2</sub>Cl. The compounds are shaken at ambient temperature for 16 h, washed with 3 cycles of the following: THF (3 cycles), toluene (3 cycles), CH<sub>2</sub>Cl<sub>2</sub> (3 cycles) and hexanes (3 cycles), and dried *in vacuo* to afford carbodiimide (6).

### GUANIDINE FORMATION / CYCLIZATION

**[0087]** To the carbodiimide functionalized resin (6) is added secondary amine (10, 0.6 eq., 500 mM) dissolved in



$\text{ClCH}_2\text{CH}_2\text{Cl}$ . The reaction mixture is heated to 50 °C in an incubator for 12-72 h to afford 2-aminoquinazoline (8).

**[0088]** All of the final products are analyzed using an Evaporative Light Scattering Detector (ELSD) detection to determine purity.

#### EXAMPLE 3

**[0089]** This example illustrates that compounds according to the invention (experiments shown were done with MOL-STRUCTURE LN0000007033 (see formulas (9)) activate luciferase reporter gene expression in a dose dependent manner mediated through GAL4-LXR $\alpha$ -LBD or GAL4-LXR $\beta$ -LBD constructs in HEK293 cells. LN0000007033 does

activate LXR beta LBD mediated luciferase activity much stronger than with LXR alpha construct which is in contrast to the similar activation of both LXR alpha and LXR beta LBD containing constructs with T0901317 (see Fig. 7). **[0090]** HEK293 cells are grown in 96 well plates and co-transfected with pFR-luc (Stratagene) and pCMV-BD-LXR $\alpha$ -LBD or pCMV-BD-LXR $\beta$ -LBD (each 100 ng of plasmid DNA per well). Transfection is carried using Lip-

fectamine 2000 (Gibco-BRL) according to the manufacturers protocol. The ligand binding domains (LBD) of LXR $\alpha$  and LXR $\beta$  are cloned into the pCMV-BD-GW (the Gateway Reading Frame Cassette B is cloned as an EcoRV fragment into SmaI site of pCMV-BD) applying the manufacturer protocols for the Gateway™ system (Invitrogen). Luciferase reporter activity is measured in triplicates from extracts of cells after incubating cells in culture medium (DMEM [Gibco-BRL] + 10% FCS [PAA laboratories]) for 16 hours (5% CO<sub>2</sub>, 37°C) containing 0,5% DMSO (control) or

0,5% DMSO with increasing concentrations of LN0000007033. The type of assay used here is a mammalian one hybrid (M1H) assay that is known to those skilled in the art. **[0091]** Dose-dependent luciferase activities originating from pFR-luc demonstrate the relative activities of the compounds with the LXR $\alpha$  or LXR $\beta$  LBDs in this mammalian one hybrid type approach.

#### EXAMPLE 4

**[0092]** This example shows that described compounds can increase the abundance of mRNA of LXR target genes like ABCA1 and ABCG1 in THP-1 cells which are treated with TPA or FAS and SREBP-1c in HepG2 cells as shown in Fig 8A and Fig. 8B.

**[0093]** THP-1 cells are seeded in 24 well plates at 3 x10<sup>5</sup> cells per well in RPMI 1640 medium containing 10 % FCS and 100 nM TPA for 24 h. HepG2 cells are seeded in poly-L-Lysine coated 24well plates at 1x10<sup>6</sup> cells per well in EMEM medium containing 10 % FCS until they are appr. 60% confluent.

Before treatment with LXR compounds, the growth medium is changed to medium containing 10% charcoal/dextran-stripped FCS for 12 h. Treatment is done for 12h (THP-1 cells) and 24h (HepG2 cells), respectively, in medium containing 10% charcoal/dextran-stripped FCS (and 100 nM PMA in the case of THP-1 cells).

LXR compounds are dissolved in DMSO, with the final solvent concentration never exceeding 0.125%. All treatments are done in triplicates and experiments repeated twice. Total RNA is extracted using the Qiagen Rneasy Mini Kit and treated with DNase (DNAfree kit, Ambion). RNA is reverse transcribed with Oligo(dT) primer and real-time reverse transcription PCR (TaqMan) is performed using the ABI Prism 7900HT Sequence Detection System and reagents supplied by Applied Biosystems. mRNA steady state levels are normalised to H3 histone (H3F3A) expression levels. The sequences of forward primers, reverse primers and TaqMan probes are as follows :

**FAS : CTGAGACGGAGGCCATATGCT, GCTGCCACACGCTCCTCTAG, FAM-  
CAGCAGTTCACGGACATGGAGCACAA-TAMRA**

**ABCA1 :TCCTGTGGTGTTTCTGGATGAAC, CTTGACAACACTTAGGGCACAATTC,  
FAM- ACCACAGGCATGGATCCCAAAGCC-TAMRA**

#### EXAMPLE 5

**[0094]** LN0000007033 causes a marked increase in cholesterol export in differentiated THP-1 macrophages (see Figure 9 A).

Strikingly, the compound T0901317 causes a marked increase in triglyceride mass in HepG2 liver cells, while compounds like LN0000007033 and LN0000007025 do not cause a significant increase in triglyceride mass.

This behavior is similar to the selective transcriptional effect of compounds like LN0000007033 and LN0000007025

on the LXR target genes in HepG2 versus THP-1 cells (see Fig 8A and 8B).

**[0095]** Methods: Cultures of the monocyte-macrophage cell line and the hepatocytes HepG2 are obtained from the American Type tissue Culture Collection, Rockville, MD and were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum, 10 mM HEPES, 2 mM Pyruvate, 50  $\mu$ M  $\beta$ -Mercaptoethanol (THP-1) and Minimum essential medium (Eagle) with 2 mM L-glutamine and Earle's BSS supplemented with 10% fetal bovine serum, 2 mM glutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate (HepG2), respectively, at 37°C in 5% CO<sub>2</sub>.

THP-1 cells are differentiated into macrophages by addition of 100 nM Phorbol 12-Myristate 13-Acetate (PMA; Sigma P8139) and PMA included in the medium of all subsequent experiments to maintain differentiation.

For cholesterol efflux measurements and triglyceride analysis cells are seeded in 6well plates at 1.8x10<sup>6</sup> cells (THP-1) and 1x10<sup>6</sup> cells (HepG2) per well, respectively.

#### CHOLESTEROL EFFLUX

**[0096]** THP-1 cells are seeded in 6well plates at 1x10<sup>6</sup> cells per well in RPMI 1640 medium containing 10 % FCS and 100 nM TPA for 72 h. After washing with PBS cells are incubated 24 h with fresh in RPMI 1640 medium containing 10 % FCS and 100 nM TPA. Cells are washed twice with PBS and RPMI 1640 medium containing 0.15% BSA and 100 nM TPA is added for further 24 h. Treatment with LXR compounds is done for 24 h in RPMI 1640 medium containing 0.15% BSA, 100 nM TPA and 40  $\mu$ g/ml ApoA1 (Calbiochem # 178452). Medium is collected, centrifuged to remove cell debris and assayed for cholesterol using a commercial fluorometric kit (Molecular Probes A-12216). The remaining cellular proteins are lysed with 0.3 N NaOH and protein content measured with the Biorad Bradford reagent.

#### TRIGLYCERIDE ASSAY

**[0097]** HepG2 cells are seeded in poly-L-Lysine coated 6well plates at 1x10<sup>6</sup> cells per well in EMEM medium containing 10 % FCS until they were appr. 60% confluent. Before treatment with LXR compounds growth medium is changed to medium containing 10% charcoal/dextran-stripped FCS for 12 h. Treatment is done for 24h in medium containing 10% charcoal/dextran-stripped FCS. Cells are washed twice with ice-cold PBS/0.2% BSA and twice with cold PBS and all liquid carefully removed. Triglyceride are extracted with 1.5 ml hexane/ isopropanol = 3:2 per well with gentle shaking for 2-3 h at RT according to Pan et al. (2002) JBC 277, 4413-4421 and Goti et al. (1998) Biochem J, 332, 57-65. The extraction solution is collected, dried under vacuum and redissolved in isopropanol/ 1.5% triton. The remaining cellular proteins are lysed with 0.3 N NaOH and protein content measured with the Biorad Bradford reagent.

Triglyceride levels are measured as esterified glycerol using a commercial enzymatic colorimetric kit (Sigma 343-25P). In a preliminary assay it is checked by omitting the lipase enzyme that contribution of free glycerol is negligible.

#### FIGURE CAPTIONS

##### FIG. 1

**[0098]** Fig. 1 shows the synthesis of the compounds according to the invention as also described in Example 2.

##### FIG. 2

**[0099]** Fig. 2 shows the measurement parameters employed by the Wallace VICTOR2V™ Multilabel Counter which was used for measuring the EC<sub>50</sub> values

##### FIG. 3

**[0100]** Shows a table with the accession numbers for the key genes

##### FIG. 4

**[0101]** Fig. 4 shows the internal molecular name used by the applicant (MOLNAME) as well as the corresponding structures of preferred compounds according to the invention. The figure further shows their respective EC<sub>50</sub> values (EC<sub>50</sub> AVG) as established according to the Example 1 in multiple experiments (see above), as well as their respective average efficacy (% activity relative to TO901317 control agonist).

**FIG. 5**

**[0102]** Figure 5 shows various known LXR ligands. The compound T0901317 is used as a reference compound here. It is apparent from their structures that the inventors have identified novel compounds which are structurally not related to these known ligands.

**FIG. 6**

**[0103]** Figure 6 shows various genes that have been found to be regulated through binding of an LXR agonist to the LXR protein.

**FIG. 7**

**[0104]** Fig 7 shows a dose dependence of LN0000007033 with LXR beta LBD containing constructs in mammalian one hybrid (M1H) type assays. The respective  $\mu\text{M}$  concentrations of the compounds are given on the x-axis and the relative light units (RLU) are depicted on the y-axis.

**Fig. 8 A and B**

**[0105]** Analysis of mRNA content of the indicated genes (LXRalpha, ABCA1, ABCG1, FAS and SREBP-1 c) in total RNA isolated from THP-1 cells (8A, LXRalpha, ABCA1, ABCG1) or HepG2 cells (8B, FAS and SREBP-1 c) treated for 12 or 24 hours with 10  $\mu\text{M}$  on x-axis of T0901317 and LN0000007033. The relative fold induction is depicted on the y-axis and the value depicted with \* for ABCG1 has to be multiplied by a factor of 10.

**Fig. 9**

**[0106]** Analysis of relative fold increase in total cholesterol from supernatants of cultivated THP-1 cells (indicated on the y-axis) incubated with ApoA1 and with or without 10 $\mu\text{M}$  of the compounds T0901317, LN0000007033 and LN0000007025 as indicated on the X-axis of Fig 9A.

Analysis of relative levels of total triglyceride (TG) content in HepG2 cells (indicated on the y-axis) treated with 25 $\mu\text{M}$  of the indicated compounds T0901317, LN0000007033 and LN0000007025 (indicated on the x-axis).

## SEQUENCE LISTING

<110> Phenex Pharmaceuticals AG

<120> Novel selective LXR Nuclear Receptor Binding Compounds with partial agonistic properties

<130> PX62425EP

<160> 22

<170> PatentIn version 3.1

<210> 1

<211> 2010

<212> DNA

<213> Homo sapiens

<400> 1  
caagaagtgg cgaagttacc tttgagggta tttgagtagc ggcggtgtgt caggggctaa 60  
agaggaggac gaagaaaagc agagcaaggg aacccagggc aacaggagta gttcactccg 120  
cgagaggccg tccacgagac cccgcgcgcg aggcattgagc cccgcccccc acgcattgagc 180  
cccgcccccc gctgttgctt ggagaggggc gggacctgga gagaggctgc tccgtgaccc 240  
caccatgtcc tctcctacca cgagttccct ggatacccc ctgcctggaa atggcccccc 300  
tcagcctggc gccccttctt cttcaccac tgtaaaggag gagggtccg agccgtggcc 360  
cggggggtccg gaccctgatg tcccaggcac tgatgaggcc agctcagcct gcagcacaga 420  
ctgggtcatc ccagatcccg aagaggaacc agagcgcaag cgaaagaagg gccagcccc 480  
gaagatgctg ggccacgagc tttgccgtgt ctgtggggac aaggcctccg gcttccacta 540  
caacgtgctc agctgcgaag gctgcaagg cttcttccg cgagtggtg tccgtgggtg 600  
ggccaggcgc tatgcctgcc ggggtggcgg aacctgccag atggacgctt tcatgcggcg 660  
caagtgccag cagtgccggc tgcgcaagt caaggaggca gggatgagg agcagtgct 720  
cctttctgaa gaacagatcc ggaagaagaa gattcggaaa cagcagcagc aggagtcaca 780  
gtcacagtcg cagtcacctg tggggccgca gggcagcagc agctcagcct ctgggcctgg 840  
ggcttccctt ggtggatctg aggcaggcag ccagggtctc ggggaaggcg aggggtgtcca 900  
gctaacagcg gctcaagaac taatgatcca gcagttggtg gcggcccaac tgcagtgcaa 960

EP 1 398 032 A1

	caaacgctcc	ttctccgacc	agcccaaagt	cacgccctgg	cccctgggcg	cagaccccc	1020
	gtcccagat	gcccgccagc	aacgctttgc	ccacttcacg	gagctggcca	tcatctcagt	1080
5	ccaggagatc	gtggacttcg	ctaagcaagt	gcctggtttc	ctgcagctgg	gccgggagga	1140
	ccagatcgcc	ctcctgaagg	catccactat	cgagatcatg	ctgctagaga	cagccaggcg	1200
	ctacaaccac	gagacagagt	gtatcacctt	cttgaaggac	ttcacctaca	gcaaggacga	1260
10	cttccaccgt	gcaggcctgc	aggtggagtt	catcaacccc	atcttcgagt	tctcgcgggc	1320
	catgcgccgg	ctgggcctgg	acgacgctga	gtacgccctg	ctcatcgcca	tcaacatctt	1380
	ctcggccgac	cggcccaacg	tgcaggagcc	gggccgcgtg	gaggcgttgc	agcagcccta	1440
15	cgtggaggcg	ctgctgtcct	acacgcgcat	caagaggccg	caggaccagc	tgcgcttccc	1500
	gcgcatgctc	atgaagctgg	tgagcctgcg	cacgctgagc	tctgtgcact	cggagcaggt	1560
	cttcgccttg	cggctccagg	acaagaagct	gccgcctctg	ctgtcggaga	tctgggacgt	1620
20	ccacgagtga	ggggctggcc	accagcccc	acagccttgc	ctgaccaccc	tccagcagat	1680
	agacgccggc	accccttcct	cttcctaggg	tggaaggggc	cctgggcgag	cctgtagacc	1740
	tatcggtctc	catcccttgg	gataagcccc	agtccaggtc	caggaggctc	cctccctgcc	1800
25	cagcgagtct	tccagaaggg	gtgaaaggg	tgcagggtccc	gaccactgac	ccttcccggc	1860
	tgccctccct	ccccagctta	cacctcaagc	ccagcacgca	gcgtaccttg	aacagagggg	1920
	ggggaggacc	catggctctc	ccccctagc	ccgggagacc	aggggccttc	ctcttcctct	1980
30	gcttttat	aaataaaa	aaaacagaaa				2010
	<210>	2					
	<211>	1528					
35	<212>	DNA					
	<213>	Homo sapiens					
40	<400>	2					
	cagtgccttg	gtaatgacca	gggctccaga	aagagatgtc	cttgtggctg	ggggcccctg	60
	tgcttgacat	tcctcctgac	tctgcggtgg	agctgtggaa	gccaggcgca	caggatgcaa	120
	gcagccaggc	ccagggaggc	agcagctgca	tcctcagaga	ggaagccagg	atgccccact	180
45	ctgctggggg	tactgcaggg	gtggggctgg	aggctgcaga	gcccacagcc	ctgctcacca	240
	gggcagagcc	cccttcagaa	cccacagaga	tccgtccaca	aaagcggaaa	aaggggccag	300
	ccccaaaaat	gctggggaac	gagctatgca	gcgtgtgtgg	ggacaaggcc	tcgggcttcc	360
50	actacaatgt	tctgagctgc	gagggtgca	agggattctt	ccgccgcagc	gtcatcaagg	420
	gagcgcacta	catctgccac	agtggcggcc	actgccccat	ggacacctac	atgcgtcgca	480
	agtgccagga	gtgtcggctt	cgcaaatgcc	gtcaggctgg	catgcgggag	gagtgtgtcc	540
55	tgtcagaaga	acagatccgc	ctgaagaaac	tgaagcggca	agaggaggaa	caggctcatg	600

EP 1 398 032 A1

ccacatcctt gccccccagg cgttcctcac ccccccaaat cctgccccag ctcagcccgg 660  
aacaactggg catgatcgag aagctcgtcg ctgcccagca acagtgtaac cggcgctcct 720  
5 tttctgaccg gcttcgagtc acgccttggc ccatggcacc agatcccat agccgggagg 780  
ccccgtcagca gcgctttgcc cacttcactg agctggccat cgtctctgtg caggagatag 840  
ttgactttgc taaacagcta cccggcttcc tgcagctcag ccgggaggac cagattgccc 900  
10 tgctgaagac ctctgcgacg gaggtgatgc ttctggagac atctcggagg tacaaccctg 960  
ggagtgaagag tatcaccttc ctcaaggatt tcagttataa ccgggaagac tttgccaaag 1020  
cagggtcgca agtgaattc atcaaccca tcttcgagtt ctccagggcc atgaatgagc 1080  
15 tgcaactcaa tgatgccgag tttgccttgc tcattgctat cagcatcttc tctgcagacc 1140  
ggcccaacgt gcaggaccag ctccagggtg agaggctgca gcacacatat gtggaagccc 1200  
tgcatgccta cgtctccatc caccatcccc atgaccgact gatgttcca cggatgctaa 1260  
20 tgaaactggg gagcctccgg accctgagca gcgtccactc agagcaagtg tttgactgac 1320  
gtctgcagga caaaaagctc ccaccgtgc tctctgagat ctgggatgtg cacgaatgac 1380  
tgttctgtcc ccatattttc tgttttcttg gccggatggc tgaggcctgg tggctgcctc 1440  
25 ctagaagtgg aacagactga gaagggcaa cattcctggg agctgggcaa ggagatcctc 1500  
ccgtggcatt aaaagagagt caaagggt 1528

<210> 3  
30 <211> 2877  
<212> DNA  
<213> Homo sapiens

35  
<400> 3  
gtggcatcct tccctttcta atcagagatt ttcttcctca gagatttttg cctagatttg 60  
40 caaaatgatg accacatcct tgatttgggg gattgctata gcagcatgct gttgtctatg 120  
gcttattctt ggaattagga gaaggcaaac ggggtgaacca cctctagaga atggattaat 180  
tccataacctg ggctgtgctc tgcaattttg tgccaatcct cttgagttcc tcagagcaaa 240  
45 tcaaaggaaa catggtcatg tttttacctg caaactaatg ggaaaatatg tccatttcat 300  
cacaaatccc ttgtcatacc ataagggtgt gtgccacgga aaatattttg attggaaaaa 360  
atttcacttt gctacttctg cgaaggcatt tgggcacaga agcattgacc cgatggatgg 420  
50 aaataccact gaaaacataa acgacacttt catcaaaacc ctgcagggcc atgccttgaa 480  
ttccctcacg gaaagcatga tggaaaacct ccaacgtatc atgagacctc cagtctcctc 540  
taactcaaag accgctgcct ggggtgacaga agggatgtat tctttctgct accgagtgat 600  
55 gtttgaagct gggatattta ctatctttgg cagagatctt acaaggcggg acacacagaa 660  
agcacatatt ctaaacaatc ttgacaactt caagcaattc gacaaagtct ttccagccct 720

## EP 1 398 032 A1

	ggtagcaggc	ctccccattc	acatgttcag	gactgcgcac	aatgcccggg	agaaactggc	780
	agagagcttg	aggcacgaga	acctccaaaa	gagggaaagc	atctcagaac	tgatcagcct	840
5	gcgcatgttt	ctcaatgaca	ctttgtccac	ctttgatgat	ctggagaagg	ccaagacaca	900
	cctcgtggtc	ctctgggcat	cgcaagcaaa	caccattcca	gcgactttct	ggagtttatt	960
	tcaaatgatt	aggaaccag	aagcaatgaa	agcagctact	gaagaagtga	aaagaacatt	1020
10	agagaatgct	ggcaaaaag	tcagcttgga	aggcaatcct	atttgtttga	gtcaagcaga	1080
	actgaatgac	ctgccagtat	taaatagtat	aatcaaggaa	tcgctgaggc	tttcagtg	1140
	ctccctcaac	atccggacag	ctaaggagga	tttcactttg	caccttgagg	acggttccta	1200
15	caacatccga	aaagatagca	tcatagctct	ttaccacag	ttaatgcact	tagatccaga	1260
	aatctacca	gaccctttga	cttttaaata	tgataggtat	cttgatgaaa	acgggaagac	1320
	aaagactacc	ttctattgta	atggactcaa	gttaaagtat	tactacatgc	cctttggatc	1380
20	gggagctaca	atatgtcctg	gaagattggt	cgctatccac	gaaatcaagc	aatttttgat	1440
	tctgatgctt	tcttattttg	aattggagct	tatagagggc	caagctaaat	gtccaccttt	1500
	ggaccagtcc	cgggcaggct	tgggcatttt	gccgccattg	aatgatattg	aatttaaata	1560
25	taaattcaag	catttggtgaa	tacatggctg	gaataagagg	acactagatg	atattacagg	1620
	actgcagaac	acctcacca	cacagtcctt	ttggacaaat	gcatttagtg	gtggtagaaa	1680
	tgattcacca	ggccaatgt	tgttcaccag	tgcttgcttg	tgaatcttaa	cattttgggtg	1740
30	acagtttcca	gatgctatca	cagactctgc	tagtgaaaag	aactagtttc	taggagcaca	1800
	ataatttggt	ttcatttgta	taagtccatg	aatgttcata	tagccagggg	ttgaagttta	1860
	ttattttcaa	aggaaaacac	ctttatttta	ttttttttca	aaatgaagat	acacattaca	1920
35	gccagggtgtg	gtagcaggca	cctgtagtct	tagctactcg	agaggccaaa	gaaggaggat	1980
	ggcttgagcc	caggagttca	agaccagcct	ggacagctta	gtgagatccc	gtctccgaag	2040
	aaaagatatg	tattctaatt	ggcagattgt	tttttcctaa	ggaaactgct	ttatttttat	2100
40	aaaactgcct	gacaattatg	aaaaaatggt	caaattcacg	ttctagtga	actgcattat	2160
	ttgttgacta	gatggtgggg	ttcttcgggt	gtgatcatat	atcataaagg	atatttcaaa	2220
	tgattatgat	tagttatgtc	ttttaataaa	aaggaaatat	ttttcaactt	cttctatatc	2280
45	caaaattcag	ggcttttaaac	atgattatct	tgatttccca	aaaacactaa	aggtggtttt	2340
	attttccctt	catgttttaa	cttattggtg	ctgaaaactc	tatgtccggc	tttaactatc	2400
	ttctctatat	ttttatttca	ttcacattaa	tgagaagagt	tttctcagag	attaaaaaag	2460
50	gtagtttttc	tgctattggt	aaatacacat	tatcactgaa	aaaatgtagc	ttttatgatg	2520
	tatgttttaa	agttaaaact	ggatggaaat	agccatttgg	aagctttggt	tatgaaacat	2580
	gtggagtgtg	ttaagtgcag	cttgacatta	tgttttat	aaatgctttt	tatcgctaaa	2640
55	tgacttgacg	atgaaaaaaa	ctaagggtgac	tcgagtgttt	aaatgcctgt	gtacaacaat	2700
	gctttgataa	aatatttttaa	ggatatgagtt	atcagctcta	tgtcaattga	tattttctgtg	2760

EP 1 398 032 A1

tagtatttat atttaaatta tatttacctt tttgcttatt ttacaaatat taagaaaata 2820  
ttctaacatt tgataatattt gaaatgattc atctttcaga aataaaagta tgaatct 2877

<210> 4

<211> 8461

<212> DNA

<213> Homo sapiens

<400> 4

gagggagcca gagagacggc agcggccccc gcctccctct ccgccgcgct tcagcctccc 60  
gctccgccgc gctccagcct cgctctccgc cgcccgacc gccgccgcg ccctcaccag 120  
agcagccatg gaggaggtgg tgattgccgg catgtccggg aagctgccag agtcggagaa 180  
cttgaggag ttctgggaca acctcatcgg cgggtgtggac atggtcacgg acgatgaccg 240  
tcgctggaag gcggggctct acggcctgcc ccggcggtcc ggcaagctga aggacctgtc 300  
taggtttgat gcctccttct tcggagtcca cccaagcag gcacacacga tggacctca 360  
gctgcggctg ctgctggaag tcacctatga agccatcgtg gacggaggca tcaaccaga 420  
ttcactccga ggaacacaca ctggcgtctg ggtgggcgtg agcggctctg agacctcgga 480  
ggccctgagc cgagaccccc agacactcgt gggctacagc atggtgggct gccagcgagc 540  
gatgatggcc aaccggctct ccttcttctt cgacttcaga gggcccagca tcgactgga 600  
cacagcctgc tcctccagcc tgatggccct gcagaacgcc taccaggcca tccacagcgg 660  
gcagtgcctt gccgccatcg tggggggcat caatgtcctg ctgaagccca acacctcgt 720  
gcagtctctg aggctgggga tgctcagccc cgagggcacc tgcaaggcct tcgacacagc 780  
ggggaatggg tactgccgct cggagggtgt ggtggccgtc ctgctgacca agaagtcctt 840  
ggcccgcgcg gtgtacgcca ccatcctgaa cgccggcacc aatacagatg gcttcaagga 900  
gcaaggcgtg accttcccc ctggggatat ccaggagcag ctcatccgct cgttgtagca 960  
gtcggccgga gtggcccctg agtcatttga atacatcgaa gccacggca caggcaccaa 1020  
ggtgggcgac cccagggagc tgaatggcat caccgagcc ctgtgcgcca ccgcccagga 1080  
gccgtgctc atcggctcca ccaagtcaa catggggcac ccggagccag cctcggggct 1140  
ggcagccctg gccaaaggct tgctgtccct ggagcacggg ctctggggcc ccaacctgca 1200  
cttccatagc cccaacctg agatcccagc gctgttggat gggcggctgc aggtggtgga 1260  
ccagcccctg ccgctccgtg gcggcaacgt gggcatcaac tcctttggct tcgggggctc 1320  
caacgtgcac atcatcctga ggcccaacac gcagccgccc ccgcacccg ccccatatgc 1380  
caccctgccc cgtctgtgc gggccagcgg acgcacccct gaggccgtgc agaagctgct 1440  
ggagcagggc ctccggcaca gccaggacct ggctttcctg agcatgctga acgacatcgc 1500  
ggctgtcccc gccaccgcca tgcccttcg tggctacgct gtgctgggtg gtgagcgcg 1560



EP 1 398 032 A1

	tgccccagag	gtgcagcagg	tgcccgtg	cgagcgcccc	ctctggttca	tctgctctgg	1620
	gatgggcaca	cagtggcgcg	ggatggggct	gagcctcatg	cgcttgacc	gcttccgaga	1680
5	ttccatccta	cgctccgatg	aggctgtgaa	gccattcggc	ctgaagggtgt	cacagctgct	1740
	gctgagcaca	gacgagagca	cctttgatga	catcgtccat	tcgtttgtga	gcctgactgc	1800
	catccagata	ggcctcatag	acctgctgag	ctgcatgggg	ctgaggccag	atggcatcgt	1860
10	cggccactcc	ctgggggagg	tggcctgtgg	ctacgccgac	ggctgcctgt	cccaggagga	1920
	ggccgtcctc	gctgcctact	ggaggggaca	gtgcatcaaa	gaagcccatc	tcccggcggg	1980
	cgccatggca	gccgtgggct	tgtcctggga	ggagtgtaaa	cagcgctgcc	ccccggcggg	2040
15	ggtgcccgcc	tgccacaact	ccaaggacac	agtcaccatc	tcgggacctc	aggccccggg	2100
	gtttgagttc	gtggagcagc	tgaggaagga	gggtgtgttt	gccaaggagg	tgcggaccgg	2160
	cggtatggcc	ttccactcct	acttcatgga	ggccatcgca	ccccactgc	tgcaggagct	2220
20	caagaagggtg	atccgggagc	cgaagccacg	ttcagcccgc	tggtcagca	cctctatccc	2280
	cgaggcccag	tggcacagca	gcctggcacg	cacgtcctcc	gccgagtaca	atgtcaacaa	2340
	cctggtgagc	cctgtgctgt	tccaggaggc	cctgtggcac	gtgcctgagc	acgcggtggt	2400
25	gctggagatc	gcgccccacg	ccctgctgca	ggctgtcctg	aagcgtggcc	tgaagccgag	2460
	ctgcaccatc	atccccctga	tgaagaagga	tcacagggac	aacctggagt	tcttcctggc	2520
	cggcatccgg	aggctgcacc	tctcaggcat	cgacgccaac	cccaatgcct	tgttcccacc	2580
30	tgtggagttc	ccagctcccc	gaggaactcc	cctcatctcc	ccactcatca	agtgggacca	2640
	cagcctggcc	tgggacgtgc	cggccgccga	ggacttcccc	aacggttcag	gttccccctc	2700
	agccgccatc	tacaacatcg	acaccagctc	cgagtctcct	gaccactacc	tggtggacca	2760
35	caccctcgac	ggctcgcgtc	tcttccccgc	cactggctac	ctgagcatag	tgtggaagac	2820
	gctggcccga	cccctggggc	tgggcgtcga	gcagctgcct	gtggtgtttg	aggatgtggt	2880
	gctgcaccag	gccaccatcc	tgcccaagac	tgggacagtg	tccctggagg	tacggctcct	2940
40	ggaggcctcc	cgtgccttcg	agggtgtcaga	gaacggcaac	ctggtagtga	gtgggaagggt	3000
	gtaccagtgg	gatgaccctg	accccaggct	cttcgaccac	ccggaaagcc	ccacccccaa	3060
	ccccacggag	cccctcttcc	tggcccaggc	tgaagtttac	aaggagctgc	gtctgcgtgg	3120
45	ctacgactac	ggccctcatt	tccagggcct	cctggaggcc	agcctggaag	gtgactcggg	3180
	gaggctgctg	tggaaggata	actgggtgag	cttcatggac	accatgctgc	agatgtccat	3240
	cctgggctcg	gccaagcacg	gcctgtacct	gcccacccgt	gtcaccgcca	tccacatcga	3300
50	ccctgccacc	cacaggcaga	agctgtacac	actgcaggac	aaggcccaag	tggtgacgt	3360
	ggtggtgagc	agggtggctga	gggtcacagt	ggccggaggc	gtccacatct	ccgggctcca	3420
	cactgagtcg	gccccgcggc	ggcagcagga	gcagcaggtg	cccatcctgg	agaagttttg	3480
55	cttcaactccc	cacacggagg	aggggtgcct	gtctgagcgc	gctgccctgc	aggaggagct	3540
	gcaactgtgc	aaggggctgg	tgcaggcact	gcagaccaag	gtgaccacgc	aggggctgaa	3600

EP 1 398 032 A1

	gatggtggtg	cccggactgg	atggggccca	gatcccccg	gaccctcac	agcaggaact	3660
	gccccggctg	ttgtcggctg	cctgcaggct	tcagctcaac	gggaacctgc	agctggagct	3720
5	ggcgcaggtg	ctggcccagg	agaggcccaa	gctgccagag	gaccctctgc	tcagcggcct	3780
	cctggactcc	ccggcactca	aggcctgcct	ggacactgcc	gtggagaaca	tgcccagcct	3840
	gaagatgaag	gtggtggagg	tgctggccgg	ccacggtcac	ctgtattccc	gcatcccagg	3900
10	cctgctcagc	ccccatcccc	tgctgcagct	gagctacacg	gccaccgacc	gccacccccca	3960
	ggccctggag	gctgcccagg	ccgagctgca	gcagcacgac	gttgcccagg	gccagtggga	4020
	tcccgcagac	cctgccccca	gcgccctggg	cagcgccgac	ctcctggtgt	gcaactgtgc	4080
15	tgtggctgcc	ctcggggacc	cggcctcagc	tctcagcaac	atggtggctg	ccctgagaga	4140
	agggggcttt	ctgctcctgc	acacactgct	ccgggggcac	ccctcgggac	atgtggcctt	4200
	cctcacctcc	actgagccgc	agtatggcca	gggcatcctg	agccaggacg	cgtgggagag	4260
20	cctctttctc	aggggtgtccg	tgcgcttgg	gggcctgaag	aagtccttct	acggctccac	4320
	gctcttcctg	tgccgccggc	ccaccccgca	ggacagcccc	atcttcctgc	cgggtggacga	4380
	taccagcttc	cgctgggtgg	agtctctgaa	gggcatcctg	gctgacgaag	actcttcccg	4440
25	gcctgtgtgg	ctgaaggcca	tcaactgtgc	cacctcgggc	gtggtgggct	tgggtgaactg	4500
	tctccgccga	gagcccggcg	gaacgctccg	gtgtgtgctg	ctctccaacc	tcagcagcac	4560
	ctcccacgtc	ccggaggtgg	acccgggctc	cgcagaactg	cagaagggtgt	tgcagggaga	4620
30	cctggtgatg	aacgtctacc	gcgacggggc	ctggggggct	ttccgccact	tcctgtctgga	4680
	ggaggacaag	cctgaggagc	cgacggcaca	tgcccttctg	agcaccctca	cccggggggga	4740
	cctgtcctcc	atccgctggg	tctgtctctc	gctgcgccat	gcccagccca	cctgccctgg	4800
35	cgcccagctc	tgacaggtct	actacgcctc	cctcaacttc	cgcgacatca	tgctggccac	4860
	tggcaagctg	tcccctgatg	ccatcccagg	gaagtggacc	tcccaggaca	gcctgtctagg	4920
	tatggagttc	tcgggccgag	acgccagcgg	caagcgtgtg	atgggactgg	tgccctgcca	4980
40	gggcctggcc	acctctgtcc	tgctgtcacc	ggacttcctc	tgggatgtgc	cttccaactg	5040
	gacgctggag	gaggcggcct	cggctgcctgt	cgtctacagc	acggcctact	acgcgtggt	5100
	ggtgcgtggg	cgggtgcgcc	ccggggagac	gctgctcatc	cactcgggct	cgggcggcgt	5160
45	gggccaggcc	gccatcgcca	tcgccctcag	tctgggctgc	cgcgcttca	ccaccgtggg	5220
	gtcggctgag	aagcgggctg	acctccaggc	cagggtcccc	cagctcgaca	gcaccagctt	5280
	cgccaaactcc	cgggacacat	ccttcgagca	gcatgtgctg	tggcacacgg	gcgggaagg	5340
50	cgttgacctg	gtcttgaact	ccttgccgga	agagaagctg	caggccagcg	tgagggtgctt	5400
	ggctacgcac	ggtcgcttcc	tggaaattgg	caaattcgac	ctttctcaga	accacccgct	5460
	cggcatggct	atcttcctga	agaacgtgac	attccacggg	gtcctactgg	atgcgttctt	5520
55	caacgagagc	agtgcctgact	ggcgggaggt	gtgggcgctt	gtgcaggccg	gcatccggga	5580
	tggggtggta	cggccccctca	agtgcacggt	gttccatggg	gcccagggtg	aggacgcctt	5640

EP 1 398 032 A1

	ccgctacatg	gccaagggga	agcacattgg	caaagtcgtc	gtgcaggtgc	ttgcggagga	5700
	gccggaggca	gtgctgaagg	gggcaaacc	caagctgatg	tcggccatct	ccaagacctt	5760
5	ctgcccggcc	cacaagagct	acatcatcgc	tggtggctctg	ggtggcttcg	gcctggagtt	5820
	ggcgagtg	ctgatacagc	gtgggggtgca	gaagctcgtg	ttgacttctc	gctccgggat	5880
	ccggacaggc	taccaggcca	agcaggtccg	ccggtggagg	cgccagggcg	tacaggtgca	5940
10	ggtgtccacc	agcaacatca	gctcactgga	gggggcccgg	ggcctcattg	ccgaggcggc	6000
	gcagcttggg	cccgtggg	gcgtcttcaa	cctggccgtg	gtcttgagag	atggcttgct	6060
	ggagaaccag	accccagagt	tcttcaggga	cgtctgcaag	cccaagtaca	gcggcaccct	6120
15	gaacctggac	agggtgacct	gagaggcgtg	ccctgagctg	gactactttg	tggtcttctc	6180
	ctctgtgagc	tgcgggcgtg	gcaatgcggg	acagagcaac	tacggctttg	ccaattccgc	6240
	catggagcgt	atctgtgaga	aacgccggca	cgaaggcctc	ccaggcctgg	ccgtgcagtg	6300
20	gggcgccatc	ggcgacgtgg	gcattttggt	ggagacgatg	agcaccaacg	acacgatcgt	6360
	cagtggcacg	ctgccccagc	gcattggcgtc	ctgcctggag	gtgctggacc	tcttcctgaa	6420
	ccagccccac	atggtcctga	gcagctttgt	gctggctgag	aaggctgcgg	cctatagggga	6480
25	caggacagc	cagcgggacc	tggtggaggc	cgtggcacac	atcctgggca	tccgcgactt	6540
	ggctgctgtc	aacctggaca	gctcactggc	ggacctgggc	ctggactcgc	tcatgagcgt	6600
	ggaggtgcgc	cagacgtgg	agcgtgagct	caacctgggtg	ctgtccgtgc	gcgaggtgcg	6660
30	gcaactcacg	ctccggaaac	tgcaggagct	gtcctcaaag	gcggatgagg	ccagcgagct	6720
	ggcatgcccc	acgcccgaag	aggatgggtct	ggcccagcag	cagactcagc	tgaacctgcg	6780
	ctccctgctg	gtgaacccgg	agggccccac	cctgatgcgg	ctcaactccg	tgcagagctc	6840
35	ggagcggccc	ctgttcctgg	tgcacccaat	cgagggctcc	accaccgtgt	tccacagcct	6900
	ggcctcccgg	ctcagcatcc	ccacctatgg	cctgcagtg	acccgagctg	cgccccctga	6960
	cagcatccac	agcctggctg	cctactacat	cgactgcac	aggcaggtgc	agccccagg	7020
40	cccctaccgc	gtggccggct	actcctacgg	ggcctgcgtg	gcctttgaaa	tgtgctccca	7080
	gctgcaggcc	cagcagagcc	cagccccac	ccacaacagc	ctcttcctgt	tcgacggctc	7140
	gcccacctac	gtactggcct	acaccagag	ctaccgggca	aagctgacct	caggctgtga	7200
45	ggctgaggct	gagacggagg	ccatatgctt	cttcgtgcag	cagttcacgg	acatggagca	7260
	caacagggtg	ctggaggcgc	tgctgccgct	gaaggcccta	gaggagcgtg	tggcagccgc	7320
	cgtggacctg	atcatcaaga	gccaccagg	cctggaccgc	caggagctga	gctttgcggc	7380
50	ccggtccttc	tactacaagc	tgctgcccgc	tgagcagtac	acaccaagg	ccaagtacca	7440
	tggaacgtg	atgctactgc	gcgccaagac	gggtggcgcc	tacggcgagg	acctgggcgc	7500
	ggactacaac	ctctcccagg	tatgcgacgg	gaaagtatcc	gtccacgtca	tcgagggtga	7560
55	ccaccgcacg	ctgctggagg	gcagcggcct	ggagtccatc	atcagcatca	tccacagctc	7620
	cctggctgag	ccacgcgtga	gcgtgcggga	gggctaggcc	cgtgcccccg	cctgccaccg	7680

EP 1 398 032 A1

	gaggtcactc caccatcccc accccacccc accccacccc cgccatgcaa cgggattgaa	7740
	gggtcctgcc ggtgggaccc tgtccggccc agtgccactg cccccgagg ctgctagacg	7800
5	taggtgttag gcatgtccca cccacccgcc gcctcccacg gcacctcggg gacaccagag	7860
	ctgccgactt ggagactcct ggtctgtgaa gagccgggtg tgcccgtgcc cgcaggaact	7920
	gggctgggcc tcgtgcgccc gtgggggtctg cgcttgggtct ttctgtgctt ggatttgcat	7980
10	atttattgca ttgctggtag agacccccag gcctgtccac cctgccaaga ctctcaggc	8040
	agcgtgtggg tcccgcactc tgccccatt tcccgatgt cccctgcggg cgcgggcagc	8100
	caccaagcc tgctggctgc ggccccctct cggccaggca ttggctcagc ccgctgagtg	8160
15	gggggtcgtg ggccagtccc cgaggagctg ggccctgca caggcacaca gggcccggcc	8220
	acaccagcg gcccccgca cagccaccg tggggtgctg cccttatgcc cggcgccggg	8280
	caccaactcc atgtttggtg tttgtctgtg tttgttttcc aagaaatgat tcaaattgct	8340
20	gcttgattt tgaaatttac tgtaactgtc agtgtacacg tctggacccc gtttcatttt	8400
	tacaccaatt tggtaaaaat gctgctctca gcctcccaca attaaaccgc atgtgatctc	8460
	c	8461
25	<210> 5	
	<211> 1444	
	<212> DNA	
30	<213> Homo sapiens	
	<400> 5	
35	acgggtcacc gttgccagct ctagccttta aattcccggc tcggggacct ccacgcaccg	60
	cggctagcgc cgacaaccag ctagcgtgca aggcgccgcg gctcagcgcg taccggcggg	120
	cttcgaaacc gcagtcctcc ggcgaccccg aactccgctc cggagcctca gccccctgga	180
40	aagtgatccc ggcacccgag agccaagatg ccggccact tgctgcagga cgatatctct	240
	agctcctata ccaccaccac caccattaca gcgcctccct ccagggtcct gcagaatgga	300
	ggagataagt tggagacgat gccccctctac ttggaagacg acattcgccc tgatataaaa	360
45	gatgatatat atgacccac ctacaaggat aaggaaggcc caagcccaa ggttgaatat	420
	gtctggagaa acatcatcct tatgtctctg ctacacttgg gagccctgta tgggatcact	480
	ttgattccta cctgcaagtt ctacacctgg ctttggggg tattctacta ttttgtcagt	540
50	gccctgggca taacagcagg agctcatcgt ctgtggagcc accgctctta caaagctcgg	600
	ctgcccctac ggctctttct gatcattgcc aacacaatgg cattccagaa tgatgtctat	660
	gaatgggctc gtgaccaccg tgcccaccac aagttttcag aaacacatgc tgatcctcat	720
55	aattcccac gtggcttttt cttctctcac gtgggttggc tgcttgtgcg caaacacca	780
	gctgtcaaag agaaggggag tacgctagac ttgtctgacc tagaagctga gaaactggtg	840

EP 1 398 032 A1

atgttccaga ggaggtacta caaacctggc ttgctgatga tgtgcttcat cctgcccacg 900  
 cttgtgccct ggtatttctg gggtgaaact tttcaaaaca gtgtgttcgt tgccactttc 960  
 5 ttgcgatatg ctgtggtgct taatgccacc tggctggtga acagtgctgc ccacctcttc 1020  
 ggatatcgtc cttatgacaa gaacattagc ccccgggaga atatcctggg ttcacttgga 1080  
 gctgtgggtg agggcttcca caactaccac cactcctttc cctatgacta ctctgccagt 1140  
 10 gagtaccgct ggcacatcaa cttcaccaca ttcttcattg attgcatggc cgccctcggt 1200  
 ctggcctatg accggaagaa agtctccaag gccgccatct tggccaggat taaaagaacc 1260  
 ggagatggaa actacaagag tggctgagtt tggggtcctt caggttcctt tttcaaaaac 1320  
 15 cagccaggca gaggttttaa tgtctgttta ttaactactg aataatgcta ccaggatgct 1380  
 aaagatgatg atgttaaccc attccagtac agtattcttt taaaattcaa aagtattgaa 1440  
 agcc 1444  
 20 <210> 6  
 <211> 4154  
 <212> DNA  
 25 <213> Homo sapiens  
 <400> 6  
 30 taacgaggaa cttttcgccg gcgccgggcc gcctctgagg ccagggcagg acacgaacgc 60  
 gcggagcggc ggcggcgact gagagccggg gccgcggcgg cgctccctag gaagggccgt 120  
 acgagggcggc gggcccggcg ggcctcccgg aggagggcggc tgcgccatgg acgagccacc 180  
 35 cttcagcgag gcggctttgg agcaggcgct gggcgagccg tgcgatctgg acgcggcgct 240  
 gctgaccgac atcgaagaca tgcttcagct tatcaacaac caagacagtg acttccctgg 300  
 cctatttgac ccaccctatg ctgggagtg ggcagggggc acagaccctg ccagccccga 360  
 40 taccagctcc ccaggcagct tgtctccacc tcctgccaca ttgagctcct ctcttgaagc 420  
 cttcctgagc gggccgcagg cagcgccctc acccctgtcc cctcccagc ctgcaccac 480  
 tccattgaag atgtacccgt ccatgcccgc tttctcccct gggcctggta tcaaggaaga 540  
 45 gtcagtgcca ctgagcatcc tgagacccc caccacacag cccctgccag gggccctcct 600  
 gccacagagc ttcccagccc cagccccacc gcagttcagc tccaccctg tgttaggcta 660  
 cccagccct ccgggaggct tctctacagg aagccctccc gggaacaccc agcagccgct 720  
 gcctggcctg cactggctt ccccgccagg ggtcccgccc gtctccttgc acaccaggt 780  
 50 ccagagtgtg gtccccagc agctactgac agtcacagct gcccacagg cagcccctgt 840  
 aacgaccact gtgacctgc agatccagca ggtcccggtc ctgctgcagc ccacttcat 900  
 55 caaggcagac tcgctgctt tgacagccat gaagacagac ggagccactg tgaaggcggc 960  
 aggtctcagt cccctggctt ctggcaccac tgtgcagaca gggcctttgc cgaccctggg 1020

EP 1 398 032 A1

	gagtggcgga	accatcttgg	caacagtccc	actggtcgta	gatgcggaga	agctgcctat	1080
	caaccggctc	gcagctggca	gcaaggcccc	ggcctctgcc	cagagccgtg	gagagaagcg	1140
5	cacagcccac	aacgccattg	agaagcgcta	ccgctcctcc	atcaatgaca	aaatcattga	1200
	gctcaaggat	ctggtggtgg	gcactgaggg	aaagctgaat	aaatctgctg	tcttgcgcaa	1260
	ggccatcgac	tacattcgct	ttctgcaaca	cagcaaccag	aaactcaagc	aggagaacct	1320
10	aagtctgctc	actgctgtcc	acaaaagcaa	atctctgaag	gatctggtgt	cggcctgtgg	1380
	cagtggaggg	aacacagacg	tgctcatgga	gggctggaag	actgaggtgg	aggacacact	1440
	gacccacccc	ccctcgatg	ctggctcacc	tttccagagc	agccccctgt	cccttggcag	1500
15	caggggcagt	ggcagcggtg	gcagtggcag	tgactcggag	cctgacagcc	cagtctttga	1560
	ggacagcaag	gcaaagccag	agcagcggcc	gtctctgcac	agccggggca	tgctggaccg	1620
	ctcccgctg	gcccgtgca	cgctcgtctt	cctctgcctg	tcctgcaacc	ccttggcctc	1680
20	cttgctgggg	gcccgggggc	ttcccagccc	ctcagatacc	accagcgtct	accatagccc	1740
	tgggcgcaac	gtgctgggca	ccgagagcag	agatggccct	ggctggggcc	agtggctgct	1800
	gccccagtg	gtctggctgc	tcaatgggct	gttggtgctc	gtctccttgg	tgcttctctt	1860
25	tgtctacggt	gagccagtca	cacggcccca	ctcaggcccc	gccgtgtact	tctggaggca	1920
	tcgcaagcag	gctgacctgg	acctggcccc	gggagacttt	gcccaggctg	cccagcagct	1980
	gtggctggcc	ctgcggggc	tgggcccggc	cctgcccacc	tcccacctgg	acctggcttg	2040
30	tagcctctc	tggaaacctca	tccgtcacct	gctgcagcgt	ctctgggtgg	gccgctggct	2100
	ggcaggcccg	gcagggggcc	tgcagcagga	ctgtgctctg	cgagtggatg	ctagcgccag	2160
	cgcccgagac	gcagccctgg	tctaccataa	gctgcaccag	ctgcacacca	tggggaagca	2220
35	cacaggcggg	cacctcactg	ccaccaacct	ggcgtgagt	gcccgaacc	tggcagagt	2280
	tgcaggggat	gccgtgtctg	tggcgacgct	ggccgagatc	tatgtggcgg	ctgcattgag	2340
	agtgaagacc	agtctccac	gggccttgca	ttttctgaca	cgcttcttcc	tgagcagtgc	2400
40	ccgccaggcc	tgcttggcac	agagtggctc	agtgcctcct	gccatgcagt	ggctctgcca	2460
	ccccgtgggc	caccgtttct	tcgtggatgg	ggactgggtc	gtgctcagta	ccccatggga	2520
	gagcctgtac	agcttggccg	ggaacccagt	ggacccccctg	gcccagggtga	ctcagctatt	2580
45	ccgggaacat	ctcttagagc	gagcactgaa	ctgtgtgacc	cagcccaacc	ccagccctgg	2640
	gtcagctgat	ggggacaagg	aattctcgga	tgccctcggg	tacctgcagc	tgctgaacag	2700
	ctgttctgat	gctgcggggg	ctcctgccta	cagcttctcc	atcagttcca	gcatggccac	2760
50	caccaccggc	gtagacccgg	tggccaagt	gtgggcctct	ctgacagctg	tggtgatcca	2820
	ctggctgcgg	cgggatgagg	aggcggctga	gcggctgtgc	ccgctgggtg	agcacctgcc	2880
	ccgggtgctg	caggagtctg	agagacccct	gcccaggggca	gctctgcact	ccttcaaggc	2940
55	tgcccggggc	ctgctgggct	gtgccaaagg	agagtctggg	ccagccagcc	tgaccatctg	3000
	tgagaaggcc	agtgggtacc	tgcaggacag	cctggctacc	acaccagcca	gcagctccat	3060

EP 1 398 032 A1

tgacaaggcc gtgcagctgt tcctgtgtga cctgcttctt gtggtgcgca ccagcctgtg 3120  
 gcggcagcag cagcccccg ccccgcccc agcagcccag ggcaccagca gcaggcccca 3180  
 5 ggcttccgcc cttgagctgc gtggcttcca acgggacctg agcagcctga ggcggtggc 3240  
 acagagcttc cggcccgcca tgcggagggt gttcctacat gaggccacgg cccggctgat 3300  
 ggcgggggcc agccccacac ggacacacca gtcctcgcac cgcagtctga ggcgggggc 3360  
 10 agggcccggt ggcaaaggag gcgcggtggc ggagctggag ccgcggccca cgcggcgga 3420  
 gcacgcggag gccttgctgc tggcctcctg ctacctgccc cccggcttcc tgtcggcgcc 3480  
 cgggcagcgc gtgggcatgc tggctgaggc ggcgcgcaca ctcgagaagc ttggcgatcg 3540  
 15 ccggctgctg cacgactgtc agcagatgct catgcgcctg ggcggtggga cactgtcac 3600  
 ttccagctag accccgtgtc cccggcctca gcacctgt ctctagccac tttggctccg 3660  
 tgcagcttct gtcctgcgtc gaagctttga aggccgaagg cagtgaaga gactctggcc 3720  
 20 tccacagttc gacctgcggc tgctgtgtgc cttcgcggtg gaaggccga ggggcgcgat 3780  
 cttgacctta agaccggcg ccatgatggt gctgacctt ggtggccgat cggggcactg 3840  
 caggggcca gccattttgg ggggcccccc tccttgctct gcaggcacct tagtggttt 3900  
 25 tttcctcctg tgtacagga agagagggt acatttccct gtgctgacgg aagccaactt 3960  
 ggctttcccg gactgaagc agggctctgc cccagaggcc tctctctccg tcgtgggaga 4020  
 gagacgtgta catagtgtag gtcagcgtgc ttagcctcct gacctgaggc tcctgtgcta 4080  
 30 ctttgccttt tgcaaacctt atttcatag attgagaagt tttgtacaga gaattaaaa 4140  
 tgaaattatt tata 4154  
  
 <210> 7  
 35 <211> 10412  
 <212> DNA  
 <213> Homo sapiens  
 40  
  
 <400> 7  
 gtaattgcga gcgagagtga gtggggccgg gaccgcaga gccgagcca ccttctctc 60  
 45 ccgggctgcg gcagggcagg gcggggagct ccgcgcacca acagagccgg ttctcagggc 120  
 gctttgctcc ttgttttttc cccggttctg ttttctcccc ttctccgga ggcttgtaa 180  
 ggggtaggag aaagagacgc aaacacaaaa gtggaaaaca gttaatgacc agccacggcg 240  
 50 tccctgctgt gagctctggc cgctgccttc cagggtctcc gagccacacg ctgggggtgc 300  
 tggctgaggg aacatggctt gttggcctca gctgaggtg ctgctgtgga agaacctcac 360  
 tttcagaaga agacaaacat gtcagctgct gctggaagt gcctggcctc tatttatctt 420  
 55 cctgatcctg atctctgttc ggctgagcta cccaccctat gaacaacatg aatgccattt 480  
 tccaaataaa gccatgccct ctgcaggaac acttccttgg gttcagggga ttatctgtaa 540

EP 1 398 032 A1

	tgccaacaac	ccctgtttcc	gttaccggac	tcctggggag	gctcccggag	ttgttgaaaa	600
	ctttaacaaa	tccattgtgg	ctcgcctgtt	ctcagatgct	cggaggcttc	ttttatacag	660
5	ccagaaagac	accagcatga	aggacatgcy	caaagttctg	agaacattac	agcagatcaa	720
	gaaatccagc	tcaaacttga	agcttcaaga	tttcctggtg	gacaatgaaa	ccttctctgg	780
	gttcctgtat	cacaacctct	ctctcccaaa	gtctactgtg	gacaagatgc	tgagggtgta	840
10	tgtcattctc	cacaaggtat	ttttgcaagg	ctaccagtta	catttgacaa	gtctgtgcaa	900
	tggatcaaaa	tcagaagaga	tgattcaact	tgggtgaccaa	gaagtttctg	agctttgtgg	960
	cctaccaagg	gagaaactgg	ctgcagcaga	gcyagtactt	cgttccaaca	tggacatcct	1020
15	gaagccaatc	ctgagaacac	taaactctac	atctcccttc	ccgagcaagg	agctggctga	1080
	agccacaaaa	acattgctgc	atagtcttgg	gactctggcc	caggagctgt	tcagcatgag	1140
	aagctggagt	gacatgcyac	aggaggtgat	gtttctgacc	aatgtgaaca	gctccagctc	1200
20	ctccacccaa	atctaccagg	ctgtgtctcg	tattgtctgc	gggcatccc	agggaggggg	1260
	gctgaagatc	aagtctctca	actggtatga	ggacaacaac	tacaaagccc	tctttggagg	1320
	caatggcact	gaggaagatg	ctgaaacctt	ctatgacaac	tctacaactc	cttactgcaa	1380
25	tgatttgatg	aagaatttgg	agtctagtcc	tctttccgc	attatctgga	aagctctgaa	1440
	gccgctgctc	gttgggaaga	tcctgtatac	acctgacact	ccagccacaa	ggcaggtcat	1500
	ggctgaggtg	aacaagacct	tccaggaact	ggctgtgttc	catgatctgg	aaggcatgtg	1560
30	ggaggaactc	agccccaaga	tctggacctt	catggagaac	agccaagaaa	tggaccttgt	1620
	ccggatgctg	ttggacagca	gggacaatga	ccacttttgg	gaacagcagt	tggatggctt	1680
	agattggaca	gccaagaca	tcgtggcggt	tttggccaag	caccagagg	atgtccagtc	1740
35	cagtaatggt	tctgtgtaca	cctggagaga	agctttcaac	gagactaacc	aggcaatccg	1800
	gaccatatct	cgcttcatgg	agtgtgtcaa	cctgaacaag	ctagaacca	tagcaacaga	1860
	agtctggctc	atcaacaagt	ccatggagct	gctggatgag	aggaagttct	gggctgggtat	1920
40	tgtgttcact	ggaattactc	caggcagcat	tgagctgccc	catcatgtca	agtacaagat	1980
	ccgaatggac	attgacaatg	tggagaggac	aaataaaatc	aaggatgggt	actgggaccc	2040
	tggctctcga	gctgaccctt	ttgaggacat	gcggtacgct	tgggggggct	tcgcctactt	2100
45	gcaggatgtg	gtggagcagg	caatcatcag	ggtgctgacg	ggcaccgaga	agaaaactgg	2160
	tgtctatatg	caacagatgc	cctatccctg	ttacgttgat	gacatctttc	tgcggtgat	2220
	gagccggctc	atgcccctct	tcatgacgct	ggcctggatt	tactcagtgg	ctgtgatcat	2280
50	caagggcatc	gtgtatgaga	aggaggcacg	gctgaaagag	accatgcgga	tcatgggcct	2340
	ggacaacagc	atcctctggt	ttagctgggt	cattagtagc	ctcattcctc	ttcttgtgag	2400
	cgctggcctg	ctagtggctc	tcctgaagtt	aggaaacctg	ctgccctaca	gtgatcccag	2460
55	cgtgggtgtt	gtcttcctgt	ccgtgtttgc	tgtgggtgaca	atcctgcagt	gcttctgat	2520
	tagcacactc	ttctccagag	ccaacctggc	agcagcctgt	gggggcatca	tctacttcac	2580



## EP 1 398 032 A1

	gctgtacctg ccctacgtcc tgtgtgtggc atggcaggac tacgtgggct tcacactcaa	2640
	gatcttcgct agcctgctgt ctccctgtggc ttttgggttt ggctgtgagt actttgacct	2700
5	ttttgaggag cagggcattg gagtgcagtg ggacaacctg tttgagagtc ctgtggagga	2760
	agatggcttc aatctcacca cttcgggtctc catgatgctg tttgacacct tcctctatgg	2820
	ggtgatgacc tgggtacattg aggctgtctt tccaggccag tacggaattc ccaggccctg	2880
10	gtattttcct tgcaccaagt cctactgggtt tggcgaggaa agtgatgaga agagccaccc	2940
	tggttccaac cagaagagaa tatcagaaat ctgcatggag gaggaaacca cccacttgaa	3000
	gctgggcgtg tccattcaga acctggtaaa agtctaccga gatgggatga aggtggctgt	3060
15	cgatggcctg gactgaatt tttatgaggg ccagatcacc tccttcctgg gccacaatgg	3120
	agcggggaag acgaccacca tgtcaatcct gaccgggttg tccccccga cctcgggcac	3180
	cgcctacatc ctgggaaaag acattcgctc tgagatgagc accatccggc agaacctggg	3240
20	ggtctgtccc cagcataacg tgctgtttga catgctgact gtcgaagaac acatctgggt	3300
	ctatgcccgc ttgaaagggc tctctgagaa gcacgtgaag gcggagatgg agcagatggc	3360
	cctggatgtt ggtttgccat caagcaagct gaaaagcaaa acaagccagc tgtcaggtgg	3420
25	aatgcagaga aagctatctg tggccttggc ctttgtcggg ggatctaagg ttgtcattct	3480
	ggatgaacct acagctggtg tggaccctta ctcccgcagg ggaatatggg agctgctgct	3540
	gaaataccga caaggccgca ccattattct ctctacacac cacatggatg aagcggacgt	3600
30	cctgggggac aggattgcc a tcatctccca tgggaagctg tgctgtgtgg gctcctccct	3660
	gtttctgaag aaccagctgg gaacaggcta ctacctgacc ttggtcaaga aagatgtgga	3720
	atcctccctc agttcctgca gaaacagtag tagcactgtg tcataacctga aaaaggagga	3780
35	cagtgtttct cagagcagtt ctgatgctgg cctgggcagc gaccatgaga gtgacacgct	3840
	gaccatcgat gtctctgcta tctccaacct catcaggaag catgtgtctg aagcccggct	3900
	ggtggaagac atagggcatg agctgacctt tgtgctgcca tatgaagctg ctaaggaggg	3960
40	agcctttgtg gaactctttc atgagattga tgaccggctc tcagacctgg gcatttctag	4020
	ttatggcatc tcagagacga ccctggaaga aatattcctc aagggtggccg aagagagtgg	4080
	ggtggatgct gagacctcag atgggtacctt gccagcaaga cgaaacaggc gggccttcgg	4140
45	ggacaagcag agctgtcttc gccggttcac tgaagatgat gctgctgac caaatgattc	4200
	tgacatagac ccagaatcca gagagacaga cttgctcagt gggatggatg gcaaagggtc	4260
	ctaccaggtg aaaggctgga aacttacaca gcaacagttt gtggcccttt tgtggaagag	4320
50	actgctaatt gccagacgga gtcggaaagg attttttgct cagattgtct tgccagctgt	4380
	gtttgtctgc attgcccttg tgttcagcct gatcgtgcca ccctttggca agtaccacag	4440
	cctggaactt cagccctgga tgtacaacga acagtacaca tttgtcagca atgatgtcc	4500
55	tgaggacacg ggaaccctgg aactcttaaa cgccctcacc aaagaccctg gcttcgggac	4560
	ccgctgtatg gaaggaaacc caatcccaga cacgccctgc caggcagggg aggaagagtg	4620

## EP 1 398 032 A1

	gaccactgcc	ccagttcccc	agaccatcat	ggacctcttc	cagaatggga	actggacaat	4680
	gcagaaccct	tcacctgcat	gccagtgtag	cagcgacaaa	atcaagaaga	tgctgcctgt	4740
5	gtgtccccc	ggggcagggg	ggctgcctcc	tccacaaaga	aaacaaaaca	ctgcagatat	4800
	ccttcaggac	ctgacaggaa	gaaacatttc	ggattatctg	gtgaagacgt	atgtgcagat	4860
	catagccaaa	agcttaaaga	acaagatctg	ggatgaatgag	tttaggtatg	gcggcctttc	4920
10	cctgggtgtc	agtaatactc	aagcacttcc	tccgagtcaa	gaagttaatg	atgccatcaa	4980
	acaaatgaag	aaacacctaa	agctggccaa	ggacagttct	gcagatcgat	ttctcaacag	5040
	cttgggaaga	tttatgacag	gactggacac	caaaaataat	gtcaagggtg	ggttcaataa	5100
15	caagggctgg	catgcaatca	gctctttcct	gaatgtcatc	aacaatgcc	ttctccgggc	5160
	caacctgcaa	aagggagaga	accctagcca	ttatggaatt	actgctttca	atcatcccct	5220
	gaatctcacc	aagcagcagc	tctcagaggt	ggctctgatg	accacatcag	tggtatgtcct	5280
20	tgtgtccatc	tgtgtcatct	ttgcaatgtc	cttcgtccca	gccagctttg	tcgtattcct	5340
	gatccaggag	cgggctcagca	aagcaaaaca	cctgcagttc	atcagtggag	tgaagcctgt	5400
	catctactgg	ctctctaatt	ttgtctggga	tatgtgcaat	tacgttggtc	ctgccacact	5460
25	ggtcattatc	atcttcatct	gcttccagca	gaagtcctat	gtgtcctcca	ccaatctgcc	5520
	tgtgctagcc	cttctacttt	tgctgtatgg	gtggtcaatc	acacctctca	tgtaccagc	5580
	ctcctttgtg	ttcaagatcc	ccagcacagc	ctatgtgggtg	ctcaccagcg	tgaacctctt	5640
30	cattggcatt	aatggcagcg	tggccacctt	tgtgctggag	ctgttcaccg	acaataagct	5700
	gaataatatc	aatgatatac	tgaagtccgt	gttcttgatc	ttcccacatt	tttgctggg	5760
	acgagggctc	atcgacatgg	tgaaaaacca	ggcaatggct	gatgccctgg	aaagggttg	5820
35	ggagaatcgc	tttgtgtcac	cattatcttg	ggacttgggtg	ggacgaaacc	tcttcgccat	5880
	ggccgtggaa	gggggtggtg	tcttcctcat	tactgttctg	atccagtaca	gattcttcat	5940
	caggcccaga	cctgtaaatg	caaagctatc	tcctctgaat	gatgaagatg	aagatgtgag	6000
40	gcgggaaaga	cagagaattc	ttgatgggtg	aggccagaat	gacatcttag	aaatcaagga	6060
	gttgacgaag	atatatagaa	ggaagcggaa	gcctgctggt	gacaggattt	gcgtgggcat	6120
	tcctcctggt	gagtgccttg	ggctcctggg	agttaatggg	gctggaaaat	catcaacttt	6180
45	caagatgtta	acaggagata	ccactgttac	cagaggagat	gctttcctta	acaaaaatag	6240
	tatcttatca	aacatccatg	aagtacatca	gaacatgggc	tactgccctc	agtttgatgc	6300
	catcacagag	ctgttgactg	ggagagaaca	cgtggagtgc	tttgcccttt	tgagaggagt	6360
50	cccagagaaa	gaagttggca	aggttgggtg	gtgggcgatt	cggaaactgg	gcctcgtgaa	6420
	gtatggagaa	aaatatgctg	gtaactatag	tgagggcaac	aaacgcaagc	tctctacagc	6480
	catggccttg	atcggcgggc	ctcctgtggt	gtttctggat	gaaccacca	caggcatgga	6540
55	tcccaaagcc	cggcgggttct	tgtggaattg	tgccctaagt	gttgtcaagg	aggggagatc	6600
	agtagtgctt	acatctcata	gtatggaaga	atgtgaagct	ctttgcacta	ggatggcaat	6660

## EP 1 398 032 A1

	catggtcaat	ggaaggttca	ggtgccttgg	cagtgtccag	catctaaaaa	ataggtttgg	6720
	agatggttat	acaatagttg	tacgaatagc	aggggtccaac	ccggacctga	agcctgtcca	6780
5	ggattttcttt	ggacttgcac	ttcctggaag	tgttctaaaa	gagaaacacc	ggaacatgct	6840
	acaataaccag	cttccatctt	cattatcttc	tctggccagg	atattcagca	tcctctccca	6900
	gagcaaaaag	cgactccaca	tagaagacta	ctctgtttct	cagacaacac	ttgaccaagt	6960
10	atgtgtgaac	tttgccaagg	accaaagtga	tgatgaccac	ttaaaagacc	tctcattaca	7020
	caaaaaccag	acagtagtgg	acgttgcagt	tctcacatct	tttctacagg	atgagaaagt	7080
	gaaagaaaagc	tatgtatgaa	gaatcctggt	catacggggg	ggctgaaagt	aaagaggaac	7140
15	tagactttcc	tttgcacat	gtgaagtgtt	gtggagaaaa	gagccagaag	ttgatgtggg	7200
	aagaagtaaa	ctggatactg	tactgatact	attcaatgca	atgcaattca	atgcaatgaa	7260
	aacaaaattc	cattacaggg	gcagtgcctt	tgtagcctat	gtcttgtatg	gctctcaagt	7320
20	gaaagacttg	aatttagttt	tttacctata	cctatgtgaa	actctattat	ggaacccaat	7380
	ggacatatgg	gtttgaactc	acactttttt	tttttttttt	gttcctgtgt	attctcattg	7440
	gggttgcaac	aataattcat	caagtaatca	tggccagcga	ttattgatca	aaatcaaaag	7500
25	gtaatgcaca	tcctcattca	ctaagccatg	ccatgcccag	gagactgggt	tcccgggtgac	7560
	acatccattg	ctggcaatga	gtgtgccaga	gttattagtg	ccaagttttt	cagaaagtgt	7620
	gaagcaccat	ggtgtgtcat	gctcactttt	gtgaaagctg	ctctgtctag	agtctatcaa	7680
30	cattgaatat	cagttgacag	aatggtgcca	tgcgtggcta	acatcctgct	ttgattccct	7740
	ctgataagct	gttctggtgg	cagtaacatg	caacaaaaat	gtgggtgtct	ccaggcacgg	7800
	gaaacttggt	tccattgtta	tattgtccta	tgcttcgagc	catgggtcta	caggggtcatc	7860
35	cttatgagac	tcttaaatat	acttagatcc	tggtaagagg	caaagaatca	acagccaaac	7920
	tgctggggct	gcaagctgct	gaagccaggg	catgggatta	aagagattgt	gcgttcaaac	7980
	ctaggggaagc	ctgtgcccac	ttgtcctgac	tgtctgctaa	catggtacac	tgcatctcaa	8040
40	gatgtttatc	tgacacaagt	gtattatttc	tggctttttg	aattaatcta	gaaaatgaaa	8100
	agatggagtt	gtattttgac	aaaaatgttt	gtacttttta	atgttatttg	gaattttaag	8160
	ttctatcagt	gacttctgaa	tccttagaat	ggcctctttg	tagaaccctg	tggtatagag	8220
45	gagtatggcc	actgccccac	tatttttatt	ttcttatgta	agtttgcata	tcagtcatga	8280
	ctagtgccta	gaaagcaatg	tgatggtcag	gatctcatga	cattatattt	gagtttcttt	8340
	cagatcattt	aggatactct	taatctcact	tcatcaatca	aatatttttt	gagtgtatgc	8400
50	tgtagctgaa	agagtatgta	cgtacgtata	agactagaga	gatattaagt	ctcagtacac	8460
	ttcctgtgcc	atgttattca	gctcactggg	ttacaaatat	agggtgtctt	gtggttgtag	8520
	gagcccactg	taacaatact	gggcagcctt	tttttttttt	tttttaattg	caacaatgca	8580
55	aaagccaaga	aagtataagg	gtcacaaagtc	taaacaatga	attcttcaac	agggaaaaca	8640
	gctagcttga	aaacttgctg	aaaaacacaa	cttgtgttta	tggcatttag	taccttcaaa	8700

EP 1 398 032 A1

	taattggctt tgcagatatt ggatacccca ttaaactctga cagtctcaaa tttttcatct	8760
	cttcaatcac tagtcaagaa aaatataaaa acaacaaata cttccatatg gagcattttt	8820
5	cagagttttc taaccagtc ttatttttct agtcagtaaa catttgtaaa aatactgttt	8880
	cactaatact tactgttaac tgtcttgaga gaaaagaaaa atatgagaga actattgttt	8940
	ggggaagttc aagtgatctt tcaatatcat tactaaacttc ttccactttt tccagaattt	9000
10	gaatattaac gctaaagggtg taagacttca gatttcaaata taatctttct atatttttta	9060
	aatttacaga atattatata acccactgct gaaaaagaaa aaaatgattg ttttagaagt	9120
	taaagtcaat attgatttta aatataagta atgaaggcat atttccaata actagtata	9180
15	tggcatcggt gcattttaca gtatcttcaa aaatacagaa tttatagaat aatttctcct	9240
	catttaatat ttttcaaaat caaagttatg gtttctcat tttactaaaa tcgtattcta	9300
	attcttcatt atagtaaatac tatgagcaac tccttacttc ggttcctctg atttcaaggc	9360
20	catattttta aaaatcaaaa ggcactgtga actattttga agaaaacaca acattttaat	9420
	acagattgaa aggacctctt ctgaagctag aaacaatcta tagttataca tcttcattaa	9480
	tactgtgtta ctttttaaaa tagtaatttt ttacattttc ctgtgtaaac ctaattgtgg	9540
25	tagaaatttt taccaactct atactcaatc aagcaaaatt tctgtatatt ccctgtggaa	9600
	tgtacctatg tgagtttcag aaattctcaa aatacgtgtt caaaaatttc tgcttttgca	9660
	tctttgggac acctcagaaa acttattaac aactgtgaat atgagaaata cagaagaaaa	9720
30	taataagccc tctatacata aatgcccagc acaattcatt gttaaaaaac aaccaaacct	9780
	cacactactg tatttcatta tctgtactga aagcaaatgc tttgtgacta ttaaatgttg	9840
	cacatcattc attcactgta tagtaatcat tgactaaagc catttgtctg tgttttcttc	9900
35	ttgtggttgt atatatcagg taaaatattt tccaaagagc catgtgtcat gtaatactga	9960
	accactttga tattgagaca ttaatttgta cccttgttat tatctactag taataatgta	10020
	atactgtaga aatattgctc taattctttt caaaattgtt gcatccccct tagaatgttt	10080
40	ctatttccat aaggatttag gtatgctatt atcccttctt ataccctaag atgaagctgt	10140
	ttttgtgctc tttgttcac attggccctc attccaagca ctttacgctg tctgtaatgg	10200
	gatctatttt tgcactggaa tatctgagaa ttgcaaaact agacaaaagt ttcacaacag	10260
45	atttctaagt taaatcattt tcattaaaag gaaaaagaa aaaaaatttt gtatgtcaat	10320
	aactttatat gaagtattaa aatgcatatt tctatgttgt aatataatga gtcacaaaat	10380
	aaagctgtga cagttctgtt ggtctacaga aa	10412
50	<210> 8	
	<211> 3473	
	<212> DNA	
55	<213> Homo sapiens	

	<400> 8						
	ttcttttccaa	gggtctcttg	gtgaggcccg	tgaccttccc	aagcctctcc	ctgtcttgtg	60
5	aaacctgggc	gtgatatacc	tcccttttag	ggctgctgcg	atcatttagg	cagattaaac	120
	ctcataagt	gtttcccata	caagaaagat	gctagcagtg	caacagacag	aacacttacc	180
	tgcttgcct	cccgccagga	ggtggtcttc	caacttttgc	ccggagtcta	cagaggggtg	240
10	gccctctctg	ctggggctcc	gggacatgg	caggagaggt	tggtctgtct	gtaccgccat	300
	tctcttggcc	agactgtggt	gtctggtccc	tactcacacc	ttctgtcag	agtatccaga	360
	ggccgcagag	tatccacacc	ctggctgggt	gtactggcta	cagatggctg	tggctccagg	420
15	tcacctgcgt	gcctgggtga	tgagaaataa	tgtcacaaca	aatatcccat	ctgcattctc	480
	tgggacactg	acccatgaag	agaaagcagt	tctcacagtt	tttacaggca	cagccacagc	540
	cgtgcatgta	caggtggcag	ctttagcttc	tgctaaactg	gagagctcag	tgtttgtgac	600
20	agactgcgtg	tcctgcaaaa	tcgaaaatgt	ctgtgattca	gctcttcagg	gaaaaaggg	660
	gccgatgtct	ggcctacagg	gctcaagcat	tgatcatcat	cccccatcca	accgtccact	720
	cgccagtgcg	gcatacctgca	cgtggtcagt	ccaagtccag	ggaggggccc	atcacctggg	780
25	ggtggtcgt	atcagtggca	aagtcttgtc	agcagctcat	ggggcaggaa	gggcctatgg	840
	ttgggggttt	cctggcgatc	ccatggagga	aggatacaag	accctcctga	aaggaatttc	900
	cgggaagttc	aatagtgggt	agttggtggc	cattatgggt	ccttcggggg	ccgggaagtc	960
30	cacgctgatg	aacatcctgg	ctggatacag	ggagacgggc	atgaaggggg	ccgtcctcat	1020
	caacggcctg	ccccgggacc	tgcgctgctt	ccggaagggt	tcctgtctaca	tcatgcagga	1080
	tgacatgctg	ctgccgcata	tcactgtgca	ggaggccatg	atggtgtcgg	cacatctgaa	1140
35	gcttcaggag	aaggatgaag	gcagaaggga	aatgggtcaag	gagatactga	cagcgctggg	1200
	cttgcgtgtc	tgcgccaaca	cgcgaccgg	gagcctgtca	ggtggtcagc	gcaagcgct	1260
	ggccatcgcg	ctggagctgg	tgaacaaccc	tccagtcatg	ttcttcgatg	agcccaccag	1320
40	cggcctggac	agcgctcct	gcttccaggt	ggtctcgctg	atgaaagggc	tcgctcaagg	1380
	gggtcgctcc	atcatttgca	ccatccacca	gccagcgcc	aaactcttcg	agctgttcga	1440
	ccagctttac	gtcctgagtc	aaggacaatg	tgtgtaccgg	ggaaaagtct	gcaatcttgt	1500
45	gccatatttg	agggatttgg	gtctgaactg	cccaacctac	cacaaccag	cagattttgt	1560
	catggagggt	gcatccggcg	agtacgggtg	tcagaacagt	cggctggtga	gagcggttcg	1620
	ggagggcag	tgtgactcag	accacaagag	agacctcggg	ggtgatgccg	aggtgaaccc	1680
50	ttttcttttg	caccggccct	ctgaagaggt	aaagcagaca	aaacgattaa	aggggttgag	1740
	aaaggactcc	tcgtccatgg	aaggctgcca	cagcttctct	gccagctgcc	tcacgcagtt	1800
	ctgcatcctc	ttcaagagga	ccttcctcag	catcatgagg	gactcgggtc	tgacacacct	1860
55	gcgcatcacc	tcgcacattg	ggatcggcct	cctcattggc	ctgctgtact	tggggatcgg	1920
	gaacgaagcc	aagaaggtct	tgagcaactc	cggcttcctc	ttcttctcca	tgctgttcct	1980

EP 1 398 032 A1

	catgttcgcg gccctcatgc ctactgttct gacatttccc ctggagatgg gagtctttct	2040
	tcggaacac ctgaactact ggtacagcct gaaggcctac tacctggcca agaccatggc	2100
5	agacgtgccc ttccagatca tgttcccagt ggcctactgc agcatcgtgt actggatgac	2160
	gtcgcagccg tccgacgccg tgcgctttgt gctgtttgcc gcgctgggca ccatgacctc	2220
	cctggtggca cagtccctgg gcctgctgat cggagccgcc tccacgtccc tgcaggtggc	2280
10	cactttcgtg ggcccagtga cagccatccc ggtgctcctg ttctcggggt tcttcgtcag	2340
	cttcgacacc atccccacgt acctacagtg gatgtcctac atctcctatg tcaggtatgg	2400
	gttcgaaggg gtcatcctct ccatctatgg cttagaccgg gaagatctgc actgtgacat	2460
15	cgacgagacg tgccacttcc agaagtcgga ggccatcctg cgggagctgg acgtggaaaa	2520
	tgccaagctg tacctggact tcatcgtact cgggattttc ttcattctcc tccgcctcat	2580
	tgccattttt gtcctcaggt acaaaatccg ggcagagagg taaaacacct gaatgccagg	2640
20	aaacaggaag attagacact gtggccgagg gcacgtctag aatcgaggag gcaagcctgt	2700
	gcccgaaccga cgacacagag actcttctga tccaaccctc agaaccgcgt tgggtttgtg	2760
	ggtgtctcgt gctcagccac tctgcccagc tgggttgatg cttctctcca ttcccctttc	2820
25	tagctttaac taggaagatg taggcagatt ggtggttttt ttttttttaa catacagaat	2880
	tttaaatacc acaactgggg cagaatttaa agctgcaaca cagctggtga tgagaggctt	2940
	cctcagtcga gtcgctcctt agcaccaggc accgtgggtc ctggatgggg aactgcaagc	3000
30	agcctctcag ctgatggctg cacagtcaga tgtctggtgg cagagagtcc gagcatggag	3060
	cgattccatt ttatgactgt tgtttttcac attttcatct ttctaagggtg tgtctctttt	3120
	ccaatgagaa gtcatttttg caagccaaaa gtcgatcaat cgcattcatt ttaagaaatt	3180
35	ataccttttt agtacttgct gaagaatgat tcagggtaaa tcacatactt tgtttagaga	3240
	ggcgaggggt ttaaccgagt caccagctg gtctcataca tagacagcac ttgtgaagga	3300
	ttgaatgcag gttccagggt gaggggaagac gtggacacca tctccactga gccatgcaga	3360
40	catttttaaa agctatacaa aaaattgtga gaagacattg gccaaactct tcaaagtctt	3420
	tctttttcca cgtgcttctt attttaagcg aaatatattg tttgtttctt cct	3473
	<210> 9	
45	<211> 2740	
	<212> DNA	
	<213> Homo sapiens	
50		
	<400> 9	
	aagtcccagt cctgctgtcc caagggactc cggggtcagg tggagcaggc agggcagtct	60
55	gccacgggct ccccaactga agccactctg gggagggtcc ggccaccaga aaatttgccc	120
	agctttgctg cctgttggcc atgggtgacc tctcatcttt gacccccgga ggggtccatgg	180

EP 1 398 032 A1

	gtctccaagt	aaacagaggc	tcccagagct	ccctggaggg	ggctcctgcc	accgccccgg	240
	agcctcacag	cctgggcatc	ctccatgcct	cctacagcgt	cagccaccgc	gtgaggccct	300
5	gggtgggacat	cacatcttgc	cggcagcagt	ggaccaggca	gatcctcaaa	gatgtctcct	360
	tgtacgtgga	gagcgggcag	atcatgtgca	tcctaggaag	ctcaggctcc	gggaaaacca	420
	cgctgctgga	cgccatgtcc	gggaggctgg	ggcgcgcggg	gaccttcctg	ggggagggtgt	480
10	atgtgaacgg	ccgggcgctg	cgccgggagc	agttccagga	ctgcttctcc	tacgtcctgc	540
	agagcgacac	cctgtgagc	agcctcaccg	tgcgcgagac	gctgcactac	accgcgctgc	600
	tggccatccg	ccgcggcaat	cccggctcct	tccagaagaa	ggaggaggcc	gtcatggcag	660
15	agctgagtct	gagccatgtg	gcagaccgac	tgattggcaa	ctacagcttg	gggggcattt	720
	ccacgggtga	gcggcgccgg	gtctccatcg	cagcccagct	gctccaggat	cctaagggtca	780
	tgctgtttga	tgagccaacc	acaggcctgg	actgcatgac	tgctaatacag	attgtcgtcc	840
20	tcctgggtgga	actggctcgc	aggaaccgaa	ttgtggttct	caccattcac	cagccccgtt	900
	ctgagctttt	tcagctcttt	gacaaaattg	ccatcctgag	cttcggagag	ctgattttct	960
	gtggcacgcc	agcggaaatg	cttgatttct	tcaatgactg	cggttaccct	tgtcctgaac	1020
25	attcaaacc	ttttgacttc	tatatggacc	tgacgtcagt	ggatacccaa	agcaagggaac	1080
	gggaaataga	aacctccaag	agagtccaga	tgatagaatc	tgcttacaag	aatcagcaa	1140
	tttgtcataa	aactttgaag	aatattgaaa	gaatgaaaca	cctgaaaacg	ttaccaatgg	1200
30	ttcctttcaa	aaccaaaagat	tctcctggag	ttttctctaa	actgggtggt	ctcctgagga	1260
	gagtgacaag	aaacttggtg	agaaataagc	tggcagtgat	tacgcgtctc	cttcagaatc	1320
	tgatcatggg	tttgttcctc	cttttcttcg	ttctgcgggt	ccgaagcaat	gtgctaaagg	1380
35	gtgctatcca	ggaccgcgta	ggctctcctt	accagtttgt	gggcgccacc	ccgtacacag	1440
	gcatgctgaa	cgctgtgaat	ctgtttcccg	tgctgcgagc	tgtcagcgac	caggagagtc	1500
	aggacggcct	ctaccagaag	tggcagatga	tgctggccta	tgactgcac	gtcctcccct	1560
40	tcagcgttgt	tgccaccatg	attttcagca	gtgtgtgcta	ctggacgctg	ggcttacatc	1620
	ctgaggttgc	ccgatttgga	tatttttctg	ctgctctctt	ggccccccac	ttaattgggtg	1680
	aattttctaac	tcttgtgcta	cttggtatcg	tccaaaatcc	aaatatagtc	aacagtgtag	1740
45	tggctctgct	gtccattgcg	ggggtgcttg	ttggatctgg	attcctcaga	aacatacaag	1800
	aaatgccc	tccttttaaa	atcatcagtt	attttacatt	ccaaaaatat	tgcagtgaga	1860
	ttcttgtagt	caatgagttc	tacggactga	atttcacttg	tggcagctca	aatgtttctg	1920
50	tgacaactaa	tccaatgtgt	gccttcactc	aaggaattca	attcattgag	aaaacctgcc	1980
	cagggtgcaac	atctagattc	acaatgaact	ttctgatttt	gtattcattt	attccagctc	2040
	ttgtcatcct	aggaatagtt	gttttcaaaa	taagggatca	tctcattagc	aggtagtgaa	2100
55	agccatggct	gggaaaaatg	aagtgaagct	gccgactgtg	catgactgct	ctgaacgtct	2160
	gaaatgagag	tgccatgtat	ttctttcttg	acaggacatc	tcaagtcttt	taaccattaa	2220

EP 1 398 032 A1

	gactccattt	gtgcctcttg	gatccaagca	ggccttgaat	gcaatggaag	tggtttatag	2280
	tcccttgctc	ttacaacttg	cagggacatg	tggttatttg	gaaattgtga	ctgagcggac	2340
5	ccaagaatgt	aaataatatt	cataaaccta	tgggagactc	gtgtgactat	tttttttcct	2400
	tgttctaggg	acagaaaaaa	ataggtcagc	ttaaaaatat	gtttacattg	gataaaggat	2460
	taggcaaaaa	taaaatgttt	caaggattcc	tgaccataag	tgacagagaa	agagagttgt	2520
10	gggttttagat	gaagcaaggt	tatcatgcag	aattgggtaa	gaatgcttct	gttcctggaa	2580
	gacccagagt	taaatgcaga	tgtccacacg	aggggtcgga	gttacctgat	cacatcgaga	2640
	gagtgcctggg	cagatggatg	gtgagcacca	ctgctacaga	gcacccagtg	attttactga	2700
15	ggattaaaat	aaaaaaccgt	aggaatgggc	tcaacagtga			2740
	<210> 10						
	<211> 2679						
20	<212> DNA						
	<213> Homo sapiens						
25	<400> 10						
	ctccaggaaa	cagagtgaag	acactggccc	tggcaggcag	cagctgggtc	taagagagct	60
	gcagcccagg	gtcacagacc	tgtggggccc	atggccggga	aggcggcaga	ggagagaggg	120
30	ctgccgaaag	gggccactcc	ccaggatacc	tcgggcctcc	aggatagatt	gttctcctct	180
	gaaagtgaca	acagcctgta	cttcacctac	agtggccagc	ccaacaccct	ggaggtcaga	240
	gacctcaact	gccaggtgga	cctggcctct	cagggtccctt	ggtttgagca	gctggctcag	300
35	ttcaagatgc	cctggacatc	tcccagctgc	cagaattctt	gtgagctggg	catccagaac	360
	ctaagcttca	aagtgagaag	tgggcagatg	ctggccatca	tagggagctc	aggttgtggg	420
	agagcctcct	tgctagatgt	gatcactggc	cgaggtcacg	gcggcaagat	caagtcaggc	480
40	cagatctgga	tcaatgggca	gcccagctcg	cctcagctgg	tgaggaagtg	tgtggcccac	540
	gtgcgccagc	acaaccagct	gctccccaac	ttgactgtgc	gagagacctt	ggccttcatt	600
	gcccagatgc	ggctgcccag	aaccttctcc	caggcccagc	gtgacaaaag	ggtggaggac	660
45	gtgatcgcg	agctgcggct	taggcagtgc	gctgacaccc	gcgtgggcaa	catgtacgtg	720
	cgggggttgt	cgggggtgta	gcgcaggaga	gtcagcattg	gggtgcagct	cctgtggaac	780
	ccaggaatcc	ttattctcga	cgaaccacc	tctgggctcg	acagcttcac	agcccacaac	840
50	ctggtgaaga	ccttgtccag	gctggccaaa	ggcaaccggc	tggtgctcat	ctccctccac	900
	cagcctcgct	ctgacatctt	caggctgttt	gatctgggtc	tcctgatgac	gtctggcacc	960
	cccatctact	taggggcggc	ccagcacatg	gtccagtatt	tcacagccat	cggctacccc	1020
55	tgtcctcgct	acagcaatcc	tgctgacttc	tatgtggacc	tgaccagcat	tgacaggcgc	1080
	agcagagagc	aggaattggc	caccagggag	aaggctcagt	cactcgcagc	cctgtttcta	1140



EP 1 398 032 A1

	gaaaaagtgc	gtgacttaga	tgactttcta	tggaaagcag	agacgaagga	tcttgacgag	1200
	gacacctgtg	tggaaagcag	cgtgacccca	ctagacacca	actgcctccc	gagtcctacg	1260
5	aagatgcctg	gggcgggtgca	gcagtttacg	acgctgatcc	gtcgtcagat	ttccaacgac	1320
	ttccgagacc	tgcccaccct	cctcatccat	ggggcgagg	cctgtctgat	gtcaatgacc	1380
	atcggcttcc	tctatttttg	ccatgggagc	atccagctct	ccttcatgga	tacagccgcc	1440
10	ctcttggtca	tgatcgggtg	tctcatccct	ttcaacgtca	ttctggatgt	catctccaaa	1500
	tggtactcag	agaggggaat	gctttactat	gaactggaag	acgggctgta	caccactggt	1560
	ccatatttct	ttgccaagat	cctcggggag	cttccggagc	actgtgccta	catcatcatc	1620
15	tacgggatgc	ccacctactg	gctggccaac	ctgaggccag	gcctccagcc	cttcctgctg	1680
	cacttcctgc	tggtgtggct	ggtggtcttc	tggtgcagga	ttatggccct	ggccgccgcg	1740
	gcccctgctc	ccaccttcca	catggcctcc	ttcttcagca	atgccctcta	caactccttc	1800
20	tacctcgccg	ggggcttcat	gataaacttg	agcagcctgt	ggacagtgcc	cgcggtggatt	1860
	tccaaagtgt	ccttcctgcg	gtggtgtttt	gaagggctga	tgaagattca	gttcagcaga	1920
	agaacttata	aaatgcctct	cgggaacctc	accatcgccg	tctcaggaga	taaaatcctc	1980
25	agtgccatgg	agctggactc	gtaccctctc	tacgccatct	acctcatcgt	cattggcctc	2040
	agcgggtggc	tcatggctct	gtactacgtg	tccttaaggt	tcatcaaaca	gaaaccaagt	2100
	caagactggg	gattcacgcc	agacgtctgc	ccgctgggtg	gggacctgag	cagacccttc	2160
30	aactgcactc	cctcctcagg	agcccccttc	tggggacagt	gaggacaatg	accctacaga	2220
	tgctcagcta	catccggccc	aggggtgctgc	ggtggcacag	accagccaca	ggatggcagt	2280
	agaataaaga	cagtcgaaag	ggatttctgc	tactggcag	gagactgcga	tgactgggag	2340
35	aaaacctgca	ctcgggtggca	cctacaacgt	tgctaattta	tttccttttg	atatgcattt	2400
	atataggcaa	ctcgatatag	gatgggagca	aactaggaat	gaattgggta	gctagactgt	2460
	gcaggaattg	ttggaacctg	gaggggaaca	taacagtacc	tagcagattt	ggcttcatct	2520
40	tccagggggc	ccacactccg	tggtgagcca	ccatcaatac	agaaagtgac	ctaagatgta	2580
	ccagcaagat	gccatccctt	ctttttgtgt	ggggtcatgg	gctccaaaag	ccaacgtgaa	2640
	caattaaaaa	tgtattgagc	atctaaaaaa	aaaaaaaaaa			2679
45	<210>	11					
	<211>	1156					
	<212>	DNA					
50	<213>	Homo sapiens					
	<400>	11					
55	cgcagcggag	gtgaaggacg	tccttcccca	ggagccgact	ggccaatcac	aggcaggaag	60
	atgaagggtt	tgtgggctgc	gttgctggtc	acattcctgg	caggatgcca	ggccaagggtg	120

EP 1 398 032 A1

	gagcaagcgg	tggagacaga	gccggagccc	gagctgcgcc	agcagaccga	gtggcagagc	180
	ggccagcgct	gggaactggc	actgggtcgc	ttttgggatt	acctgcgctg	ggtgcagaca	240
5	ctgtctgagc	aggtgcagga	ggagctgctc	agctcccagg	tcacccagga	actgagggcg	300
	ctgatggacg	agaccatgaa	ggagttgaag	gcctacaaat	cggaaactgga	ggaacaactg	360
	accccgggtg	cggaggagac	gcgggcacgg	ctgtccaagg	agctgcaggc	ggcgcaggcc	420
10	cggctgggcg	cggacatgga	ggacgtgtgc	ggccgccttg	tgcagtaccg	cggcgagggtg	480
	caggccatgc	tcggccagag	caccgaggag	ctgcgggtgc	gcctcgcctc	ccacctgcgc	540
	aagctgcgta	agcggctcct	ccgcgatgcc	gatgacctgc	agaagcgcct	ggcagtgtac	600
15	caggccgggg	cccgcgaggg	cgccgagcgc	ggcctcagcg	ccatccgcga	gcgcctgggg	660
	cccctgggtg	aacagggccg	cgtgcgggcc	gccactgttg	gctccctggc	cggccagccg	720
	ctacaggagc	gggcccaggc	ctggggcgag	cggctgcgcg	cgcggatgga	ggagatgggc	780
20	agccggaccc	gcgaccgcct	ggacgagggtg	aaggagcagg	tggcggaggt	gcgcgccaag	840
	ctggaggagc	aggcccagca	gatagcctg	caggccgagg	ccttccaggc	ccgcctcaag	900
	agctggttcg	agcccctggt	ggaagacatg	cagcgccagt	gggcccgggt	ggtggagaag	960
25	gtgcaggctg	ccgtgggcac	cagcgccgcc	cctgtgccca	gcgacaatca	ctgaacgccg	1020
	aagcctgcag	ccatgcgacc	ccacgccacc	ccgtgcctcc	tgctccgcg	cagcctgcag	1080
	cgggagaccc	tgtccccgcc	ccagccgtcc	tcctgggggtg	gaccctagtt	taataaagat	1140
30	tcaccaagtt	tcacgc					1156

<210> 12

<211> 417

35 <212> DNA

<213> Homo sapiens

40 <400> 12

	acctcccaac	caagccctcc	agcaaggatt	caggagtgcc	cctcgggcct	cgccatgagg	60
	ctcttcctgt	cgctcccggg	cctggtgggtg	gttctgtcga	tcgtcttgga	aggcccagcc	120
	ccagcccagg	ggaccccaga	cgtctccagt	gccttgata	agctgaagga	gtttggaaac	180
45	acactggagg	acaaggctcg	ggaactcatc	agccgcatca	aacagagtga	actttctgcc	240
	aagatgcggg	agtggttttc	agagacattt	cagaaagtga	aggagaaact	caagattgac	300
	tcatgaggac	ctgaagggtg	acatccagga	ggggcctctg	aaatttccca	caccccagcg	360
50	cctgtgctga	ggactcccgc	catgtggccc	cagggtgccac	caataaaaat	cctaccg	417

<210> 13

55 <211> 753

<212> DNA

&lt;213&gt; Homo sapiens

5 <400> 13  
 gttgtggctg tggagcggaa gtgggtctca accactataa atcctctctg tgcccgtccg 60  
 gagctggtga ggacagcctg ccagagtctg gtctctggac actatgggca cagactcct 120  
 10 cccagctctg tttcttgtcc tcctggtatt gggatttgag gtccagggga cccaacagcc 180  
 ccagcaagat gagatgccta gcccgcctt cctcaccag gtgaaggaat ctctctccag 240  
 ttactgggag tcagcaaaga cagccgcca gaacctgtac gagaagacat acctgcccgc 300  
 15 tgtagatgag aaactcaggg acttgtagcag caaaagcaca gcagccatga gcacttacac 360  
 aggcatTTTT actgaccaag ttctttctgt gctgaaggga gaggagtaac agccagaccc 420  
 cccatcagtg gacaagggga gagtcccccta ctcccctgat ccccaggtt cagactgagc 480  
 20 tcccccttcc cagtagctct tgcatcctcc tccaactct agcctgaatt cttttcaata 540  
 aaaaatacaa ttcaagttgc ttctcatgga tggcactgct tttctgagga ctcaagggcc 600  
 aagatggagg ggctgactca gtccagccaa catttaatga gcacctactt tatgtatgga 660  
 25 gctctaacc atgggtccat ggggaataaag cagtgaatag taacaataaa taatcgtaac 720  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 753

&lt;210&gt; 14

30 &lt;211&gt; 5950

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

35  
 <400> 14  
 gaattccagg ggacatctgt tgcgcaccta ctgtgctcac gctggggcct ctgggatgga 60  
 40 caggattctg ccaaggcaga catctgggtc aagacagtcc tgcacagttg ttcaggttgt 120  
 ggccaagggtt gcgtttgcag atttgccatg taaaaataca ggatgctcag ttacatttga 180  
 atttcagatt aatagcaaaa aaaacttttt ggtataattc tgaaatattt catgggacat 240  
 45 atttatacta aaacgtcatg cactgttgat ttgaaattca aatgtaattg ggctcctct 300  
 atttcgtctg gcaagcgtag acaaaagaat ccagtccagg ccaggcgagc tggctcaagc 360  
 ctgtaatccc agcactttgg gagggcgagg cgggcggatc acgaggtcag gagatcgaga 420  
 ccatcctggc taacacggtg aaaccccgtc tctactaaaa atacaaaaaa ttagctgggc 480  
 50 gtggtggcgg gtgcctgtag tcccagctac tcgggaggct gaggcaggag aatggcgtga 540  
 acctgggagg cggagcttgc agtgagccga gatcgcgcca cagcactcca gcctgggcga 600  
 cagagccaga ctctgtctca aaaaaaaaaa aaagaatcca gtccatagtc ccctgagcca 660  
 55 tgtgccctgg ggtgcagctg ggtccttcag gagaaaaatg ctctatttct ggactggga 720

## EP 1 398 032 A1

	ccgagcctga	tgtggggttt	ttgttggttt	ttgttggtgt	tattgttttt	gagacaaggt	780
	ctcgctccac	cacacccggc	taatttttgt	atttttagta	gagacgggg	ttcactacgt	840
5	tggccaggct	ggtcttgaac	tcctgacctc	aagtgaagccg	cctgcctcgg	cctcccaaag	900
	tgctgggatt	acaggtggga	gccaccgccc	tggccctggg	cctgatgttg	atgacctcct	960
	actatgtgca	cctgcagctc	tcctgcatag	gcctcagccg	tcctgcatga	ggacactggg	1020
10	aggcagggtg	tccttatcaa	ccccgtgtta	cagttgaaca	aactgagccc	cagaaaagaa	1080
	aacgtatttg	cccaggtcac	acggtgaaga	agtgaaggat	tcgaagccca	ggtccatctg	1140
	aagccagagt	caccagagg	agaaagagtt	ggaattgaga	actcaaggaa	tgcttggaag	1200
15	tgatcgggct	cgagcccacc	taggaagaaa	cagaggctgg	agacatgaga	ctgtgttgct	1260
	atttcctctc	atcaaccctt	gggccctatt	gaggccctac	cacaagcctg	gccctgcagc	1320
	ccagtgacta	ggagaaatta	gacacaagat	aataataaca	gcaatgatct	tttttttttt	1380
20	tctgagacgg	agtcttgctc	tttcgcccag	gctggactgc	agtggcgcga	tctcggctca	1440
	atgcaagctc	cacctcccag	gttcacgcca	ttctcctgcc	tcagcctccc	gagtagctag	1500
	gactacaggc	gcctgccacc	acgcctggct	aatttttcat	atttttagta	gagatgggg	1560
25	ttcaccgtgt	tagccaagat	ggtctcaatc	tcctgacctc	gtgatccgcc	tgccctcggc	1620
	tcccaaagtg	ttggggttac	aggcatgagc	caccgcgcct	ggccaacagc	aatgatcttt	1680
	gagcacctat	attgccagtc	tccacggtaa	gagctttctt	cattttttgt	tttgttttgt	1740
30	ttcaagacag	agtcttgctc	tgtcaccag	gctggagtgc	agtgggtgta	tcgcggctca	1800
	ctgcagcctt	cacttcccgg	gttcaagcca	ttctcctgcc	tcagcctccc	aagtagctgg	1860
	gattacaggc	acgcatcact	acttctggct	aatttttgta	tttttagtag	ggacagggtt	1920
35	tttcaccatg	ttggccagg	tggtctcaaa	ctcctggcct	catatgatct	gcccacctcg	1980
	gcctcccaaa	gtgctgggat	tacaggcgtg	agccactgcg	cctttctttg	tatttgttca	2040
	agtaatatat	tgaatatatg	actgtgcctc	ccactttatg	gaggaggaaa	ctgaggccag	2100
40	caaatgaggc	tgtcatggga	ggtggagaca	ggatttgaac	ctgcctcagt	gcaggaggct	2160
	caagagcctc	tgtcttctct	cagggcactg	tgtgggaggg	tgagaaggag	ggaggccac	2220
	agaggcatga	cctctgattg	ccactgtcac	ctgggccctg	ctctctgaag	tctctgccaa	2280
45	gcggggagg	ggccggggga	gggccctgct	ctgtgcagcc	tcccctcccc	cggcccgcag	2340
	agttgagcac	agagggacag	aggcacggaa	ccccagaaa	tgtccctcct	cagaaacagg	2400
	ctccaggccc	tgccctgcc	gtgcctctgc	gtgctggctc	tggcctgcat	tgggggtgag	2460
50	aagaagtggg	tggagggatg	tggggccac	acctggtggg	tgtgagtgtg	gctgtgtgtc	2520
	ctgtggctct	gtagccacgt	gagacatgag	tacggagtgt	gtgcgtttca	tggcgtgcgt	2580
	atgcatgtgc	gtgtcgggga	gtgtgtgtgt	cgggtggctga	gagtgaagtg	tgaatgtcac	2640
55	attgggtaca	actgggatca	tctgtgtgtg	tgcacgtgcg	tgctgtggaag	tgggagtatg	2700
	cagtcgtgg	aaaaaagtgc	atgtctgtgt	gcatatgtgt	atttgtgtgc	acctgtctct	2760

## EP 1 398 032 A1

	ctgtggggtgta	tgtgtgtgca	aaatatttga	gtgtgtggac	atgtgtgagg	gggtgagtgt	2820
	gtgctggtgt	gtacgtctgt	gttttgcata	tgcatttttt	tttttttttt	ttagacggag	2880
5	tctcactctg	tcacccaggc	tggagtgcag	tggtagcagt	ggtgcgatct	tggctcactg	2940
	catcatccgc	ctacccgttt	caagggattc	tcctgcctca	gtcttcagag	tatttgggac	3000
	tacagacaca	cgccaccatg	cctggctaata	tttttttttt	tgagacggag	tctcgtctctg	3060
10	ttacccaggc	tggagtgcag	tggcgtgatc	ttggctcact	gcaagctccg	cctcccgggt	3120
	tcacgccatt	ctcctgcctc	agcctcccga	gtagctggga	ctacaggagc	ccaccaccac	3180
	gcctggctaa	ttttttgtat	ttttactaga	gacggggttt	cgccgtgtta	gccaggatgg	3240
15	tctccatata	ctgacctcgt	gatccgcctg	cctcggcctt	ccaaagtgct	aggattatag	3300
	gcgtgagcca	ctgcgcctgg	ccaatgcctg	gctaattttt	ttatatattt	ggtagagaca	3360
	gggttttgcc	atgttgccca	ggctgggtctt	gaaatcctga	cctcagggtga	tccgcccgcc	3420
20	ttggcctccc	aaagtgctgg	gattacaggc	atgagccacc	acgcccggcc	atgtacttta	3480
	tgttaaaatg	ggatcatatt	ctagatcagc	attatccagt	agaaatttaa	atttttaata	3540
	cagggccagg	cacggtggct	catgcctgta	atcccagcac	tttcggaggc	cgaggcgggt	3600
25	ggatcgcaag	gtcaggagat	ttgagatcat	cctggctaac	agatgggtaa	aaacccatct	3660
	ctactaaaaa	tacaaaaaat	tagccatgca	tgggtggcatg	cgctgtagt	cccagctact	3720
	cgggaggctg	aggccggaga	atcacttgaa	cccgggaggc	agaggttgca	gtgagccgag	3780
30	atcgcgccac	tgcattccaa	cctgggtgac	agagcgagac	tccgtctgaa	aaaaaaaaaa	3840
	aatttaacac	gtatgtagac	aatgtgcaag	gcaccattcc	atgtgcatcg	tatgtagtaa	3900
	ctcttaattc	tcacgataac	cctgaggtag	atattattac	cccgttctac	aaaaggagaa	3960
35	acagtcctgg	ggagacagga	taagtcaccg	gccaaggcac	acagctagct	acatgtggcc	4020
	cccgcgtgac	ggctgggtctc	tgtaggcgag	gctttgtcca	gatgcgtggg	tagaaggctc	4080
	ggcccggaaa	gaggaactga	cagcaaggct	aagccaatgt	ctgcccctgg	gggcagaaaag	4140
40	tcacctcctg	ctctccctcc	actgtccaca	gaggtagctc	agacagggtg	ggggtcacag	4200
	gagaacgaag	ggagaagggg	gtagttcctg	ggcagcaaaa	tcagggtggg	aaggagggca	4260
	tcagaggatg	gcaattagag	aggccattag	aggggaacca	caggcagaca	gggtgacagg	4320
45	agggactact	gacacaagggt	gaagagatgg	cccagccgga	cgggggtggct	cacatctgta	4380
	atcccagcat	tttgggagcc	cgagggtgggt	ggatcacttg	aggtcaggag	ttcgaggccc	4440
	caacatggca	aaaccccatc	tcttctaaaa	atacaaaaat	tagccgggca	tgatggcaga	4500
50	tgcttgaat	ccctgctact	cgggaggctg	aggcaggaaa	attgcctgaa	tccaggagggt	4560
	ggagggttgca	atgagacgag	atcatgacac	tgactccac	cctgggcaac	agagcaagag	4620
	actgactctg	tctcataaaa	aaaaagaaaa	aagaaaaaaa	aaaagagatg	gctgatgggt	4680
55	aaagaggggt	tagcggtcag	gggacacata	agggtaaagg	caggaggcaa	gaggactggc	4740
	agggggctgc	ccctgggcca	ccgggagcga	cacaggatga	gcatggaggg	aaaggagaaa	4800

EP 1 398 032 A1

	ggggattcta	gggtcccagc	ctacccaagt	tgccctctgg	ttccacctag	catgccagcc	4860
	agaggcccag	gaaggaaccc	tgagcccccc	accaaagcta	aagatgagtc	gctggagcct	4920
5	ggtgaggggc	aggatgaagg	agctgctgga	gacagtgggtg	aacaggacca	gagacgggtg	4980
	gcaatggttc	tggtgagggg	gtgctggcct	gggtgggtggg	aggggactcc	tggtgtctgag	5040
	ggaggagggg	ctggggcctg	gacccctgag	tctcaggagg	gaggaaaggg	tggtgagtggtg	5100
10	gctgtgaccc	ctaggtctgg	gaggagtggg	gggttagagc	tgagagcagg	aactcctagg	5160
	tcacagagag	gagcggataa	atggggcaga	gaacacctgg	ggagagctgg	ggcctccact	5220
	gtgatgtcct	ctctcctgta	ggagcccag	caccttccgg	ggcttcatgc	agacctacta	5280
15	tgacgaccac	ctgagggacc	tggttccgct	caccaaggcc	tggttcctcg	aatccaaaga	5340
	cagcctcttg	aagaagaccc	acagcctgtg	ccccaggctt	gtctgtgggg	acaaggacca	5400
	gggttaaaat	gttcataaaa	gccaggtgtg	gttggtggcg	gtgcctgtag	tcccagctac	5460
20	tcaggaggct	gaggtaggat	gatggcttga	gcccaggagt	tcgagaccag	cctgggcaac	5520
	acagcgagat	ctcttggggg	taaaacaaaa	agaaaaaaaa	aagttcatac	ttctccaata	5580
	aataaagtct	cacctgtgtc	cctgtctgga	tccttcccca	gtgtggccag	aaaaaaaccc	5640
25	acccactgc	ctcccaggaa	tcaatgagta	gaagaggtga	cacctgatgg	ggaaggaaga	5700
	gtagggaggt	cgggaagggt	atcaaggaat	aacaccctat	tgtgggcttg	cggagaatgg	5760
	gggacttcaa	ggcgtgtcag	tttcaggagg	gtgagggcag	gagcgtgggt	ggagtcagca	5820
30	ggtcccatg	atggccctca	ctgagagctt	cgcccttgtc	tcctacaagc	tctgactcca	5880
	ttcccagtg	gcacccagca	cctccaaccc	ctccacagcc	cccaaccag	cctctgtcgg	5940
	aggcgaattc						5950
35	<210>	15					
	<211>	3549					
	<212>	DNA					
40	<213>	Homo sapiens					
	<400>	15					
45	cccctcttcc	tcctcctcaa	gggaaagctg	cccacttcta	gctgccctgc	catccccttt	60
	aaagggcgac	ttgctcagcg	ccaaaccgcg	gctccagccc	tctccagcct	ccggctcagc	120
	cggctcatca	gtcgggtccgc	gccttgacgc	tcctccagag	ggacgcgccc	cgagatggag	180
50	agcaaagccc	tgctcgtgct	gactctggcc	gtgtggctcc	agagtctgac	cgctcccg	240
	ggaggggtgg	ccgccgccga	ccaaagaaga	gattttatcg	acatcgaaag	taaatttgcc	300
	ctaaggaccc	ctgaagacac	agctgaggac	acttgccacc	tcattcccgg	agtagcagag	360
55	tccgtggcta	cctgtcattt	caatcacagc	agcaaaacct	tcattggtgat	ccatggctgg	420
	acggtaacag	gaatgtatga	gagttgggtg	ccaaaacttg	tggccgcct	gtacaagaga	480

## EP 1 398 032 A1

	gaaccagact	ccaatgtcat	tgtggtggac	tggctgtcac	gggctcagga	gcattaccca	540
	gtgtccgcgg	gctacaccaa	actggtggga	caggatgtgg	cccggtttat	caactggatg	600
5	gaggaggagt	ttaactaccc	tctggacaat	gtccatctct	tgggatacag	ccttggagcc	660
	catgctgctg	gcattgcagg	aagtctgacc	aataagaaag	tcaacagaat	tactggcctc	720
	gatccagctg	gacctaactt	tgagtatgca	gaagccccga	gtcgtctttc	tcctgatgat	780
10	gcagattttg	tagacgtctt	acacacattc	accagagggg	cccctggtcg	aagcattgga	840
	atccagaaac	cagttgggca	tgttgacatt	tacccgaatg	gagggtacttt	tcagccagga	900
	tgtaacattg	gagaagctat	ccgcgtgatt	gcagagagag	gacttggaga	tgtggaccag	960
15	ctagtgaagt	gctcccacga	gcgctccatt	catctcttca	tcgactctct	gttgaatgaa	1020
	gaaaatccaa	gtaaggccta	cagggtgcagt	tccaaggaag	cctttgagaa	agggctctgc	1080
	ttgagttgta	gaaagaaccg	ctgcaacaat	ctgggctatg	agatcaataa	agtcagagcc	1140
20	aaaagaagca	gcaaaatgta	cctgaagact	cgttctcaga	tgccctacaa	agtcttccat	1200
	taccaagtaa	agattcattt	ttctgggact	gagagtgaag	cccataccaa	tcaggccttt	1260
	gagattttct	tgtatggcac	cgtaggcccag	agtgagaaca	tcccattcac	tctgcctgaa	1320
25	gtttccacaa	ataagaccta	ctccttccta	atttacacag	aggtagatat	tggagaacta	1380
	ctcatgttga	agctcaaagt	gaagagtgat	tcatacttta	gctggtcaga	ctggtaggagc	1440
	agtcccggct	tcgccattca	gaagatcaga	gtaaaagcag	gagagactca	gaaaaagggtg	1500
30	atcttctgtt	ctagggagaa	agtgtctcat	ttgcagaaag	gaaaggcacc	tgcggtattt	1560
	gtgaaatgcc	atgacaagtc	tctgaataag	aagtcaggct	gaaactgggc	gaatctacag	1620
	aacaaagaac	ggcatgtgaa	ttctgtgaag	aatgaagtgg	aggaagtaac	ttttacaaaa	1680
35	catacccagt	gtttgggggtg	tttcaaaagt	ggatttttct	gaatattaat	cccagcccta	1740
	cccttgtag	ttatttttagg	agacagtctc	aagcactaaa	aagtggctaa	ttcaatttat	1800
	gggtatag	ggccaaatag	cacatcctcc	aacgttaaaa	gacagtggat	catgaaaagt	1860
40	gctgttttgt	cctttgagaa	agaaataatt	gtttgagcgc	agagtaaaat	aaggctcctt	1920
	catgtggcgt	attgggccat	agcctataat	tgggttagaac	ctcctatfff	aattggaatt	1980
	ctggatcttt	cggactgagg	ccttctcaaa	ctttactcta	agtctccaag	aatacagaaa	2040
45	atgcttttcc	gcggcacgaa	tcagactcat	ctacacagca	gtatgaatga	tgttttagaa	2100
	tgattccctc	ttgctatttg	aatgtggtcc	agacgtcaac	caggaacatg	taacttggag	2160
	aggacgaag	aaagggtctg	ataaacacag	aggtttttaa	cagtccctac	cattggcctg	2220
50	catcatgaca	aagttacaaa	ttcaaggaga	tataaaatct	agatcaatta	attcttaata	2280
	ggctttatcg	tttattgctt	aatccctctc	tcccccttct	tttttgtctc	aagattatat	2340
	tataataatg	ttctctgggt	agggtgtgaa	aatgagcctg	taatcctcag	ctgacacata	2400
55	atttgaatgg	tgcagaaaaa	aaaaagatac	cgtaatttta	ttattagatt	ctccaaatga	2460
	ttttcatcaa	tttaaaatca	ttcaatatct	gacagttact	cttcagtttt	aggcttacct	2520

EP 1 398 032 A1

	tggtcatgct	tcagttgtac	ttccagtgcg	tctcttttgt	tcctggcttt	gacatgaaaa	2580
	gataggtttg	agttcaaatt	ttgcattgtg	tgagcttcta	cagatttttag	acaaggaccg	2640
5	tttttactaa	gtaaaaggg	ggagagggtt	ctggggtgga	ttcctaagca	gtgcttgtaa	2700
	accatcgcgt	gcaatgagcc	agatggagta	ccatgaggg	tgttatttgt	tgtttttaac	2760
	aactaatcaa	gagtgagtga	acaactat	ataaactaga	tctcctat	ttcagaatgc	2820
10	tcttctacgt	ataaatatga	aatgataaag	atgtcaaata	tctcagaggc	tatagctggg	2880
	aacccgactg	tgaaagtatg	tgatatctga	acacatacta	gaaagctctg	catgtgtgtt	2940
	gtccttcagc	ataattcgg	agggaaaaca	gtcgatcaag	ggatgtattg	gaacatgtcg	3000
15	gagtagaaat	tgttcctgat	gtgccagaac	ttcgaccctt	tctctgagag	agatgatcgt	3060
	gcctataaat	agtaggacca	atgttgtgat	taacatcatc	aggcttgga	tgaattctct	3120
	ctaaaaataa	aatgatgtat	gatttgttgt	tggcatcccc	tttattaatt	cattaaattt	3180
20	ctggatttgg	gttgtgacct	aggggtgcatt	aacttaaaag	attcactaaa	gcagcacata	3240
	gcactgggaa	ctctggctcc	gaaaaacttt	gttatatata	tcaaggatgt	tctggcttta	3300
	cattttat	attagctgta	aatacatgtg	tggatgtgta	aatggagctt	gtacatattg	3360
25	gaaaggatcat	tgtggctatc	tgcatttata	aatgtgtggt	gctaactgta	tgtgtcttta	3420
	tcagtgatgg	tctcacagag	ccaactcact	cttatgaaat	gggctttaac	aaaacaagaa	3480
	agaaacgtac	ttaactgtgt	gaagaaatgg	aatcagcttt	taataaaatt	gacaacattt	3540
30	tattaccac						3549
	<210> 16						
	<211> 1790						
35	<212> DNA						
	<213> Homo sapiens						
40	<400> 16						
	gtgaatctct	ggggccagga	agaccctgct	gcccgggaaga	gcctcatgtt	ccgtgggggc	60
	tgggcgga	tacatatag	ggctccaggc	tgaacggctc	gggccactta	cacaccactg	120
45	cctgataacc	atgctggctg	ccacagtcct	gaccctggcc	ctgctgggca	atgcccattg	180
	ctgctccaaa	ggcacctcgc	acgaggcagg	catcgtgtgc	cgcacacca	agcctgccct	240
	cctgggtgtt	aaccacgaga	ctgccaagg	gatccagacc	gccttccagc	gagccagcta	300
50	cccagatatc	acgggcgaga	aggccatgat	gctccttggc	caagtcaagt	atgggttgca	360
	caacatccag	atcagccact	tgtccatcgc	cagcagccag	gtggagctgg	tgggaagccaa	420
	gtccattgat	gtctccattc	agaacgtgtc	tgtgggtcttc	aaggggaccc	tgaagtattg	480
55	ctacaccact	gcctgggtggc	tgggtattga	tcagtccatt	gacttcgaga	tcgactctgc	540
	cattgacctc	cagatcaaca	cacagctgac	ctgtgactct	ggtagagtgc	ggaccgatgc	600



EP 1 398 032 A1

	ccctgactgc	tacctgtctt	tccataagct	gctcctgcat	ctccaagggg	agcgagagcc	660
	tgggtggatc	aagcagctgt	tcacaaat	catctccttc	accctgaagc	tggtcctgaa	720
5	gggacagatc	tgcaaagaga	tcaacgtcat	ctctaacatc	atggccgatt	ttgtccagac	780
	aagggctgcc	agcatccttt	cagatggaga	cattgggggtg	gacatttccc	tgacaggtga	840
	tcccgtcatc	acagcctcct	acctggagtc	ccatcacaa	ggtcatttca	tctacaagaa	900
10	tgtctcagag	gacctcccc	tccccacctt	ctcgcaccaca	ctgctggggg	actcccgcac	960
	gctgtacttc	tggttctctg	agcaggtctt	ccactcgctg	gccaaagtag	ctttccagga	1020
	tggccgcctc	atgctcagcc	tgatgggaga	cgagttcaag	gcagtgtctg	agacctgggg	1080
15	cttcaacacc	aaccaggaaa	tcttccaaga	ggttgtcggc	ggcttccccca	gccaggccca	1140
	agtcaccgtc	cactgcctca	agatgcccaa	gatctcctgc	caaaacaagg	gagtcgtggt	1200
	caattcttca	gtgatggtga	aattcctctt	tccacgccca	gaccagcaac	attctgtagc	1260
20	ttacacattt	gaagaggata	tcgtgactac	cgtccaggcc	tcctattcta	agaaaaagct	1320
	cttcttaagc	ctcttggtg	tccagattac	accaaagact	gtttccaact	tgactgagag	1380
	cagctccgag	tccatccaga	gcttcctgca	gtcaatgatc	accgctgtgg	gcatccctga	1440
25	ggcatgtctt	cggctcgagg	tagtggtttac	agccctcatg	aacagcaaag	gcgtgagcct	1500
	cttcgacatc	atcaaccctg	agattatcac	tcgagatggc	ttcctgctgc	tgcatatgga	1560
	ctttggcttc	cctgagcacc	tgctgggtgga	tttctccag	agcttgagct	agaagtctcc	1620
30	aaggaggctc	ggatggggct	tgtagcagaa	ggcaagcacc	aggctcacag	ctggaaccct	1680
	gggtgtctct	ccagcgtggt	ggaagttggg	ttaggagtac	ggagatggag	attggctccc	1740
	aactcctccc	tatcctaaag	gcccactggc	attaaagtgc	tgtatccaag		1790
35	<210> 17						
	<211> 2688						
	<212> DNA						
40	<213> Homo sapiens						
	<400> 17						
45	tttaaagctg	ggaggttctg	ccaccaagca	cggccttccc	actgggaaca	caaacttgct	60
	ggcgggaaga	gcccggaaag	aaacctgtgg	atctcccttc	gagatcatcc	aaagagaaga	120
	aaggtgacct	cacattcgtg	ccccttagca	gcactctgca	gaaatgcctc	ctcagctgca	180
50	aaacggcctg	aacctctcgg	ccaaagttgt	ccagggaagc	ctggacagcc	tgccccaggc	240
	agtgagggag	tttctcgaga	ataacgctga	gctgtgtcag	cctgatcaca	tccacatctg	300
	tgacggctct	gaggaggaga	atgggcggct	tctgggccag	atggaggaag	agggcatcct	360
55	caggcggctg	aagaagtatg	acaactgctg	gttggctctc	actgacccca	gggatgtggc	420
	caggatcgaa	agcaagacgg	ttatcgtcac	ccaagagcaa	agagacacag	tgcccatccc	480

EP 1 398 032 A1

	caaaacaggc	ctcagccagc	tcggtcgctg	gatgtcagag	gaggattttg	agaaagcgtt	540
	caatgccagg	ttcccaggg	gcatgaaagg	tcgcaccatg	tacgtcatcc	cattcagcat	600
5	ggggccgctg	ggctcgcctc	tgtcaaagat	cggcatcgag	ctgacggatt	caccctacgt	660
	ggtggccagc	atgcggatca	tgacgcggat	gggcacgccc	gtcctggaag	cactgggcga	720
	tggggagttt	gtcaaagtc	tccattctgt	ggggtgccct	ctgcctttac	aaaagccttt	780
10	ggtcaacaac	tggccctgca	acccggagct	gacgctcatc	gcccacctgc	ctgaccgcag	840
	agagatcatc	tcctttggca	gtgggtacgg	cgggaactcg	ctgctcggga	agaagtgcct	900
	tgctctcagg	atggccagcc	ggctggccaa	ggaggaaggg	tggctggcag	agcacatgct	960
15	ggttctgagg	ataaccaacc	ctgaggggtg	gaagaagtac	ctggcggccg	catttcccg	1020
	cgcctgcggg	aagaccaacc	tggccatgat	gaaccccgag	ctccccgggt	ggaagggtga	1080
	gtgcgtcggg	gatgacattg	cctggatgaa	gtttgacgca	caaggctcatt	taagggccat	1140
20	caaccacaga	aatggctttt	tcggtgtcgc	tcctgggact	tcagtgaaga	ccaaccccaa	1200
	tgccatcaag	accatccaga	agaacacaat	ctttaccaat	gtggccgaga	ccagcgacgg	1260
	gggcgtttac	tgggaaggca	ttgatgagcc	gctagcttca	ggtgtcacca	tcacgtcctg	1320
25	gaagaataag	gagtggagct	cagaggatgg	ggaaccttgt	gcccacccca	actcgagggt	1380
	ctgcacccct	gccagccagt	gccccatcat	tgatgtctgc	tgggagtctc	cggaagggtg	1440
	tcccatgtga	ggcattatct	ttggaggccg	tagacctgct	ggtgtccctc	tagtctatga	1500
30	agctctcagc	tggcaacatg	gagtccttgt	gggggcggcc	atgagatcag	aggccacagc	1560
	ggctgcagaa	cataaaggca	aaatcatcat	gcatgacccc	tttgccatgc	ggcccttctt	1620
	tgggtacaac	ttcggcaaat	acctggccca	ctggcttagc	atggcccagc	accagcagc	1680
35	caaactgccc	aagatcttcc	atgtcaactg	gttccggaag	gacaaggaag	gcaaattcct	1740
	ctggccaggc	tttgagagaga	actccagggt	gctggagtgg	atgttcaacc	ggatcgatgg	1800
	aaaagccagc	accaagctca	cgcccatagg	ctacatcccc	aaggaggatg	ccctgaacct	1860
40	gaaaggcctg	gggcacatca	acatgatgga	gcttttcagc	atctccaagg	aattctggga	1920
	gaaggagggtg	gaagacatcg	agaagtatct	ggaggatcaa	gtcaatgccg	acctcccctg	1980
	tgaaatcgag	agagagatcc	ttgccttgaa	gcaaagaata	agccagatgt	aatcagggcc	2040
45	tgagtgcctt	acctttaaaa	tcattccctt	tcccatccat	aagggtgcagt	aggagcaaga	2100
	gagggcaagt	gttcccaaat	tgacgccacc	ataataatca	tcaccacacc	gtgagcagat	2160
	ctgaaaggca	cactttgatt	tttttaagga	taagaaccac	agaacactgg	gtagtagcta	2220
50	atgaaattga	gaagggaaat	cttagcatgc	ctccaaaaat	tcacatccaa	tgcatagttt	2280
	gttcaaattt	aaggttactc	aggcattgat	cttttcagtg	ttttttcact	ttagctatgt	2340
	ggattagcta	gaatgcacac	caaaaaaata	cttgagctgt	atatatatat	gtgtgtgtgt	2400
55	gtgtgtgtgt	gtgtgtgtgt	gtgtgcatgt	atgtgcacat	gtgtctgtgt	ggtatatattg	2460
	tgtatgtgta	tttgtatgta	ctgttattga	aaatatattt	aatacctttg	gaaaaatcct	2520

gggcaagatg acctactagt tttccttgaa aaaaagttgc tttgttatta atattgtgct 2580  
 taaattatatt ttatacacca ttgttcctta cctttacata attgcaatat ttccccctta 2640  
 5 ctacttcttg gaaaaaaatt acaaaatgaa gttttataga aaagatgg 2688  
  
 <210> 18  
 <211> 3095  
 10 <212> DNA  
 <213> Homo sapiens  
  
 15 <400> 18  
 tagcagagca atcaccacca agcctggaat aactgcaagg gctctgctga catcttcctg 60  
 aggtgccaaag gaaatgagga tggaggaagg aatgaatgtt ctccatgact ttgggatcca 120  
 20 gtcaacacat tacctccagg tgaattacca agactcccag gactggttca tcttggtgtc 180  
 cgtgatcgca gacctcagga atgccttcta cgtcctcttc cccatctggt tccatcttca 240  
 ggaagctgtg ggcattaaac tcctttgggt agctgtgatt ggagactggc tcaacctcgt 300  
 25 ctttaagtgg attctctttg gacagcgtcc atactggtgg gttttggata ctgactacta 360  
 cagcaacact tccgtgcccc tgataaagca gttccctgta acctgtgaga ctggaccagg 420  
 gagccccctt ggccatgcca tgggcacagc aggtgtatac tacgtgatgg tcacatctac 480  
 30 tctttccatc ttccagggaa agataaagcc gacctacaga ttccggtgct tgaatgtcat 540  
 tttgtggttg ggattctggg ctgtgcagct gaatgtctgt ctgtcacgaa tctaccttgc 600  
 tgctcatttt cctcatcaag ttgttgctgg agtcctgtca ggcattgctg ttacagaaac 660  
 35 tttcagccac atccacagca tctataatgc cagcctcaag aaatatattc tcattacctt 720  
 ctccctgttc agcttcgcca tcggatttta tctgtgtctc aagggactgg gtgtagacct 780  
 cctgtggact ctggagaaag cccagaggtg gtgcgagcag ccagaatggg tccacattga 840  
 40 caccacaccc ttgccagcc tcctcaagaa cctgggcacg ctctttggcc tggggctggc 900  
 tctcaactcc agcatgtaca gggagagctg caaggggaaa ctcagcaagt ggctccatt 960  
 ccgcctcagc tctattgtag cctccctcgt cctcctgcac gtctttgact ccttgaaacc 1020  
 45 cccatcccaa gtcgagctgg tcttctacgt cttgtccttc tgcaagagtg cggtagtgcc 1080  
 cctggcatcc gtcagtgtca tcccctactg cctcgcccag gtcctgggcc agccgcacaa 1140  
 gaagtcgttg taagagatgt ggagtcttcg gtgtttaaag tcaacaacca tgccagggat 1200  
 50 tgaggaggac tactatttga agcaatgggc actggtatatt ggagcaagtg acatgccatc 1260  
 cattctgccg tcgtggaatt aaatcacgga tggcagattg gagggtcgcc tggcttattc 1320  
 ccatgtgtga ctccagcctg ccctcagcac agactctttc agatggagggt gccatatcac 1380  
 55 gtacaccata tgcaagtttc ccgccaggag gtcctcctct ctctacttga atactctcac 1440  
 aagtagggag ctactccca ctggaacagc ccattttatc tttgaatggt cttctgccag 1500

## EP 1 398 032 A1

cccattttga ggccagaggt gctgtcagct cagggtgggcc tcttttataa tcctaatacat 1560  
 attgggtaaat gtttttgaaa agctaatagaa gctattgaga aagacctgtt gctagaagtt 1620  
 5 gggttgttct ggattttccc ctgaagactt acttattctt ccgtcacata tacaaaagca 1680  
 agacttccag gtagggccag ctcacaagcc caggctggag atcctaactg agaattttct 1740  
 acctgtgttc attcttaccg agaaaaggag aaaggagctc tgaatctgat aggaaaagaa 1800  
 10 ggctgcctaa ggaggagttt ttagtatgtg gcgtatcatg caagtgtat gccaaagccat 1860  
 gtctaaatgg ctttaattat atagtaatgc actctcagta atgggggacc agcttaagta 1920  
 taattaatag atggttagtg gggtaattct gcttctagta ttttttttac tgtgcataca 1980  
 15 tgttcatcgt atttccttgg atttctgaat ggctgcagtg acccagatat tgcactaggt 2040  
 caaaacattc aggtatagct gacatctcct ctatcacatt acatcatcct ccttataagc 2100  
 ccagctctgc tttttccaga ttcttccact ggctccacat ccacccact ggatcttcag 2160  
 20 aaggctagag ggcgactctg gtggtgcttt tgtatgtttc aattaggctc tgaaatcttg 2220  
 ggcaaaatga caaggggagg gccaggattc ctctctcagg tcaactccagt gttactttta 2280  
 attcctagag ggtaaatatg actcctttct ctatccaag ccaaccaaga gcacattctt 2340  
 25 aaagggaaaag tcaacatctt ctctcttttt tttttttttt gagacagggt ctactatgt 2400  
 tgcccaggct gctcttgaat tcctgggctc aagcagtcct cccaccctac cacagcgctc 2460  
 cgcgtagctg gcatacaggt gcaagccact atgtccagct agccaactcc tccttgctg 2520  
 30 cttttctttt tttttctttt tttgagacgg cgcacctatc acccaggctg gagtggagtg 2580  
 gcacgatctt ggctcactgc aacctcttcc tcctgggtca agcgattctc atgtctcagc 2640  
 ctctcagta gctaggacta ccggcggtgca ccaccatgcc aggctaattt ttatatattt 2700  
 35 agaatttttag aagagatggg atttcatcat gttggccagg ctggtctcga actcctgacc 2760  
 tcaagtgatc cacctgcctt ggctcccaa ggtgctagga ttacaggcat gagccaccgc 2820  
 accgggccct ccttgctgt ttttcaatct catctgatat gcagagtatt tctgccccac 2880  
 40 ccacctacc cccaaaaaaa gctgaagcct atttatttga aagtccttgt ttttgctact 2940  
 aattatatag tataccatac attatcattc aaaacaacca tcctgctcat aacatctttg 3000  
 aaaagaaaaa tatatatgtg cagtatttta ttaaagcaac attttattta agaataaagt 3060  
 45 cttgttaatt actatatattt agatgcaatg tgatc 3095  
  
 <210> 19  
 <211> 2128  
 50 <212> DNA  
 <213> Homo sapiens  
  
 55 <400> 19  
 ggggggtcca tcggggccgc cctcgcacgt cactccggga cccccgcggc ctccgcaggt 60

EP 1 398 032 A1

	tctgcgctcc	aggccggagt	cagagactcc	aggatcgggt	ctttcatctt	cgccgcccct	120
	gcgcgtccag	ctcttctaag	acgagatgcc	gtcgggcttc	caacagatag	gctccgaaga	180
5	tggggaaccc	cctcagcagc	gagtgactgg	gaccctggtc	cttgctgtgt	tctctgcggt	240
	gcttggctcc	ctgcagtttg	ggtacaacat	tggggtcatc	aatgcccctc	agaaggtgat	300
	tgaacagagc	tacaatgaga	cgtggctggg	gaggcagggg	cctgagggac	ccagctccat	360
10	ccctccaggc	accctcacca	ccctctgggc	cctctccgtg	gccatctttt	ccgtgggcgg	420
	catgatttcc	tccttcctca	ttggtatcat	ctctcagtgg	cttggaagga	aaagggccat	480
	gctgggtcaac	aatgtcctgg	cggtgctggg	gggcagcctc	atgggcctgg	ccaacgctgc	540
15	tgcctcctat	gaaatgctca	tccttggaag	attcctcatt	ggcgcctact	cagggctgac	600
	atcagggctg	gtgcccattg	acgtggggga	gattgctccc	actcacctgc	ggggcgccct	660
	ggggacgctc	aaccaactgg	ccattgttat	cggcattctg	atcgcccagg	tgctgggctt	720
20	ggagtccctc	ctgggcactg	ccagcctgtg	gccactgctc	ctgggcctca	cagtgtctacc	780
	tgccctcctg	cagctgggtc	tgctgcccct	ctgtcccagag	agcccccgct	acctctacat	840
	catccagaat	ctcgaggggc	ctgccagaaa	gagtctgaag	cgcttgacag	gctgggcccga	900
25	tgtttctgga	gtgctggctg	agctgaagga	tgagaagcgg	aagctggagc	gtgagcggcc	960
	actgtccctg	ctccagctcc	tgggcagccg	taccacccgg	cagcccctga	tcattgcggt	1020
	cgtgtctgag	ctgagccagc	agctctctgg	catcaatgct	gttttctatt	attcgaccag	1080
30	catcttcgag	acagcagggg	taggccagcc	tgccatgccc	accataggag	ctggtgtggt	1140
	caacacagtc	ttcaccttgg	tctcggtgtt	gttggtggag	cgggcggggc	gccggacgct	1200
	ccatctcctg	ggcctggcgg	gcatgtgtgg	ctgtgccatc	ctgatgactg	tggtcttgct	1260
35	cctgtctggag	cgagttccag	ccatgagcta	cgtctccatt	gtggccatct	ttggcttcgt	1320
	ggcatttttt	gagattggcc	ctggcccat	tccttggttc	atcgtggccg	agctcttcag	1380
	ccagggaccc	cgcccgagc	ccatggctgt	ggctggtttc	tccaactgga	cgagcaactt	1440
40	catcattggc	atgggtttcc	agtatgttgc	ggaggctatg	gggccctacg	tcttccttct	1500
	atctgcggtc	ctcctgctgg	gcttcttcat	cttcaccttc	ttaagagtac	ctgaaactcg	1560
	aggccggacg	tttgaccaga	tctcagctgc	cttcacccgg	acaccctctc	ttttagagca	1620
45	ggagggtgaaa	cccagcacag	aacttgagta	tttagggcca	gatgagaacg	actgaggggc	1680
	caggcagggg	tgggagagcc	agctctctct	acccggccca	gagacccttc	cctttcctct	1740
	gcagcacttt	aaccctctct	tccctattat	ttccgggtgg	aaaagaatcc	ctgcagcctg	1800
50	gtagaattgg	gaagctgggg	gaagggtggt	ctgagcacc	cctcattccc	ctcgtgtgac	1860
	tctcttgga	tatttatgtg	ttgtggtttg	gccgtggcca	tcagggtggg	ccactctccc	1920
	ctccctcttc	cttcccccat	cccctttcct	ccccaccttc	cccagactca	gctccagaat	1980
55	accttcttcg	ctgctagaga	agggggattg	gagggaagac	aggtctagac	tttctcagt	2040
	ggacaaacca	gagcagagag	caggacagga	gacaagaaat	ccagtttccc	accaccttgg	2100

actcctccca caatctggga ctttcact 2128

<210> 20

<211> 1496

<212> DNA

<213> Homo sapiens

<400> 20

ggcacgagga aaatcaagat aaaaatgttc acaattaagc tccttctttt tattgttcct 60  
ctagtatttt cctccagaat tgatcaagac aattcatcat ttgattctct atctccagag 120  
ccaaaatcaa gatttgctat gttagacgat gtaaaaattt tagccaatgg cctccttcag 180  
ttgggacatg gtcctaaaga ctttgtccat aagacgaagg gccaaattaa tgacatattt 240  
caaaaactca acatatttga tcagtctttt tatgatctat cgctgcaaac cagtgaatc 300  
aaagaagaag aaaaggaact gagaagaact acatataaac tacaagtcaa aaatgaagag 360  
gtaaagaata tgtcacttga actcaactca aaacttgaaa gcctcctaga agaaaaaatt 420  
ctacttcaac aaaaagtga atatttagaa gagcaactaa ctaacttaat tcaaatcaa 480  
cctgaaactc cagaacaccc agaagtaact tcacttaaaa cttttgtaga aaaacaagat 540  
aatagcatca aagaccttct ccagaccgtg gaagaccaat ataaacaatt aaaccaacag 600  
catagtcaaa taaaagaaat agaaaatcag ctcagaagga ctagtattca agaaccaca 660  
gaaatttctc tatcttccaa gccaagagca ccaagaacta ctccctttct tcagttgaat 720  
gaaataagaa atgtaaaaca tgatggcatt cctgctgaat gtaccaccat ttataacaga 780  
ggtgaacata caagtggcat gtatgccatc agaccagca actctcaagt ttttcatgtc 840  
tactgtgatg ttatatcagg tagtccatgg acattaattc aacatcgaat agatggatca 900  
caaaacttca atgaaacgtg ggagaactac aaatatggtt ttgggaggct tgatggagaa 960  
ttttggttgg gcctagagaa gatatactcc atagtgaagc aatctaatta tgttttacga 1020  
attgagttgg aagactggaa agacaacaaa cattatattg aatattcttt ttacttgga 1080  
aatcacgaaa ccaactatac gctacatcta gttgcgatta ctggcaatgt cccaatgca 1140  
atcccggaaa acaaagattt ggtgttttct acttgggatc acaaagcaaa aggacacttc 1200  
aactgtccag agggttattc aggaggctgg tggtggcatg atgagtgtgg agaaaacaac 1260  
ctaatggta aatataacaa accaagagca aaatctaagc cagagaggag aagaggatta 1320  
tcttggaagt ctcaaaatgg aaggttatac tctataaaat caaccaaatt gttgatccat 1380  
ccaacagatt cagaaagctt tgaatgaact gaggcaaatt taaaaggcaa taatttaaac 1440  
attaacctca ttccaagtta atgtggtcta ataactggt attaaatcct taagag 1496

<210> 21

<211> 1415

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

5

&lt;400&gt; 21

ggaggaggga gagagagaga agagaagaaa aagaaaaaag aacatcaata aaaagaagtc 60  
 agatttggtc gaaatcttga ggagtcttca ggccagctcc ctgtcggatg gcttttatga 120  
 10 aaaaatatct cctccccatt ctggggctct tcatggccta ctactactat tctgcaaacg 180  
 aggaattcag accagagatg ctccaaggaa agaaagtgat tgtcacaggg gccagcaaag 240  
 ggatcggaag agagatggct tatcatctgg cgaagatggg agcccatgtg gtggtgacag 300  
 15 cgagggtcaa agaaactcta cagaagggtg tatccactg cctggagctt ggagcagcct 360  
 cagcacacta cattgctggc accatggaag acatgacctt cgagagcaa tttgttgccc 420  
 aagcaggaaa gctcatggga ggactagaca tgctcattct caaccacatc accaacactt 480  
 20 ctttgaatct ttttcatgat gatattcacc atgtgcgcaa aagcatggaa gtcaacttcc 540  
 tcagttacgt ggtcctgact gtagctgcct tgcccatgct gaagcagagc aatggaagca 600  
 ttgttgtcgt ctctctctg gctgggaaa ggtcttatcc aatggttgct gcctattctg 660  
 25 caagcaagtt tgctttggat gggttcttct cctccatcag aaaggaatat tcagtgtcca 720  
 ggggtcaatgt atcaatcact ctctgtgttc ttggcctcat agacacagaa acagccatga 780  
 aggcagtttc tgggatatgc catatgcaag cagctccaaa ggaggaatgt gccctggaga 840  
 30 tcatcaaagg gggagctctg cgccaagaag aagtgtatta tgacagctca ctctggacca 900  
 ctcttctgat cagaaatcca tgcaggaaga tcctggaatt tctctactca acgagctata 960  
 atatggacag attcataaac aagtaggaac tccctgaggg ctgggcatgc tgagggattt 1020  
 35 tgggactgtt ctgtctcatg tttatctgag ctcttatcta tgaagacatc ttcccagagt 1080  
 gtccccagag acatgcaagt catgggtcac acctgacaaa tgggaaggagt tcctctaaca 1140  
 tttgcaaaat ggaaatgtaa taataatgaa tgtcatgcac cgctgcagcc agcagttgta 1200  
 40 aaattgttag taaacatagg tataattacc agatagttat attaaattta tatcttatat 1260  
 ataataatat gtgatgatta atacaatatt aattataata aaggtcacat aaactttata 1320  
 aattcataac tggtagctat aacttgagct tattcaggat ggtttcttta aaaccataaa 1380  
 45 ctgtacaaat gaaatttttc aatatttggt tctta 1415

&lt;210&gt; 22

50 &lt;211&gt; 1405

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

55

&lt;400&gt; 22

acaattcaga ggctgctgcc tgcttaggag gttgtagaaa gctctgtagg ttctctctgt 60  
 gtgtcctaca ggagtcttca ggccagctcc ctgtcggatg gcttttatga aaaaatatct 120  
 5 cctccccatt ctggggctct tcatggccta ctactactat tctgcaaacg aggaattcag 180  
 accagagatg ctccaaggaa agaaagtgat tgtcacaggg gccagcaaag ggatcggaa 240  
 agagatggct tatcatctgg cgaagatggg agcccatgtg gtggtgacag cgaggtaaaa 300  
 10 agaaactcta cagaaggtgg tatccactg cctggagctt ggagcagcct cagcacacta 360  
 cattgctggc accatggaag acatgacctt cgcagagcaa tttgttgccc aagcaggaaa 420  
 gctcatggga ggactagaca tgctcattct caaccacatc accaactctt ctttgaatct 480  
 15 ttttcatgat gatattcacc atgtgcgcaa aagcatggaa gtcaacttcc tcagttacgt 540  
 ggtcctgact gtagctgcct tgcccatgct gaagcagagc aatggaagca ttgttgctgt 600  
 ctctctcttg gctgggaaag tggcttatcc aatggttgct gcctattctg caagcaagtt 660  
 20 tgctttggat gggttcttct cctccatcag aaaggaatat tcagtgcca gggtaaatgt 720  
 atcaatcact ctctgtgttc ttggcctcat agacacagaa acagccatga aggagtttc 780  
 tgggatagtc catatgcaag cagctccaaa ggaggaatgt gccctggaga tcatcaaagg 840  
 25 gggagctctg cgccaagaag aagtgtatta tgacagctca ctctggacca ctcttctgat 900  
 cagaaatcca tgcaggaaga tcctggaatt tctctactca acgagctata atatggacag 960  
 attcataaac aagtaggaac tccctgaggg ctgggcagtc tgagggattt tgggactgtt 1020  
 30 ctgtctcatg tttatctgag ctcttatcta tgaagacatc ttcccagagt gtccccagag 1080  
 acatgcaagt catgggtcac acctgacaaa tggaaggagt tcctctaaca tttgcaaaat 1140  
 ggaaatgtaa taataatgaa tgtcatgcac cgctgcagcc agcagttgta aaattgttag 1200  
 35 taaacatagg tataattacc agatagttat attaaattta tatcttatat ataataatat 1260  
 gtgatgatta atacaatatt aattataata aaggtcacat aaactttata aattcataac 1320  
 tggtagctat aacttgagct tattcaggat ggtttcttta aaaccataaa ctgtacaaat 1380  
 40 gaaatttttc aatatttggt tctta 1405


#### 45 Claims

1. A compound of the formula (I), or pharmaceutically acceptable salts or solvates thereof,

50

55





(I)


wherein the substituents and indices have the following meanings:

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub>, is H, halogen, hydroxy, protected hydroxy, cyano, nitro, C<sub>1</sub> to C<sub>6</sub> alkyl, C<sub>1</sub> to C<sub>6</sub> substituted alkyl, C<sub>1</sub> to C<sub>7</sub> alkoxy, C<sub>1</sub> to C<sub>7</sub> substituted alkoxy, C<sub>1</sub> to C<sub>7</sub> acyl, C<sub>1</sub> to C<sub>7</sub> substituted acyl, C<sub>1</sub> to C<sub>7</sub> acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, protected N-(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, N, N-di(C<sub>1</sub> to C<sub>6</sub> alkyl)carboxamide, trifluoromethyl, N-((C<sub>1</sub> to C<sub>6</sub> alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or substituted or unsubstituted phenyl,

R<sub>5</sub> is H, C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>3</sub> to C<sub>8</sub> cycloalkyl, C<sub>3</sub> to C<sub>8</sub> substituted cycloalkyl, aryl, substituted aryl, C<sub>1</sub> to C<sub>6</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl

R<sub>6</sub> is H, a secondary or a tertiary amine, C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>3</sub> to C<sub>8</sub> cycloalkyl, C<sub>3</sub> to C<sub>8</sub> substituted cycloalkyl, aryl, substituted aryl, C<sub>1</sub> to C<sub>6</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl

2. A compound according to claim 1, or pharmaceutically acceptable salts or solvates thereof, of formula (II)




(II)

wherein the substituents and indices have the following meanings:

R<sub>7</sub> is C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>3</sub> to C<sub>8</sub> cycloalkyl, C<sub>3</sub> to C<sub>8</sub> substituted cycloalkyl, aryl, substituted aryl, C<sub>1</sub> to C<sub>6</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl

3. A compound according to claim 1, or pharmaceutically acceptable salts or solvates thereof, of formula (III)



(III)

Wherein the substituents and indices have the following meanings:

$R_1, R_2, R_3, R_4$ , is H, halogen, hydroxy, protected hydroxy, cyano, nitro,  $C_1$  to  $C_6$  alkyl,  $C_1$  to  $C_6$  substituted alkyl,  $C_1$  to  $C_7$  alkoxy,  $C_1$  to  $C_7$  substituted alkoxy,  $C_1$  to  $C_7$  acyl,  $C_1$  to  $C_7$  substituted acyl,  $C_1$  to  $C_7$  acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-( $C_1$  to  $C_6$  alkyl)carboxamide, protected N-( $C_1$  to  $C_6$  alkyl)carboxamide, N, N-di( $C_1$  to  $C_6$  alkyl)carboxamide, trifluoromethyl, N-(( $C_1$  to  $C_6$  alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl,

$R_5$  in formula (III) is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_3$  to  $C_8$  cycloalkyl,  $C_3$  to  $C_8$  substituted cycloalkyl, aryl, substituted aryl,  $C_1$  to  $C_6$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl,

$R_8$  in formula (III) is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_3$  to  $C_8$  cycloalkyl,  $C_3$  to  $C_8$  substituted cycloalkyl,  $C_1$  to  $C_7$  acyl,  $C_1$  to  $C_7$  substituted acyl, aryl, substituted aryl,  $C_1$  to  $C_6$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl, carboxamide, protected carboxamide, N-( $C_1$  to  $C_6$  alkyl)carboxamide, protected N-( $C_1$  to  $C_6$  alkyl)carboxamide, N, N-di( $C_1$  to  $C_6$  alkyl)carboxamide, trifluoromethyl, N-(( $C_1$  to  $C_6$  alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl,

$R_9$  in formula (III) is H,  $C_1$  to  $C_8$  alkyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_3$  to  $C_8$  cycloalkyl,  $C_3$  to  $C_8$  substituted cycloalkyl,  $C_1$  to  $C_7$  acyl,  $C_1$  to  $C_7$  substituted acyl, aryl, substituted aryl,  $C_1$  to  $C_6$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl, carboxamide, protected carboxamide, N-( $C_1$  to  $C_6$  alkyl)carboxamide, protected N-( $C_1$  to  $C_6$  alkyl)carboxamide, N, N-di( $C_1$  to  $C_6$  alkyl)carboxamide, trifluoromethyl, N-(( $C_1$  to  $C_6$  alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl,

$R_8$  and  $R_9$  in formula (III) are taken together with the N in formula (III) to form a ring of the following types:

$C_3$  to  $C_8$  mono, di- or tri- heteroatom-substituted cycloalkyl, preferably piperidino, morpholino, thiomorpholino, piperazino, or  $C_1$  to  $C_6$  alkyl-,  $C_1$  to  $C_6$  substituted alkyl substituted- or benzocondensated derivatives thereof,

$C_4$  to  $C_{10}$  mono, di- or tri- heteroatom-substituted bi- or tricycloalkyl derivatives thereof or  $C_1$  to  $C_6$  alkyl-,  $C_1$  to  $C_6$  substituted alkyl substituted- or benzocondensated derivatives thereof,

$C_3$  to  $C_8$  mono, di- or tri- heteroatom-substituted heteroaryl, preferably pyrrolo, pyrazolo, oxazolo, thiazolo, pyridino, pyridazino, pyrimidino, pyrazino, triazino, indolo, quinolino, quinazolino, or  $C_1$  to  $C_6$  alkyl-,  $C_1$  to  $C_6$  substituted alkyl substituted- or benzocondensated derivatives thereof

#### 4. A compound according to claim 3 wherein

$R_1$  and  $R_3$  are H,

$R_2$  and  $R_4$  are H, or iodo, bromo, chloro or fluoro or hydroxy methyl, trifluoromethyl, methoxy, amino, alkylated amino, or nitro

$R_5$  is H,  $C_1$  to  $C_8$  alkyl, preferably isopropyl, vinyl, 2-isobutyl, or cyclohexyl,  $C_1$  to  $C_8$  substituted alkyl,  $C_3$  to  $C_8$  cycloalkyl,  $C_3$  to  $C_8$  substituted cycloalkyl, aryl, substituted aryl,  $C_1$  to  $C_6$  alkylphenyl or  $C_7$  to  $C_{12}$  substituted phenylalkyl,

$R_8$  and  $R_9$  in formula (III) are taken together with the N in formula (III) to form a ring of the following types:

C<sub>3</sub> to C<sub>8</sub> mono, di- or tri- heteroatom-substituted cycloalkyl, preferably piperidino, morpholino, thiomorpholino, piperazino, or C<sub>1</sub> to C<sub>6</sub> alkyl-C<sub>1</sub>-C<sub>6</sub> substituted or benzocondensated derivatives thereof, more preferably a 4-aryl- or 4-heteroaryl- or 4-alkyl-substituted piperazino or a 4-alkyl-substituted piperidino

C<sub>4</sub> to C<sub>10</sub> mono, di- or tri- heteroatom-substituted bi- or tricycloalkyl or C<sub>1</sub> to C<sub>6</sub> alkyl-, C<sub>1</sub>-C<sub>6</sub> substituted alkyl substituted- or benzocondensated derivatives thereof

C<sub>3</sub> to C<sub>8</sub> mono, di- or tri- heteroatom-substituted heteroaryl, preferably pyrrolo, pyrazolo, oxazolo, thiazolo, pyridino, pyridazino, pyrimidino, pyrazino, triazino, indolo, quinolino, quinazolino or C<sub>1</sub> to C<sub>6</sub> alkyl- C<sub>1</sub> to C<sub>6</sub> substituted alkyl substituted- or benzocondensated derivatives thereof

5. A compound according to any of claims 1 to 3 wherein


R<sub>1</sub> and R<sub>3</sub> are H,

R<sub>2</sub> and R<sub>4</sub> are H, or iodo, bromo, chloro or fluoro or hydroxy methyl, trifluoromethyl, methoxy, amino, alkylated amino, or nitro

R<sub>5</sub> is H, C<sub>1</sub> to C<sub>8</sub> alkyl, preferably isopropyl, vinyl, 2-isobutyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>3</sub> to C<sub>8</sub> cycloalkyl, C<sub>3</sub> to C<sub>8</sub> substituted cycloalkyl, aryl, substituted aryl, C<sub>1</sub> to C<sub>6</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl, R<sub>8</sub> is a C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>3</sub> to C<sub>8</sub> cycloalkyl, C<sub>3</sub> to C<sub>8</sub> substituted cycloalkyl, C<sub>1</sub> to C<sub>6</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl, preferably benzyl or (furan-2-yl)-methyl or (thiophen-2-yl)-methyl


and R<sub>9</sub> in formula is C<sub>1</sub> to C<sub>8</sub> alkyl, C<sub>1</sub> to C<sub>8</sub> substituted alkyl, C<sub>3</sub> to C<sub>8</sub> cycloalkyl, C<sub>3</sub> to C<sub>8</sub> substituted cycloalkyl, C<sub>1</sub> to C<sub>6</sub> alkylphenyl or C<sub>7</sub> to C<sub>12</sub> substituted phenylalkyl, preferably (ethyl)-propion-1-yl

6. A compound according to any of claims 1 to 5 being



(IV)

7. A compound according to any of claims 1 to 5 being



(V)

8. A compound according to any of claims 1 to 5 being



15

20




30

35




50

55




(IX)

12. A compound according to any of claims 1 and 5 being




(X)

13. A compound according to any of claims 1 and 5 being




(XI)

14. A compound according to any of claims 1 and 5 being



(XII)

15. A compound according to any of claims 1 and 5 being



(XIII)

16. A compound according to any of claims 1 to 15 wherein said compound is capable of binding the NR1H3 receptor protein encoded by a nucleic acid comprising SEQ ID NO:2 or a portion thereof or a mammalian homologue thereof.

17. A compound according to any of claims 1 to 15 wherein said compound is capable of binding the NR1H2 receptor protein encoded by a nucleic acid comprising SEQ ID NO:1 or a portion thereof or a mammalian homologue thereof.

18. A compound according to any of claims 1 to 15 for use as a medicament.

19. A method for prevention or treatment of a NR1H3 and/or NR1H2 receptor protein mediated disease or NR1H3 and/or NR1H2 receptor protein homologue mediated disease or condition in a mammal comprising administration of a therapeutically effective amount of a compound according to claims 1 to 15 wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according to claims 1 to 15 to the NR1H3 and/or NR1H2 receptor proteins or to the NR1H3 and/or NR1H2 receptor protein homologues.

20. A method for regulating the cholesterol synthesis or transport in a mammal which comprises activating the NR1H3 and/or NR1H2 receptors with a therapeutically effective amount of a compound according to claims 1 to 15.

21. A method of treating in mammal a disease which is affected by cholesterol, triglyceride, bile acid, glucose or glucocorticoid levels comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 15.
- 5 22. A method of treating in a mammal Atherosclerosis, Alzheimers disease, Type II diabetes, lipid disorders, obesity, an inflammatory or a cardiovascular disorder comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claims 1 to 15.
- 10 23. A method according to any of claims 19 to 22, wherein the expression of one or more of the genes out of the group comprising ABCA1, ABCG1, ABCG5, ABCG8, apolipoprotein-CI, -CII, -CIV, -E, LPL (lipoprotein lipase), CETP (cholesteryl ester transfer protein) or other genes that positively regulate cholesterol homeostasis is increased upon compound administration.
- 15 24. A method according to any of claims 19 to 22, wherein the expression of one or more of the genes out of the group comprising 11- $\beta$ -HSD (11- $\beta$  hydroxysteroid dehydrogenase), PEPCK (phosphoenolpyruvat carboxykinase), G-6-P (glucose-6-phosphatase) is reduced upon compound administration.
- 20 25. A method according to any of claims 19 to 22, wherein the expression of one or more of the genes out of the group comprising FAS (Fatty Acid Synthase), SREBP-1c (Sterol-response element binding protein), SCD-1 (Stearoyl-CoA Desaturase), Angiopoietin like protein 3 (Angptl3) or other genes which are relevant for controlling serum triglyceride or glucose levels are not or more weakly increased in liver and or other organs compared to administration of a full agonist like T0901317.
- 25 26. A method of blocking in a mammal the cholesterol or fatty acid absorption in the intestine of a mammal in need of such blocking comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound as defined in any of claims 1 to 15.
- 30 27. A method for treating obesity in a mammal comprising administering a therapeutically effective amount of a compound as defined in any of claims 1 to 15.
- 35 28. A method of modulating a gene whose expression is regulated by the NR1H3 and/or NR1H2 receptor in a mammal comprising administering a therapeutically effective amount of a compound as defined in any claims 1 to 15.
29. A method according to any of claims 19 to 28 wherein the expression of ABCA1 and/or ABCG1 and/or ABCG5 and/or ABCG8 is increased.
30. Use of a compound as defined in any of claims 1 to 15 in a method according to claims 19 to 29 wherein the mammal is a human.
- 40 31. Use of a compound as defined in any of claims 1 to 15 for the manufacture of a medicament for the prevention or treatment of a NR1H3 and/or NR1H2 receptor protein or NR1H3 and/or NR1H2 receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound to the NR1H3 and/or NR1H2 receptor protein or NR1H3 and/or NR1H2 receptor protein homologue.
- 45 32. Use of a compound as defined in any of claims 1 to 15 for the manufacture of a medicament for prevention or treatment of a NR1H3 and/or NR1H2 receptor protein mediated disease or condition wherein the mammal is a human.
- 50 33. Use of a compound as defined in any of claims 1 to 15 for the manufacture of a medicament for regulating the cholesterol transport system in a mammal by activating the NR1H3 and/or NR1H2 receptor.
34. Use of a compound as defined in any of claims 1 to 15 for the manufacture of a medicament for regulating levels of cholesterol, triglyceride, and/or bile acid.
- 55 35. Use of a compound as defined in any of claims 1 to 15 for the manufacture of a medicament for treating in a mammal atherosclerosis, Alzheimer disease, gallstone disease, lipid disorders, inflammatory disorder, type II diabetes, obesity or a cardiovascular disorder.

36. Use of a compound as defined in any of claims 1 to 15 for the manufacture of a medicament capable for blocking in a mammal the cholesterol and/or fatty acid absorption in the intestine.

37. Use of a compound as defined in any of claims 1 to 15 for the manufacture of a medicament for treating obesity in a mammal.


38. Use of a compound as defined in any of claims 1 to 15 for the manufacture of a medicament for modulating a gene whose expression is regulated by the NR1H3 and/or NR1H2 receptor.

39. Use of a compound as defined in any of claims 1 to 15 in a mammal for the selective up-regulation of one or more genes selected from the group comprising ABCA1, ABCG1, ABCG5, ABCG8, apolipoprotein-CI, -CII, -CIV, -E, LPL (lipoprotein lipase), CETP (cholesteryl ester transfer protein) or other genes that positively regulate cholesterol homeostasis are increased and a weaker regulation of one or more of the genes selected from the group comprising FAS and SREBP-1c or other genes that positively regulate lipogenesis, said compound showing a larger difference in regulation of the two groups of genes when compared with the regulatory behaviour of a full agonist like T0901317 on both groups of genes.

40. The use according to any of claims 31 to 39, wherein the mammal is human.



Fig.1






**Fig. 2**




Number of repeats .....	1
plate: GREINER FIA-Plate black 384 well med. binding	
Measurement height .....	3.50 mm
Label technology .....	TR-F Lance
Emission filter name .....	D615
Emission filter slot .....	A1
Emission aperture .....	Normal
Excitation filter .....	D340
Delay .....	50 $\mu$ s
Window time .....	400 $\mu$ s
Cycle .....	1000 $\mu$ s
Light integrator capacitors .....	1
Light integrator ref. level .....	95
Flash energy area .....	High
Flash energy level .....	223
Flash absorbance measurement .....	No
Beam .....	Normal
Label technology .....	TR-F Lance
Emission filter name .....	D665
Emission filter slot .....	A8
Emission aperture .....	Normal
Excitation filter .....	D340
Delay .....	50 $\mu$ s
Window time .....	400 $\mu$ s
Cycle .....	1000 $\mu$ s
Light integrator capacitors .....	1
Light integrator ref. level .....	95
Flash energy area .....	High
Flash energy level .....	223
Flash absorbance measurement .....	No
Beam .....	Normal




**Fig. 3**




<b>Gene definition</b>	<b>NCBI Accession number of gene</b>	<b>Corresponding SEQ ID Number</b>
Liver X receptor beta NR1H2	NM_007121	<b>1</b>
Liver X receptor alpha NR1H3	NM_005693	<b>2</b>
Steroid receptor coactivator 1	U90661	<b>3</b>




Fig. 4

MOLNAME	MOLECULE STRUCTURE	EC50 AVG [μM]	% EFIC AVG
TO901317	 <p>TO901317</p>	0,1	100
LN0000007033		5	50
LN0000007025		4	60

LN0000007184	 <chem>C=CC1=NC(=O)c2ccccc2N1N(C3CCc4ccccc4CC3C(=O)OCC)C5=CC=CC=C5</chem>	0,5	130
LN0000007031	 <chem>CC(C)C1=NC(=O)c2cc(F)ccc2N1N(C3CCc4ccncc4CC3)C5=CC=CC=C5</chem>	4	50
LN0000007032	 <chem>c1ccc(cc1)CCN1C(=O)c2cc(F)ccc2N1N(C3CCc4ccncc4CC3)C5=CC=CC=C5</chem>	42	150

LN0000006672			
LN0000007172		1,1	21
LN0000007174		32	>100

LN0000007179		0,8	127
LN0000007180		0,16	128
LN0000007181		0,12	89

LN0000007182	 <chem>C=CCN1C(=O)c2ccccc2N1C3CCN(CC3)C(=O)OCC</chem>	2,4	108
LN0000007183	 <chem>C=CCN1C(=O)c2ccccc2N1C3CCN(CC3)C(=O)OCC</chem>	2,6	117
LN0000007184	 <chem>C=CCN1C(=O)c2ccccc2N1C3CCN(CC3Cc4ccccc4)C(=O)OCC</chem>	0,55	130





LN0000007185	 <chem>CCOC(=O)C1CCN(C1Cc2ccccc2C(=O)N3C=CC=C3)C=C3C=CC=C3</chem>	0,34	142
--------------	--	------	-----


Fig. 5




**Fig. 6**

<b>Protein / Gene Name</b>	<b>NCBI Accesion number of gene</b>	<b>Corresponding SEQ ID number</b>
Liver X receptor beta, LXR $\beta$	NM_007121	<b>1</b>
Liver X receptor alpha, LXR $\alpha$	NM_005693	<b>2</b>
Cholesterol 7 $\alpha$ hydroxylase, Cyp7A1	NM_000780	<b>3</b>
Fatty Acid Synthase FAS	NM_004104	<b>4</b>
Stearyl CoA desaturase, SCD	XM_030447	<b>5</b>
Sterol Response Element Binding Protein 1C, SREBP-1C	NM_004176	<b>6</b>
ATP binding cassette transporter A1; ABCA1	NM_005502	<b>7</b>
ATP binding cassette transporter G1; ABCG1	XM_032950	<b>8</b>
ATP binding cassette transporter G5; ABCG5	NM_022436	<b>9</b>
ATP binding cassette transporter G8; ABCG8	AF324494	<b>10</b>
Apolipoprotein E, apoE	NM_000041	<b>11</b>
Apolipoprotein C-I, apoC-I	NM_001645	<b>12</b>
Apolipoprotein C-II apoC-II	NM_000483	<b>13</b>
Apolipoprotein C-IV, apoC-IV	U32576	<b>14</b>
Lipoprotein Lipase, LPL	M15856	<b>15</b>
Cholesteryl Ester Transfer Protein, CETP	NM_000078	<b>16</b>
Phosphoenolpyruvate carboxykinase 1 (PEPCK)	NM_002591	<b>17</b>
Glucose-6-phosphatase (G6P)	NM_000151	<b>18</b>
Insulin-responsive glucose transporter (GLUT4)	M20747	<b>19</b>
Angiopoietin-like 3, ANGPTL3	NM_01445	<b>20</b>
11-beta Hydroxysteroid dehydrogenase HSD11B1 variant 2	NM_181755	<b>21</b>
11-beta Hydroxysteroid dehydrogenase HSD11B1 variant 1	NM_005525	<b>22</b>


**Fig. 7**




**Fig. 8A**




**Fig. 8B**




**Fig. 9 A**



**Fig. 9 B**



**Fig. 10**



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 03 02 0417  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 02/062798 A (REDDY RESEARCH FOUNDATION) 15 August 2002 (2002-08-15) * claim 1 * * page 106, line 22 - page 107, line 6 * * page 1, line 17 - page 2, line 16 * -----	1,3-5, 16-40	A61K31/517 C07D239/95 C07D401/12 C07D405/12 A61P3/06
X	WO 97/20823 A (CRISCIONE LEOLUCA ;YAMAGUCHI YASUCHIKA (CH); CIBA GEIGY AG (CH); M) 12 June 1997 (1997-06-12) * page 74; example 28 * * page 1, paragraph 1 * * claim 12 * -----	1,3,5, 16-40	
X	WO 02/48152 A (BAKTHAVATCHALAM RAJAGOPAL ;BRIELMANN HARRY L (US); ELLIOTT RICHARD) 20 June 2002 (2002-06-20) * page 59; example 12 * * page 6, paragraph 17 * -----	1,3,4, 16-40	
X	US 3 609 152 A (HESS HANS-JURGEN E ET AL) 28 September 1971 (1971-09-28) * examples III-X * ----- -/--	1,3-5, 16-40	TECHNICAL FIELDS SEARCHED (Int.Cl.7)  C07D A61K A61P
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search: see sheet C</p>			
Place of search	Date of completion of the search	Examiner	
Munich	10 December 2003	Kollmannsberger, M	
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... &amp; : member of the same patent family, corresponding document</p>	
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p>			

EPO FORM 1503 03 02 (P040307)





European Patent  
Office

INCOMPLETE SEARCH  
SHEET C

Application Number  
EP 03 02 0417

Claim(s) searched completely:  
6-15

Claim(s) searched incompletely:  
1-5, 16-40

Reason for the limitation of the search:

Claims 1-5 encompass a large number of known compounds. Also the use of these compounds in the treatment of diseases as listed e. g. in claim 22 appears to be well known. The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 84 EPC). For these reasons, a meaningful search over the whole breadth of the claims is impossible. Consequently, the search is only complete for:

Compounds according to claim 1 which are explicitly stated in the prior art to have binding affinity to the LXR receptor; compounds as such according to claims 5-16.

Only some documents relevant to other subject-matter of the claims have been cited for illustration.



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 03 02 0417

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	WO 01/021598 A (ASTRAZENECA UK LTD ; ASTRAZENECA AB (SE)) 29 March 2001 (2001-03-29) . * claims 1,10 *	1,3, 16-40	
X	----- US 6 337 332 B1 (CARPINO PHILIP A) 8 January 2002 (2002-01-08) * column 1 * * examples 1-7 * * tables 1-5 *	1,16-40	
X	----- HESS, HANS J. ET AL: "Antihypertensive 2-amino-4(3H)-quinazolinones" JOURNAL OF MEDICINAL CHEMISTRY, 11(1), 130-6 CODEN: JMCMAR; ISSN: 0022-2623, 1968, XP002264555 * column 1, paragraph 1 * * page 132 - page 133; table 1 *	1,3-5, 16-40	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	----- GUPTA C M ET AL: "Drugs acting on the central nervous system. Syntheses of substituted quinazolones and quinazolines and triazepino- and triazocinoquinazolones" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 11, no. 2, 26 February 1968 (1968-02-26), pages 392-395, XP002156695 ISSN: 0022-2623 * examples 4-7,13-16,20,22,23,38; table 2 * ----- -/--	1-5,18	



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 03 02 0417

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ZAIDI, NAFEESA B. ET AL: "Synthesis of some new 4(3H)-quinazolones and their derivatives as possible antitubercular agents" XP002264556 retrieved from STN Database accession no. 1982:616118 * abstract * & ACTA CIENCIA INDICA, CHEMISTRY, 7(1-4), 63-8 CODEN: ACICDV; ISSN: 0253-7338, 1981,	2,18	
X	MANABU HORI ET AL: "Novel 4-Substituted 2-Piperazinylquinazolines as potent Anticonvulsive and Antihypoxic Agents" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP, vol. 38, no. 5, 1990, pages 1286-1291, XP002128282 ISSN: 0009-2363 * examples 3A-3H; table II *	1,3-5	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002225148 Order Number: TRG10400#07364-D; TRG10400#01891-D; TRG10400#01815-D; TRG10400#01814-D; TRG10400#01812-D; TRG10400#01811-D; TRG10400#01809-D; TRG10400#01736-D; TRG10400#01735-D; TRG10400#01732-D; TRG10400#01729-D -/--	1,3-5	

Application Number

EP 03 02 0417

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
	& "Chem.Folio" 15 January 2001 (2001-01-15), LION BIOSCIENCE AG , HEIDELBERG, GERMANY -----		
X	US 3 867 384 A (SHEERAN PATRICK J ET AL) 18 February 1975 (1975-02-18) * column 1 - page 2 * * column 5; table 1 * -----	1-5	
X	US 3 755 582 A (BULLOCK G) 28 August 1973 (1973-08-28) * examples 1-6,8,12-14 * -----	2	
A	WO 02/24632 A (GLAXO GROUP LTD ; COLLINS JON LOREN (US); FIVUSH ADAM M (US); MALONEY) 28 March 2002 (2002-03-28) * claims * -----	1-40	TECHNICAL FIELDS SEARCHED (Int.Cl.7)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 03 02 0417

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10-12-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02062798	A	15-08-2002	CA 2436738 A1	15-08-2002
			EP 1363913 A2	26-11-2003
			WO 02062798 A2	15-08-2002
			CA 2436741 A1	15-08-2002
			EP 1363914 A1	26-11-2003
			WO 02062799 A1	15-08-2002
			US 2002169175 A1	14-11-2002
WO 9720823	A	12-06-1997	AU 7692996 A	27-06-1997
			WO 9720823 A2	12-06-1997
			ZA 9610020 A	01-06-1997
WO 0248152	A	20-06-2002	AU 2027602 A	24-06-2002
			EP 1347982 A2	01-10-2003
			WO 0248152 A2	20-06-2002
			US 2003036652 A1	20-02-2003
US 3609152	A	28-09-1971	BE 678216 A	22-09-1966
			DE 1620127 A1	12-03-1970
			FR 5267 M	31-07-1967
			GB 1062357 A	22-03-1967
			GB 1174272 A	17-12-1969
			GB 1174273 A	17-12-1969
WO 0121598	A	29-03-2001	AU 7031500 A	24-04-2001
			EP 1218358 A1	03-07-2002
			WO 0121598 A1	29-03-2001
			JP 2003509501 T	11-03-2003
			US 6399603 B1	04-06-2002
US 6337332	B1	08-01-2002	NONE	
US 3867384	A	18-02-1975	NONE	
US 3755582	A	28-08-1973	NONE	
WO 0224632	A	28-03-2002	AU 1121602 A	02-04-2002
			EP 1318976 A2	18-06-2003
			WO 0224632 A2	28-03-2002

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82